Title: Loading and release of water-insoluble drugs

Applicant/Assignee: SCIMED LIFE SYSTEMS, INC

Application No.: 11/188850   Filing Date: 26/Jul/2005

Abstract:A medical device, polymer composition, and method for delivering substantially water-insoluble drugs to tissue at desired locations within the body. At least a portion of the exterior surface of the medical device is provided with a polymer coating. Incorporated in the polymer coating is a solution of at least one substantially water-insoluble drug in a volatile organic solvent. The medical device is positioned to a desired target location within the body, whereupon the drug diffuses out of the polymer coating.

Priority: US2001-978763 Applic. Date: 2001-10-18; US1998-172026 Applic. Date: 1998-10-14; US1998-133603 Applic. Date: 1998-08-13; US1997-910136 Applic. Date: 1997-08-13

Inventor: BARRY JAMES J [US]; PALASIS MARIA [US]

Title: Process for improvement of virus-safe biological fluids

Applicant/Assignee: RELIANCE LIFE SCIENCES PVT., LTD RELIANCE LIFE SCIENCES PVT. LTD

Application No.: 11/171877   Filing Date: 29/Jun/2005

Abstract:The present invention relates to a process of disinfecting biological materials. In particular, a novel process is provided for removing detergent and/or solvent added to biological materials for the inactivation of viral contaminants. Safe, efficient, and economical methods for removing virucidal agents such as solvent-detergent from virus-inactivated pooled plasma by hydrophobic interaction chromatography are provided. Methods for clearing solvent-detergent from virus-inactivated biological materials in a single step are also provided.

Priority: IN2004MU00695 Applic. Date: 2004-06-29

Inventor: VISWANATHAN CHANDRA [IN]; KUPPUSAMY MOSUVAN [IN]; KAMATH MANJUNATH [IN]; BAIKAR VILAS [IN]; TANAVADE ARATI [IN]; PRASAD NARAHARI R [IN]

Title: Embolic filtering method and apparatus

Applicant/Assignee:

Application No.: 11/184069   Filing Date: 19/Jul/2005

Abstract:The present invention relates generally to a device and method for preventing the undesired passage of emboli from a venous blood pool to an arterial blood pool. The invention relates especially to a device and method for treating certain cardiac defects, especially patent foramen ovales and other septal defects, through the use of an embolic filtering device capable of instantaneously deterring the passage of emboli from the moment of implantation. The device consists of a frame, and a braided mesh of sufficient dimensions to prevent passage of emboli through the mesh. The device is preferably composed of shape memory allow, such as nitinol, which conforms to the shape and dimension of the defect to be treated.

Priority: US2004-847909 Applic. Date: 2004-05-19; US20030471555P Applic. Date: 2003-05-19

Inventor: KLESHINSKI STEPHEN J [US]; RUSSELL SCOTT M [US]

Title: Percutaneous aortic valve

Applicant/Assignee: REX MEDICAL REX MEDICAL, L.P

Application No.: 11/222570   Filing Date: 09/Sep/2005

Abstract:The present invention provides a valve configured for insertion on the proximal and distal sides of a heart valve annulus to replace the heart valve of a patient. The valve comprises a first substantially annular portion adapted to be positioned on a proximal side of the annulus of a patient and a second substantially annular portion adapted to be positioned on a distal side of the annulus of a patient, wherein at least one of the first and second substantially annular portions is movable towards the other portion to a clamped position to clamp around the annulus. The second portion has a flow restricting portion extending therefrom and is movable between a first position to permit the flow of blood and a second position to restrict the flow of blood.

In one embodiment, the valve has a suture joining the first and second portions to draw the first and second portions into closer proximity and a cinch member to secure the suture to maintain the first and second portions in the clamped position. In another embodiment, the first and second portions are connected by a first segment which biases the first and second portions toward the clamped position.

Priority: US2003-429536 Applic. Date: 2003-05-05

Inventor: MCGUCKIN JAMES F JR [US]; HINCHLIFFE PETER W [US]

Title: Reagent carrier

Applicant/Assignee: SCIL ANIMAL CARE COMPANY GMBH

Application No.: 11/183389   Filing Date: 18/Jul/2005

Abstract:A reagent carrier has a first chamber, which contains a reagent. The reagent carrier is characterized in that at least one second chamber is provided to hold blood, a third chamber is provided to hold a dye and a fourth chamber is designed as a measurement chamber.

Priority: DE200410034801 Applic. Date: 2004-07-19

Inventor: RUDLOFF PETER [DE]

Title: Clinical method for the genetic screening of newborns using tandem mass spectrometry

Applicant/Assignee: PERKINELMER GENETICS, INC

Application No.: 11/225615   Filing Date: 13/Sep/2005

Abstract:A method for screening newborns using electrospray tandem mass spectrometry. The method improves the current protocols that use tandem mass spectrometry by assuring accurate and consistent results at the clinical level through enhanced quality controls and quality assurance protocols as applied to the scan profiling and sample preparation of blood spots from newborns. Specific additives are used in precise concentrations of internal standards, employing detailed controls adapted to distinguish twenty metabolites, which are scanned and vigorously compared to known spectra results. Revealing peaks, metabolite concentration, and scan intensities in the quality assurance steps are then compared to a range of thresholds to determine whether or not the sample is contaminated, drug-ridden, diagnosable, or unacceptable.

All spectra results and quality assurance flags are organized in spreadsheet form and exported to a database where values are compiled and stored for daily output results and trend analysis. The method provides for high-throughput and quality results, having a consistent predictability for genetically testing newborns efficiently and accurately.

Priority: US2005-169158 Applic. Date: 2005-06-28; US2002-252115 Applic. Date: 2002-09-23; US1999-464132 Applic. Date: 1999-12-16; US1999-277119 Applic. Date: 1999-03-26; US19990117880P Applic. Date: 1999-01-30

Inventor: CHACE DONALD H [US]

Title: Method for analyzing blood for cholesterol components

Applicant/Assignee:

Application No.: 11/104285   Filing Date: 12/Apr/2005

Abstract:A method for detecting and quantifying lipoprotein subgroup concentration in a blood serum sample in a single spin cycle using a fluorescent dye and a self generating continuous gradient followed fluorescent dye detection and quantitation.

Priority: US20040561463P Applic. Date: 2004-04-12

Inventor: TROUP JAN M [US]

Title: Catheter flushing fluid lock system and method

Applicant/Assignee:

Application No.: 10/533749   Filing Date: 10/May/2005

Abstract:A catheter-flushing fluid lock system ( 100 ) for maintaining the patency of the lumen of an indwelling catheter ( 203 ). The system is comprised of a fluid locked system such as a tubing system ( 104 ) in fluid connection with an indwelling catheter, said tubing system defining an internal volume and at least one proximal terminal ( 106 ) for intermittent connection with an external fluid source

Priority: WO2002US35163 Applic. Date: 2002-11-04

Inventor: LYNN LAWRENCE A [US]

Title: Mediwatch

Applicant/Assignee:

Application No.: 10/796916   Filing Date: 02/Jul/2004

Abstract:A combined watch, storage container and a medical alert bracelet, thus eliminating the need for wearing a separate medical alert bracelet/necklace with separate alarms alerting the wearer when to take medication. The combined watch, pillbox storage container, with a locking device is hinged to the base, having a main face with four individual watch faces within. Control mechanisms fixedly mounted on the underside, of the lid and is adapted for tracking the time of day as well as the ability to set alarms independently and is powered by a battery. Fitting snuggly, the underside lid contains a two-sided removable disc for listing medications and important medical information. Storage device, which is the base housing, having bottom and peripheral walls coupled to and away from the peripheral edge and securely hinged to the lid.

Storage device has multiple removable divisional inserts, allowing the choice for number of compartments with a plastic covered, rotating shield, which the wearer spins to open over the selected compartment. The underside engraved base serves as a medical alert bracelet with medical information permanently engraved

Priority:

Inventor: PITOCCO THERESA A [US]; PITOCCO MICHELLE C [US]

Title: Novel drug delivery system

Applicant/Assignee:

Application No.: 11/134631   Filing Date: 19/May/2005

Abstract:A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

Priority: IN2002MU00698 Applic. Date: 2002-08-05; IN2002MU00696 Applic. Date: 2002-08-05; IN2003MU00081 Applic. Date: 2003-01-22; US2003-630348 Applic. Date: 2003-07-29

Inventor: VAYA NAVIN [IN]; KARAN RAJESH S [IN]; NADKARNI SUNIL S [IN]; GUPTA VINOD K [IN]

Title: Novel drug delivery system

Applicant/Assignee:

Application No.: 11/134632   Filing Date: 19/May/2005

Abstract:A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

Priority: IN2002MU00698 Applic. Date: 2002-08-05; IN2002MU00696 Applic. Date: 2002-08-05; IN2003MU00081 Applic. Date: 2003-01-22; US2003-630348 Applic. Date: 2003-07-29

Inventor: VAYA NAVIN [IN]; KARAN RAJESH S [IN]; NADKARNI SUNIL S [IN]; GUPTA VINOD K [IN]

Title: Modern blood banking employing improved cell preservation composition

Applicant/Assignee: SHANBROM TECHNOLOGIES, LLC

Application No.: 10/897632   Filing Date: 22/Jul/2004

Abstract:An improved anticoagulant is based on a higher level of citric acid than is usual (at least about 0.2% weight by volume). The higher citrate is combined with an amino acid as a counterion. The amino acid prevents cellular damage often caused by elevated citrate levels. The amino acid citrate mixture also serves to preserve platelet concentrates and platelet rich plasma during room incubation. Not only does the amino acid citrate combination enhance platelet integrity, it completely inhibits the growth of bacteria such as Staphylococcus epidermidis. Collecting blood of plasma into such higher levels of citrate prevents activation of blood proteins so that fractions made from the blood or plasma have superior characteristics.

Priority:

Inventor: SHANBROM EDWARD [US]

Title: Methods and apparatuses for conducting assays

Applicant/Assignee: MESO SCALE DIAGNOSTICS, LLC MESO SCALE TECHNOLOGIES, LLC

Application No.: 11/145528   Filing Date: 03/Jun/2005

Abstract:Disclosed are methods for conducting assays of samples, such as whole blood, that may contain cells or other particulate matter. Also disclosed are systems, devices, equipment, kits and reagents for use in such methods. One advantage of certain disclosed methods and systems is the ability to rapidly measure the concentration of an analyte of interest in blood plasma from a whole blood sample without blood separation and hematocrit correction.

Priority: US20040576710P Applic. Date: 2004-06-03

Inventor: BILLADEAU MARK A [US]; DEBAD JEFF D [US]; GLEZER ELI N [US]; LELAND JONATHAN K [US]; WIJAYAWARDHANA CHARLES A [US]

Title: Collection means and a method for collecting cord blood

Applicant/Assignee:

Application No.: 11/186415   Filing Date: 20/Jul/2005

Abstract:The invention provided herein comprises a kit, where the kit includes at least one collecting receptacle for collecting cord blood, and a pre-measured non-liquid anticoagulant which is optionally pre-loaded into the receptacle. The anticoagulant is preferably selected from the group consisting of heparin or heparin type additives, citrates, EDTA (ethylenediaminetetraacetic acid), and oxalates and any other anticoagulant that can be used to decrease the clotting ability of the blood. The invention provided herein also comprises a method for collecting cord blood, where the method comprises collecting a desired amount of cord blood from the umbilical cord using a collection receptacle of the invention, wherein the collection receptacle is pre-loaded with a pre-measured amount of non-liquid anticoagulant.

Priority: US20040590386P Applic. Date: 2004-07-20

Inventor: MOORE THOMAS E [US]; MAPOTHER BETH [US]

Title: Novel dosage form

Applicant/Assignee:

Application No.: 11/134633   Filing Date: 19/May/2005

Abstract:A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg

a process for preparing the dosage form.

Priority: IN2002MU00699 Applic. Date: 2002-08-05; IN2002MU00697 Applic. Date: 2002-08-05; IN2003MU00080 Applic. Date: 2003-01-22; IN2003MU00082 Applic. Date: 2003-01-22; US2003-630446 Applic. Date: 2003-07-29

Inventor: VAYA NAVIN [IN]; KARAN RAJESH S [IN]; SADANAND SUNIL [IN]; GUPTA VINOD K [IN]

Title: Variants of factor XllA

Applicant/Assignee:

Application No.: 10/539720   Filing Date: 18/Jul/2005

Abstract:Factor XIIa (activated Factor XII) exists in a variety of forms in the blood. Measurement of different forms provides information relevant for diagnosing, monitoring, or predicting the susceptibility to, progress of, or outcome of a disease or disorder, or of treatment of the disease or disorder in a subject having or suspected of having the disease or disorder.

Priority: GB20020029837 Applic. Date: 2002-12-20; GB20020029835 Applic. Date: 2002-12-20; GB20020029832 Applic. Date: 2002-12-20; GB20020029828 Applic. Date: 2002-12-20; WO2003GB05612 Applic. Date: 2003-12-22

Inventor: PRITCHARD DAVID J [GB]

Title: Device and method for flow mixing of a biological fluid and a solution

Applicant/Assignee:

Application No.: 11/196706   Filing Date: 03/Aug/2005

Abstract:The disclosure relates to a mixing machine, system, and method including: a measurement device able to measure a volume of a biological fluid

a pumping device able to pump an anticoagulant and/or preservation solution into the biological fluid

and a control system for the pumping device. The control system may include: a device for determining an actual volume of the solution previously pumped by the pumping device and an automatic control able to control a pumping speed of the pumping device. The automatic control may control the pumping speed by calculating a theoretical volume of the solution to be mixed with the biological fluid previously pumped by the pumping device as a function of a determined ratio of the biological fluid collected and the solution pumped

comparing the theoretical volume to the actual volume

and adjusting the pumping speed of the pumping device to approach the determined ratio.

Priority: FR20040051769 Applic. Date: 2004-08-03

Inventor: BEHAGUE MAURICE [FR]

Title: Composition and method for the repair and regeneration of cartilage and other tissues

Applicant/Assignee: BIO SYNTECH CANADA INC ECOLE POLYTECHNIQUE

Application No.: 11/031325   Filing Date: 07/Jan/2005

Abstract:The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention.

Priority: US2001-896912 Applic. Date: 2001-06-29; US20000214717P Applic. Date: 2000-06-29

Inventor: HOEMANN CAROLINE D [CA]; BUSCHMANN MICHAEL D [CA]; MCKEE MARC D [CA]

Title: Plasma or serum separation membrane and filter apparatus including the plasma or serum separation membrane

Applicant/Assignee: SEKISUI CHEMICAL CO., LTD

Application No.: 10/533539   Filing Date: 02/May/2005

Abstract:A Plasma or serum separation membrane that enables omitting centrifugal separation, is free from hemolysis attributed to destruction of red blood cells and realizes easy and rapid separation of plasma or serum from blood

and a filter apparatus including the plasma or serum separation membrane. In particular, a plasma or serum separation membrane being a membrane for separation of plasma or serum from blood and having a void ratio of 30% or below

and a filter apparatus comprising a filter member capable of attaining movement of plasma swifter than movement of blood cells and a plasma or serum separation membrane connected in series with a rear side of the filter member.

Priority: JP20020335606 Applic. Date: 2002-11-19; JP20020335607 Applic. Date: 2002-11-19; JP20030124335 Applic. Date: 2003-04-28; WO2003JP14625 Applic. Date: 2003-11-18

Inventor: TOGAWA KATSUYA [JP]; OKAMOTO RYUSUKE [JP]; ISOGAWA HIRONOBU [JP]

Title: Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same

Applicant/Assignee:

Application No.: 11/194056   Filing Date: 29/Jul/2005

Abstract:An erythrocyte sedimentation rate (ESR) measurement instrument having a Blood Collection Configuration and an ESR Measurement Configuration. The ESR measurement instrument comprises a sedimentation measurement tube having an hollow interior volume containing a predetermined quantity of blood sample diluting agent therewithin and being air/fluid sealed with respect to the ambient environment

and a blood collection tube having a hollow interior volume containing a predetermined quantity of anti-coagulant and being vacuum-sealed with respect to the ambient environment, and physically coupled to the air-sealed sedimentation measurement tube, by at least a portion of the sedimentation measurement tube being inserted within a portion of the hollow interior volume of the blood collection tube. The sedimentation measurement tube and the blood collection tube are maintained stationarily fixed relative to each other as a unitary assembly having a syringe-like form factor when the ESR measurement instrument is arranged in the Blood Collection Configuration. During this configuration, a needle-supporting connector can be connected to the blood collection tube and a sample of whole blood from a patient vacuum-drawn and injected into the blood collection tube. After the sample of anti-coagulated blood has been collected in the blood collection tube and the needle-supporting connector is disconnected therefrom, the air/fluid seal of the sedimentation measurement tube can be broken and then the sedimentation measurement tube can be manually plunged into and to the bottom of the hollow interior volume of said blood collection tube, using a single-handed operation to rearrange the ESR measurement instrument into the ESR Measurement Configuration. The anti-coagulated sample of blood fills up a substantially portion of the sedimentation measurement tube and mixes with the blood sample diluting agent to enable the blood plasma/erythrocyte cell (P/E) interface level within the sedimentation measurement tube to settle downwards toward the blood collection tube during a predetermined time period when said ESR measurement instrument is oriented in a gravity vertical position. By virtue of the present invention, the erythrocyte sedimentation rate (ESR) of the collected blood sample can be measured by determining how far the P/E interface level has moved against graduation markings formed along the length of the sedimentation measurement tube during the predetermined time period.

Priority: US2003-395860 Applic. Date: 2003-03-21

Inventor: BOUBOULIS DENIS A [US]

Title: Methods of treating a subject for a condition

Applicant/Assignee:

Application No.: 10/917270   Filing Date: 11/Aug/2004

Abstract:Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g., simultaneously. Also provided are kits for use in practicing the subject methods.

Priority:

Inventor: YUN ANTHONY J [US]; LEE PATRICK Y [US]

Title: Method and composition for inhibiting or slowing blood coagulation

Applicant/Assignee: BRIGHAM & WOMEN'S HOSPITAL, INC THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

Application No.: 10/516450   Filing Date: 02/Dec/2004

Abstract:A method and composition for inhibiting or slowing blood coagulation includes lactadherin, a fragment of lactadherin, a functional equivalent of lactadherin, or a functional equivalent of a fragment of lactadherin.

Priority: US20020386562P Applic. Date: 2002-06-07; WO2003US15404 Applic. Date: 2003-06-06

Inventor: GILBERT GARY E [US]; SHI JIALIN [US]

Title: Multi-functional biocompatible coatings for intravascular devices

Applicant/Assignee:

Application No.: 10/924102   Filing Date: 23/Aug/2004

Abstract:A polymeric coating is adapted to substantially eliminate thrombus formation when in contact with blood. The polymeric coating includes a first polymeric layer and a second polymeric layer. Interposed between the first and second polymeric layers is a polymeric matrix layer doped with at least one of a nitric oxide donor and a nitric oxide generator. The nitric oxide donor and/or the nitric oxide generator are capable of releasing or generating NO. A bioactive agent is either immobilized to the surface of the second polymeric layer or is incorporated into the polymeric matrix layer.

Priority:

Inventor: ZHOU ZHENGRONG [US]; MEYERHOFF MARK E [US]; REYNOLDS MELISSA M [US]

Title: Biological tissue regenerative agent and method for preparing same

Applicant/Assignee:

Application No.: 10/923237   Filing Date: 20/Aug/2004

Abstract:A biological tissue regenerative agent and method for preparing the same. The agent comprises the compounds that are usually found sequestered within platelets, along with platelet cytosolic components, and serum. The agent is prepared by preparing two quanta of blood. The first is clotted, the cells discarded and the serum retained. The second quantum undergoes concentration and lysis of the platelets therein, followed by recombination of the lysed platelets and platelet internal products with serum to form the agent. In a preferred embodiment, lysis of platelets is accomplished by providing an effective amount of calcium. The agent may be further purified and may be frozen or freeze dried for storage.

Priority:

Inventor: BARRUETA ALBERTO G [ES]; ELIZUNDIA JOSU S [ES]; BARBERA-GUILLEM EMILIO [US]

Title: Biological tissue regenerative agent and method for preparing and using same

Applicant/Assignee:

Application No.: 11/208231   Filing Date: 19/Aug/2005

Abstract:A biological tissue regenerative agent and method for preparing the same. The agent comprises the compounds that are usually found sequestered within platelets, along with platelet cytosolic components, and serum. The agent is prepared by preparing two quanta of blood. The first is clotted, the cells discarded and the serum retained. The second quantum undergoes concentration and lysis of the platelets therein, followed by recombination of the lysed platelets and platelet internal products with serum to form the agent. In a preferred embodiment, lysis of platelets is accomplished by providing an effective amount of calcium. The avoidance of a platelet release reaction and the presence of alpha-2 macroglobulin in the serum suppresses active TGF-beta in the agent. The agent may be further purified and may be frozen or freeze dried for storage.

Priority: US2004-923237 Applic. Date: 2004-08-20

Inventor: BARRUETA ALBERTO GORROCHATEGUI [ES]; ELIZUNDIA JOSU SIMON [ES]; BARBERA-GUILLEM EMILIO [US]

Title: Formulation for blood clot inhibitor for use with bow hunting broadheads and method for using same

Applicant/Assignee:

Application No.: 11/206463   Filing Date: 18/Aug/2005

Abstract:A method and formulation are disclosed toward the enhancing of a blood trail by a wounded target animal. A topical application for use with broadheads is disclosed as well as a method for using same.

Priority: US20040603691P Applic. Date: 2004-08-21

Inventor: JONES BRANDON C [US]

Title: Diketopiperazine salts for drug delivery and related methods

Applicant/Assignee: MANNKIND CORPORATION

Application No.: 11/210710   Filing Date: 23/Aug/2005

Abstract:Biologically active agent delivery compositions, which comprise diketopiperazine carboxylate salts are provided. Related methods for making and using the biologically active agent delivery compositions are also provided.

Priority: US20040603761P Applic. Date: 2004-08-23

Inventor: LEONE-BAY ANDREA [US]; MOYE-SHERMAN DESTARDI [US]; WILSON BRYAN R [US]

Title: Two stage hemofiltration that generates replacement fluid

Applicant/Assignee: KKJ, INC

Application No.: 10/922763   Filing Date: 20/Aug/2004

Abstract:The present invention relates to a system for two-stage blood dialysis of a patient. In one embodiment, the system comprises a first filtration device for receiving the blood from the patient and for producing a first filtrate and processed blood. The system further comprises a second filtration device for receiving the first filtrate and producing replacement fluid and waste product. At least one of the first and second filtration devices preferably comprises a Taylor vortex-enhanced blood filtration device.

Priority:

Inventor: MCLAUGHLIN JENNIFER K [US]; SCHOENDORFER DON [US]

Title: Differential expression of molecules associated with acute stroke

Applicant/Assignee: THE GOV. OF THE U.S.A AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

Application No.: 11/155835   Filing Date: 17/Jun/2005

Abstract:Methods are provided for evaluating a stroke, for example for determining whether a subject has had an ischemic stroke, determining the severity or likely neurological recovery of a subject who has had an ischemic stroke, and determining a treatment regimen for a subject who has had an ischemic stroke, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes screening for expression in ischemic stroke related genes (or proteins), such as white blood cell activation and differentiation genes (or proteins), genes (or proteins) related to hypoxia, genes (or proteins) involved in vascular repair, and genes (or proteins) related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment.

Also provided are methods of identifying one or more agents that alter the activity (such as the expression) of an ischemic stroke-related molecule.

Priority: WO2005US18744 Applic. Date: 2005-05-27; US20040575279P Applic. Date: 2004-05-27

Inventor: BAIRD ALISON E [US]; MOORE DAVID F [US]; GOLDIN EHUD [US]

Title: New method to reduce complete blood count variation of peripheral blood sample

Applicant/Assignee: HONEYWELL INTERNATIONAL, INC

Application No.: 10/924689   Filing Date: 24/Aug/2004

Abstract:The invention sets forth a method for reducing coagulation in a blood sample collected most conveniently from an acral body site such as the fingertip or heel, commonly referred to as capillary blood collection. The method includes the steps of applying an anticoagulant composition to the acral site, lancing the skin in contact with the anticoagulant composition and allowing blood and anticoagulant to mix on the skin at the site prior to collecting the blood for analysis.

Priority:

Inventor: GU YUANDONG [US]

Title: Ultrasound catheter devices and methods

Applicant/Assignee: FLOWCARDIA, INC

Application No.: 10/927966   Filing Date: 26/Aug/2004

Abstract:Ultrasound catheter devices and methods provide enhanced disruption of blood vessel obstructions. Generally, an ultrasound catheter device includes an elongate flexible catheter body with one or more lumens, an ultrasound transmission member extending longitudinally through the catheter body lumen and a distal head coupled with the transmission member and positioned adjacent the distal end of the catheter body for disrupting occlusions. A proximal housing of the catheter device may include one or more features for dissipating heat from the ultrasound transmission wire, such as a fluid inlet aperture for passage of fluid, use of heat conductive materials in the proximal housing, surface features to increase the housing's surface area, heat conductive members disposed adjacent the transmission member and the like.

Various irrigation fluids may be used, such as cooled, oxygen supersaturated or lubricious fluids.

Priority:

Inventor: NITA HENRY [US]; SARGE JEFF [US]; SPANO RICHARD [US]

Title: Injection of bone marrow-derived conditioned medium for angiogenesis

Applicant/Assignee: MYOCARDIAL THERAPEUTICS, INC

Application No.: 11/117607   Filing Date: 27/Apr/2005

Abstract:Methods are provided for promoting formation of collateral blood supply at an ischemic site in tissue by culturing early attaching cells derived from growth of bone marrow aspirate in vitro, collecting early attaching cells produced by the bone marrow culture and injecting conditioned medium produced by culture of the early attaching cells into an ischemic site in heart or limb. The preferred early attaching cells for use in the invention methods are marrow-derived stromal cells. Any donor's bone marrow can be used in preparation of the conditioned medium. Optionally, the early attaching cells can be transfected with an angiogenesis promoting transgene encoding hypoxia inducing factor 1 alpha, a fibroblast growth factor and/or a nitric oxide synthase. Conditioned media containing angiogenic cytokines produced such cells are also provided for injection into tissue, such as heart or peripheral limb muscle, requiring formation of collateral blood supply.

Priority: US2002-160514 Applic. Date: 2002-05-30; US2001-868411 Applic. Date: 2001-06-14; WO2000US08353 Applic. Date: 2000-03-30; US20040566332P Applic. Date: 2004-04-28; US19990138379P Applic. Date: 1999-06-09; US19990126800P Applic. Date: 1999-03-30

Inventor: KORNOWSKI RAN [IL]; FUCHS SHMUEL [US]; EPSTEIN STEPHEN [US]; LEON MARTIN B [US]

Title: Diagnostic test for determining the concentration of transient proteolytic activity in composite biological media

Applicant/Assignee: SYNAPSE B. V

Application No.: 10/514269   Filing Date: 01/Aug/2005

Abstract:A method is provided for determining in real time the course of thrombin activity in a sample of blood or plasma as it appears in and disappears from the simple which comprises adding a thrombin substrate to the sample that, per unit time, produces a detectable signal in a quantity that bears relation to the amount of thrombin present. Simultaneously, in a control sample of the same blood or plasma in which thrombin generation is not triggered, the activity of a standard preparation with invariable thrombin activity is measured. The exact molar amount of thrombin present at any moment is obtained by comparison of the activity measured in clotting blood and the simultaneously measured calibrator. The method is useful inter alia for diagnosing hyper- and hypo-coaguable states, either congenital, acquired or drug-induced in humans and animals. Also provided is a kit for use in this method.

Priority: EP20020076744 Applic. Date: 2002-05-01; WO2003EP04705 Applic. Date: 2003-05-01

Inventor: GIESEN PETER [NL]; HEMKER HENDRIK [NL]; AL DIERI RAED [NL]; BEGUIN SUZETTE L [NL]; WAGENVOORD ROBERT [NL]

Title: Blood contacting sensor

Applicant/Assignee: MEDTRONIC MINIMED, INC

Application No.: 10/935954   Filing Date: 08/Sep/2004

Abstract:The invention provides methods and apparatus for detecting an analyte in blood. The apparatus is particularly suited for bringing a sensor into direct contact with blood in vivo. The apparatus comprises a sensor that detects the presence of an analyte and an assembly means. The assembly means has a sensor end, wherein the sensor end of the assembly means is affixed to the sensor, and the assembly means is adapted for coupling with a venous flow device. By coupling with a venous flow device, the assembly means brings the sensor into direct contact with blood flowing through the venous flow device. Examples of venous flow devices that bring the sensor into direct contact with the blood of a subject include, but are not limited to, intravenous catheters and external blood loops, such as are used in extra corporeal membrane oxygenation or hemodialysis.

Priority:

Inventor: VAN ANTWERP NANNETTE M [US]; ENEGREN BRADLEY J [US]; MASTROTOTARO JOHN J [US]; SHAH RAJIV [US]; HOSS UDO [US]; ZHANG YANAN [US]; WANG JENN-HANN [US]; CLARK KENT L [US]

Title: Blood component separation system with stationary separation chamber

Applicant/Assignee:

Application No.: 11/167784   Filing Date: 27/Jun/2005

Abstract:Provided is a blood processing system having a stationary component separation chamber. Individual blood components as well as other particles and contaminates are separated from blood flowing through the separation chamber by optical traps configured to manipulate specific components are projected into the flow field of the chamber. Cells or particles of the selected components that are manipulated by the optical traps then may be directed from the flow field to individual reservoirs to collect quantities of the selected components.

Priority: US20040583929P Applic. Date: 2004-06-28

Inventor: RAGUSA MICHAEL [US]; STACEY GARY R [US]; PAGES ETIENNE [FR]

Title: Biocompatible hydrogel compositions

Applicant/Assignee:

Application No.: 10/948765   Filing Date: 23/Sep/2004

Abstract:Compositions, instruments, systems, and methods are providing for creating families of materials having diverse therapeutic indications and possessing enhanced biocompatibility. The genus platform for the families includes a biocompatible synthetic electrophilic component mixed with a nucleophilic component. The electrophilic component can include a functionalized electrophilic poly (anhydride ester) material. The nucleophilic material can include a natural, autologous protein. The components, when mixed in a liquid state, react by cross-linking, forming a solid matrix composition, or hydrogel.

Priority:

Inventor: HNOJEWYJ OLEXANDER [US]

Title: IL-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses

Applicant/Assignee: CENTOCOR, INC

Application No.: 11/234011   Filing Date: 23/Sep/2005

Abstract:An anti-IL-23 specific human Ig derived protein, isolated nucleic acids that encode at least one anti-IL-23 Ig derived protein, vectors, host cells, transgenic animals or plants, and methods of making and using thereof are useful as therapeutic and diagnostic compositions, methods and devices. The anti-IL-23 Ig derived protein preferably binds to one or more of the Seg 1, Seg 2, and Seg 3 epitopes of the p40 subunit of IL-23.

Priority: US20040612866P Applic. Date: 2004-09-24; US20040616832P Applic. Date: 2004-10-07

Inventor: BENSON JACQUELINE [US]; CUNNINGHAM MARK [US]; LUO JEFFREY [US]

Title: Individual need-based system for providing supplements

Applicant/Assignee: NUTRI-CHECK TECHNOLOGIES, LLC

Application No.: 10/541621   Filing Date: 06/Jul/2005

Abstract:A system for individual need-based determinations relative to the use of a substance is presented in various embodiments. As applied to supplements the system may be configured to present a test modality ( 6 ) which may be attached to a distribution container ( 1 ) within which supplements ( 2 ) or the like may be contained. The test modality ( 6 ) may be a user practical test modality that may be provided to a user with an information display ( 11 ) that may include an internal display ( 12 ) to educate the user on a particular test modality ( 6 ). Provisions for the options of a test result recordation enablement element ( 10 ) are provided in both manual and internet forms. The test modality ( 6 ) may be test strips compactly assembled and provided attached to the distribution container ( 1 ).

Priority: US20030438426P Applic. Date: 2003-01-06; WO2004US00179 Applic. Date: 2004-01-06

Inventor: JENSEN JAMES C [US]; SUGERMAN HERBERT L [US]

Title: Systems and methods of identifying biomarkers for subsequent screening and monitoring of diseases

Applicant/Assignee: VITRIMARK, INC

Application No.: 11/232597   Filing Date: 22/Sep/2005

Abstract:A system for generating an image of ultrastructural biomarkers from a biological sample is provided. The system includes a grid onto which a sample to be imaged may be placed and a cryogenic reservoir into which the grid and sample may be immersed for vitrification of the sample. The system also includes a stage onto which the grid and sample may be situated for subsequent imaging in a high contrast imager to permit identification of ultrastructural biomarkers therein. A method for generating an image of ultrastructural biomarkers from a biological sample is also provided. The generated image of ultrastructural biomarkers may be used subsequently for screening and monitoring diseases, evaluating drug and therapeutic efficacy, and assessing risks associated with a drug or therapeutic candidate, among other things.

Priority: US20040612713P Applic. Date: 2004-09-24

Inventor: BOSE ARIJIT [US]; AZIZ NAZNEEN [US]

Title: Substituted 2H-1,3-benzoxazin-4(3H)-ones

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 11/236051   Filing Date: 26/Sep/2005

Abstract:Substituted benzoxazin-4(3H)-ones are provided which are useful for treating thrombosis and for reducing the likelihood and/or severity of a secondary ischemic event in a patient.

Priority: US20040614564P Applic. Date: 2004-09-29

Inventor: SCARBOROUGH ROBERT M [US]; VENKATRAMAN MEENAKSHI S [US]; ZHANG XIAOMING [US]; PANDEY ANJALI [US]

Title: Conveniently implantable sustained release drug compositions

Applicant/Assignee:

Application No.: 11/236426   Filing Date: 27/Sep/2005

Abstract:This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

Priority: US20040614484P Applic. Date: 2004-10-01; US20050709665P Applic. Date: 2005-08-19

Inventor: WONG VERNON G [US]; WOOD LOUIS L [US]

Title: Methods of preventing weight gain

Applicant/Assignee: MOR RESEARCH APPLICATIONS LTD

Application No.: 11/283928   Filing Date: 22/Nov/2005

Abstract:Methods for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed.

Priority: IL20040161595 Applic. Date: 2004-04-22; WO2005IL00440 Applic. Date: 2005-04-21; US20050670290P Applic. Date: 2005-04-12

Inventor: BARAK NIR [IL]

Title: Biocompatible polymer and filter for selectively eliminating leucocytes using the same

Applicant/Assignee: ASAHI KASEI KURARAY MEDICAL CO., LTD

Application No.: 10/518351   Filing Date: 30/Aug/2005

Abstract:It is intended to provide a polymer which is scarcely eluted, has a high biocompatibility and is useful in a filter for selectively eliminating leucocytes. It is also intended to provide a filter for selectively eliminating leucocytes, a filtration apparatus for selectively eliminating leucocytes and a system for selectively eliminating leucocytes, each having the above-described polymer. The above objects can be achieved by providing a polymer which comprises from 8% by mol to 45% by mol of a unit originating in a polymerizable monomer having a polyalkylene oxide chain, from 30% by mol to 90% by mol of a unit originating in a polymerizable monomer having a hydrophobic group, and from 2% by mol to 50% by mol of a unit originating in polymerizable monomer having a hydroxyl group.

Priority: JP20020176332 Applic. Date: 2002-06-17; JP20020176333 Applic. Date: 2002-06-17; WO2003JP07687 Applic. Date: 2003-06-17

Inventor: KUNO SUSUMU [JP]; ONODERA HIROKAZU [JP]; SAKURAI MASAMI [JP]

Title: Device for draining the coronary sinus

Applicant/Assignee:

Application No.: 10/956973   Filing Date: 01/Oct/2004

Abstract:A device for draining a coronary sinus comprises a first catheter having a distal end, a proximal end, and a passage there through, the distal end adapted to be placed in a coronary sinus, a second catheter having a distal end, a proximal end, and a passage there through, the distal end adapted to be placed in a right side of a heart, and a control system for receiving signals indicative of a coronary sinus needing to be drained of blood, the control system comprising a pump for pumping blood from a coronary sinus through the first catheter to the second catheter into a right side of a heart.

Priority:

Inventor: STAMOS THOMAS S [US]

Title: Energy based devices and methods for treatment of anatomic tissue defects

Applicant/Assignee: CIERRA, INC

Application No.: 10/952492   Filing Date: 27/Sep/2004

Abstract:Methods for treating anatomic tissue defects such as patent foramen ovale (PFO) generally involve positioning a distal end of an elongate catheter device at the site of the anatomic defect, exposing an expandable housing and energy transmission member out of the distal end of the catheter device, engaging the housing with tissues at the site of the anatomic defect, applying suction to the tissues via the housing to bring the tissues together

and applying energy to the tissues with the energy transmission member to substantially close the anatomic defect acutely. Apparatus generally include an elongate catheter body, a housing extending from a distal end of the catheter body for engaging tissues at the site of the anatomic defect, and an energy transmission member adjacent a distal end of the housing, the energy transmission member having at least one substantially planar surface.

Priority: US2004-873348 Applic. Date: 2004-06-21

Inventor: MALECKI WILLIAM [US]; FRANCIS DAN [US]; HORNE KENNETH [US]; DEEM MARK E [US]; GIFFORD HANSON [US]; ALEJANDRO JOSE [US]

Title: Methods of food intake management

Applicant/Assignee: MOR RESEARCH APPLICATIONS LTD

Application No.: 11/283865   Filing Date: 22/Nov/2005

Abstract:Methods for regulating food intake in a human subject

for improving a compliance of a human subject to caloric restriction

and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.

Priority: IL20040161595 Applic. Date: 2004-04-22; US20050670290P Applic. Date: 2005-04-12

Inventor: BARAK NIR [IL]

Title: 5-Ht4 receptor antagonists for the treatment of heart failure

Applicant/Assignee:

Application No.: 10/514386   Filing Date: 26/Aug/2005

Abstract:This invention provides the use of a 5-HT4 receptor antagonist in the manufacture of a medicament for treating or preventing heart failure. Particular heart disorders to be treated are selected from the group comprising chronic heart failure, congestive heart failure, chronic congestive heart failure and heart failure resulting from ischaemic heart disease. Methods of treating heart failure using 5-HT4 receptor antagonists and pharmaceutical compositions containing 5-HT4 receptor antagonists are also provided.

Priority: GB20020011230 Applic. Date: 2002-05-16; WO2003GB02134 Applic. Date: 2003-05-16

Inventor: LEVY FINN O [NO]

Title: Autonomous, ambulatory analyte monitor or drug delivery device

Applicant/Assignee: ROSEDALE MEDICAL

Application No.: 11/311667   Filing Date: 20/Dec/2005

Abstract:The invention relates to analyte monitoring/drug (pharmaceutical agent) delivery device. The invention is suited for monitoring various blood constituents such as glucose. The device has a housing that at least partially encloses a plurality of microneedles disposed on a carrier and an electronics portion. Each microneedle is in fluid communication with a corresponding microchannel. Each microneedle is individually addressable. That is, each microneedle can be extended and retracted individually via an actuator. The electronics portion includes a processor and associated circuitry (e.g., memory, supporting electronics and the like), a motor or the like, a sensor, a power supply (e.g., battery) and optionally an interface. In general, the processor controls the operation of the device and is data communication with the actuator, motor, sensor and interface. The invention provides for autonomous operation, that is, without intervention of the user. The invention can optionally provide for calibration without intervention of the user. The invention can also provide for semi-continuous monitoring for day and night time. The invention can provide for up to four, or more, weeks of operation. The invention can provide for a device that is relative small in size, and therefore unobtrusive. The invention can also provide for device with remote control and interactive electronics. The invention may be also used for the delivery of various pharmaceutical agents including high potency drugs to minimize patient intervention and minimize discomfort.

Priority: US2002-131268 Applic. Date: 2002-04-23; US20020355195P Applic. Date: 2002-02-08

Inventor: ACETI JOHN G [US]; MCBRIDE STERLING E [US]; MORONEY RICHARD M [US]; GREGORY CHRISTOPHER C [US]; ZANZUCCHI PETER J [US]

Title: Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use

Applicant/Assignee:

Application No.: 11/018710   Filing Date: 20/Dec/2004

Abstract:The present invention relates to a method of treating a subject for a condition mediated by a deficiency in angiogenesis by administering to the subject a PAR2 agonist under conditions effective to promote angiogenesis and treat the conditions mediated by a deficiency in angiogenesis. A further aspect of the present invention is a method of treating a subject for condition mediated by excessive or pathological angiogenesis by administering to the subject a PAR2 antagonist or inhibitor under conditions effective to inhibit angiogenesis and treat the subject for the condition mediated by excessive or pathological angiogenesis.

Priority: US20040629190P Applic. Date: 2004-11-18

Inventor: MOUSA SHAKER A [US]

Title: Apparatus and method for in-vivo plasmapheresis using periodic backflush containing anticoagulant

Applicant/Assignee: TRANSVIVO INC

Application No.: 11/320866   Filing Date: 29/Dec/2005

Abstract:Method for in-vivo plasmapheresis utilizing a plurality of elongated hollow microporous filter fibers periodically interrupt diffusion of blood plasma from a patient, and, for a selected time, directing backflush fluid into the fibers at a pressure and interval sufficient to cleanse the fiber pores, after which plasma diffusion is resumed. The backflush fluid, preferably a normal saline solution, may contain an anticoagulant such as heparin, citrate or NO donor in suitable concentration for systemic anti-coagulation or for treating the fiber for thromboresistance.

Priority: US2003-408657 Applic. Date: 2003-04-04; US2001-754773 Applic. Date: 2001-01-04

Inventor: GORSUCH REYNOLDS G [US]; COOPER TOMMY G [US]; HANDLEY HAROLD H JR [US]; PETERS HAROLD W [US]

Title: Medium for culturing autologous human progenitor stem cells and applications thereof

Applicant/Assignee: INSTITUTO CIENTIFICO Y TECHNOLOGICO DE NAVARRA, SA

Application No.: 10/519974   Filing Date: 11/Jun/2003

Abstract:Described is a medium for the autologous culture of autologous human progenitor stem cells, which comprises: between 0.1 and 90 wt.-% autologous human serum

between 0.1 and 10,000 UI/ml heparin

between 0.1 and 10,000 UI/ml protamine

and a culture medium consisting of basic nutrients with or without glutamine, in a sufficient quantity to make up 100 wt.-%, which can be used to culture and expand autologous human progenitor stem cells. Compositions containing said cells can be implanted in the patient using an autologous cellular cardiomyoplasty method in order to create, regenerate and repair dysfunctional myocardial tissue.

Priority: ES20020001540 Applic. Date: 2002-07-02; WO2003ES00285 Applic. Date: 2003-06-11

Inventor: PROSPER CARDOSO FELIPE [ES]; GONZALEZ JESUS H [ES]

Title: Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 11/000572   Filing Date: 30/Nov/2004

Abstract:This document discloses a family of tyrosine carbonate polymers and polymer mixtures that may contain bioactive or biobeneficial polymers or constituents. Methods of making these polymers and mixtures are disclosed, as well. Also, implantable or partially implantable medical devies constructed with or from these polymers are disclosed.

Priority:

Inventor: PACETTI STEPHEN D [US]

Title: Biocompatible hydrogel compositions

Applicant/Assignee:

Application No.: 11/233737   Filing Date: 23/Sep/2005

Abstract:Compositions, instruments, systems, and methods are providing for creating families of materials having diverse therapeutic indications and possessing enhanced biocompatibility. One genus platform for the families includes a biocompatible synthetic electrophilic component mixed with a nucleophilic component. The electrophilic component can include a functionalized electrophilic poly (anhydride ester) material. The nucleophilic material can include a natural, autologous protein. The components, when mixed in a liquid state, react by cross-linking, forming a solid matrix composition, or hydrogel.

Priority: US2004-948765 Applic. Date: 2004-09-23

Inventor: HNOJEWYJ OLEXANDER [US]

Title: Chelating and binding chemicals to a medical implant, medical device formed, and therapeutic applications

Applicant/Assignee:

Application No.: 11/284832   Filing Date: 23/Nov/2005

Abstract:Chelating and binding chemicals to a medical implant, and therapeutic applications. Implantable metal chelated surface and chemical coated medical implant device-drug (or biological moiety) coated or drug eluting stent, prosthesis, or other, includes a medical implant component having metal surface (M) with chemical entity (X) bound via chelator (C) chelated to the metal surface in an (M)-(C)-(X) configuration. Chelator or/and chemical entity-drug (or biological moiety), linker bonded to a drug (or biological moiety), other, are bound at surface concentration greater than 100 picograms per cm<2>. Manufacturing the implantable medical device. Medical implant system including medical implant component and delivery device for delivering and implanting medical implant component in a subject. Implanting the medical device. Preventing or/and treating medical conditions, such as restenosis or/and thrombosis, by implanting the medical device, wherein activity of bound chemical entity exhibits efficacy towards the medical condition.

Priority: US20040630560P Applic. Date: 2004-11-26

Inventor: GENGRINOVITCH STELA [IL]

Title: Extracorporeal blood treatment and system having reversible blood pumps

Applicant/Assignee: CHF SOLUTIONS INC

Application No.: 11/002442   Filing Date: 03/Dec/2004

Abstract:An extracorporeal blood treatment system including: a blood circuit having a first blood passage coupled at a first end to a first end of a blood treatment device and a second blood passage coupled at a first end to a second end of the treatment device, wherein the first and second blood passages each have a second end adapted to be coupled to a vascular system of a human patient

a first blood pump connectable to the first blood passage and a second blood pump connectable to the second blood passage, wherein said first and second blood pumps are adapted to move blood through the first and second blood passages in a first direction and in a reverse direction, and a pump controller operatively connected to the first and second blood pumps, said controller operates the blood pumps to cyclically move blood through the first and second blood passages in the first direction and the reverse direction.

Priority:

Inventor: O'MAHONY JOHN J [IE]

Title: System and method for determining and controlling core body temperature

Applicant/Assignee: RADIANT MEDICAL,INC RADIANT MEDICAL, INC

Application No.: 10/525625   Filing Date: 03/Oct/2005

Abstract:Systems and methods for accurate temperature modification of a patient, or selected regions thereof, including inducing hypothermia. The temperature modification is accomplished using an in-dwelling heat exchange catheter within which a fluid heat exchange medium circulates. A heat exchange cassette attached to the circulatory flow lines of the catheter, the heat exchange cassette being sized to engage a cavity within a control unit. A temperature measurement scheme for obtaining body core temperature is provided, including methods of obtaining and analyzing temperature data to provide feedback to the control unit for use in controlling the heating and cooling of the heat exchange medium so as to heat or cool a patient to a desired target temperature.

Priority: US20020410096P Applic. Date: 2002-09-12; WO2003US28683 Applic. Date: 2003-09-12

Inventor: CALLISTER JEFFREY [US]; STULL PAUL M [US]; WU ANDREW E [US]; SCOTT DAVID J [US]

Title: Fused protein with the function of both hemolysis and anticoagulation and use of it

Applicant/Assignee:

Application No.: 10/526682   Filing Date: 10/Nov/2005

Abstract:This application relates to a fusion protein, which is composed of a thrombolytic protein, an anticoagulant protein, and a linker peptide. In particular, the fusion protein is composed of an anticoagulant protein and a protein molecule having plasminogen-activating activity, wherein said two proteins are linked together via a linker peptide, which can be recognized and cleaved by blood coagulation factors. The application also relates to the medical use of said fusion protein, and to the use of the linker peptide which can be recognized by blood coagulation factor in linking a thrombolytic protein and an anticoagulation protein.

Priority: WO2003CN00743 Applic. Date: 2003-09-03; CN20021029086 Applic. Date: 2002-09-03

Inventor: SHI BINGXING [CN]; WU ZUZE [CN]; YU AIPING [CN]; DONG CHUNNA [CN]

Title: Magnetism based rapid cell separation

Applicant/Assignee: CAPITALBIO CORPORATION TSINGHUA UNIVERSITY

Application No.: 10/538498   Filing Date: 31/Dec/2002

Abstract:This invention relates generally to the field of. In particular, the invention provides processes and kits for isolating a target cell, cellular organelle or virus from a sample, using inter alia, non- or low-specific binding between a target cell, cellular organelle or virus with a magnetic microbead.

Priority: CN20021053992 Applic. Date: 2002-12-09; WO2002CN00942 Applic. Date: 2002-12-31

Inventor: ZHANG XU [CN]; XIE XIN [CN]; CHEN DEPU [CN]; FEI WEIYANG [CN]; CHENG JING [CN]

Title: Method and system for determining platelet-mediated clot formation

Applicant/Assignee:

Application No.: 11/022339   Filing Date: 27/Dec/2004

Abstract:The present invention concerns methods for determining platelet medicated clot formation. Specifically, the invention provides a method for determining platelet-medicated clot formation in a blood sample comprising: (i) obtaining sample of blood, and optionally mixing same with an anti-coagulant in an amount effective to inhibit clot formation

(ii) in a vessel, mixing the sample with a minute amount of an initiator to obtain a mixed sample, the amount being effective to initiate coagulation

(iii) rotating the mixed sample inside the vessel, whereby shear forces are developed at the surface of said vessel in a manner and for a time sufficient to allow adhesion of platelets at the surface of said vessel

(iv) determining clot formation at the surface of said adherent platelets.

The method has different applications, among others, for determining a coagulation disorder in a subject having a coagulation factor dysfunction.

Priority:

Inventor: GITEL SANFORD N [IL]

Title: Apparatus and method for autologous normovolemic hemodilution

Applicant/Assignee: UNIVERSITY HOSPITALS OF CLEVELAND CASE WESTERN RESERVE UNIVERSITY

Application No.: 11/318286   Filing Date: 23/Dec/2005

Abstract:A system and method for autologous normovolemic hemodilution (ANH) are disclosed. The system can include a vacuum canister, which is sized to accept donor bags of a predetermined capacity. The vacuum canister is connected to a vacuum source which applies a suction to the donor bag within the canister. The system can include a canister having a self-generated vacuum, which includes compressible sidewalls that are spring-loaded to provide negative pressure needed to collect blood from a patient without the use of a gravity-induced siphon gradient. Also disclosed are ANH systems and kits that rely on a gravity-induced siphon gradient for blood collection.

Priority: US20040639246P Applic. Date: 2004-12-27

Inventor: TRICKETT JAMES R [US]

Title: Acylated 4-amidino-and-4-guanidinobenzylamines for inhibition of plasma kallikrein

Applicant/Assignee:

Application No.: 10/540958   Filing Date: 15/Jan/2004

Abstract:The invention relates to the use of acylated 4-amidino- or 4-guanidinobenzylamine in accordance with the general formula I P4-P3-P2-P1 (I), where P4 is a monosubstituted or polysubstituted or unsubstituted benzylsulfonyl group, P3 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural alpha-amino acid or alpha-imino acid in the D configuration, P2 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural alpha-amino acid or alpha-imino acid in the L configuration, and P1 is a monosubstituted or polysubstituted or unsubstituted 4-amidino- or 4-guanidinobenzylamine group, for inhibiting plasma kallikrein (PK), factor XIa and factor XIIa, in particular for preventing the activation of coagulation at synthetic surfaces and for systemic administration as anticoagulants/-antithrombotic agents, in particular for preventing the activation of coagulation at synthetic surfaces for the purpose of averting thromboembolic events.

Priority: DE20031001300 Applic. Date: 2003-01-15; WO2004EP00247 Applic. Date: 2004-01-15

Inventor: STURZEBECHER JORG [DE]; STEINMETZER TORSTEN [DE]; SCHWEINITZ ANDREA [DE]

Title: Self-sealing male connector device with collapsible body

Applicant/Assignee: CAREFUSION 303 INC

Application No.: 11/026002   Filing Date: 30/Dec/2004

Abstract:A self-sealing male connector device for connection with a female Luer connector. The device has an elongated male body configured with lengthwise relatively rigid and flexible wall segments cooperating to allow the body to be radially compressed from an expanded configuration to a contracted configuration. A closure cap formed with a resealable aperture is disposed on the distal end of the male body so as to be responsive to the compression of the male body. The relatively flexible wall segments may be installed within notches in the male body or be formed integral with the relatively rigid wall segments.

Priority:

Inventor: RAYBUCK JOHN [US]

Title: Method and apparatus for determining anticoagulant therapy factors

Applicant/Assignee: WADA, INC

Application No.: 11/359667   Filing Date: 22/Feb/2006

Abstract:Methods and apparatus are disclosed for determining a new anticoagulant therapy factor (nATF) for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. In one embodiment, the new anticoagulant therapy factor is based upon a determination of a new fibrinogen transformation rate (nFTR) which, in turn, is dependent on a maximum acceleration point (MAP) for fibrinogen (FBG) conversion. The new anticoagulant therapy factor quantity is also based upon the time to maximum acceleration from the time of reagent injection (TX) into a plasma sample, but does not require the difficulty of obtaining prior art International Normalized Ratio (INR) and International Sensitivity Index (ISI) parameters.

Other embodiments provide methods and apparatus for determining an anticoagulant therapy factor without requiring use of a mean normal prothrombin time determination or ISI.

Priority: US2003-662043 Applic. Date: 2003-09-12; US2003-428708 Applic. Date: 2003-05-02; US20050679423P Applic. Date: 2005-05-10

Inventor: CARROLL WALLACE E [US]; JACKSON R D [US]

Title: Patient usable emergency medical kit

Applicant/Assignee:

Application No.: 11/372838   Filing Date: 10/Mar/2006

Abstract:An emergency medical kit to be carried by a patient having a known high risk of suffering a sudden ischemic event such as a heart attack or a stroke. The kit includes a breathable oxygen delivery system configured for self administration of breathable oxygen by the patient. The breathable oxygen increases oxygen saturation in the blood upon the onset of symptoms of the sudden ischemic event. The kit also includes one or more medications specifically prescribed to the patient by a physician. The medications are of a type and dosage suitable for self administration include specific elements selected to prevent the death of the patient when taken in combination with breathable oxygen immediately upon the onset of symptoms of the sudden ischemic event. The kit includes a portable container to hold the breathable oxygen delivery system and the medication therein. The kit may be carried by the patient or stored near the patient.

Priority: US2002-075088 Applic. Date: 2002-02-16

Inventor: SPRUIELL GRAHAM L [US]

Title: Device for sucking liquid and method for sucking liquid

Applicant/Assignee:

Application No.: 10/524440   Filing Date: 01/Apr/2005

Abstract:When a plurality of liquids are simultaneously sucked using a plurality of suction paths connected to a single pump, one suction end may hinder other acts of suction. A multiple valve for connecting each suction path and the pump in a one-by-one manner is disposed between the plurality of suction paths and the pump. Suction is conducted while the communication between the suction paths and the pump is successively switched in a time-sharing manner. At a certain period of time, the pump and a given path is independent of other suction paths. Whereby, suction can be conducted without being influenced by suction ends of other suction paths.

Priority: WO2002JP09555 Applic. Date: 2002-09-18

Inventor: SHOJI YOSHIYUKI [JP]; YOKOBAYASHI TOSHIAKI [JP]

Title: Method and apparatus for collecting a blood component and performing a photopheresis treatment

Applicant/Assignee: THERAKOS, INC

Application No.: 11/304092   Filing Date: 15/Dec/2005

Abstract:Methods and apparatus for collecting and treating blood component. An apparatus and methods for improvement of an extracorporeal photopheresis treatment is described. A cassette having flexible tubes inside its housing and on the bottom surface outside the cassette housing for ease of manufacturing is operated with a centrifuge bowl having an inlet and two outlets, pressure domes for measuring pressures in tubes, an improved irradiation plate, and a dual chamber bag in an extracorporeal photopheresis treatment.

Priority: US20040637985P Applic. Date: 2004-12-21

Inventor: GARA STEPHEN [US]; STAR CYNTHIA [US]; BRIGGS DENNIS [US]; HUTCHINSON MICHAEL [US]; WATTERS TOM [US]

Title: Device and methods for identifying and treating aspirin non-responsive patients

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 11/304054   Filing Date: 14/Dec/2005

Abstract:The present invention relates to methods and compositions for identifying and treating subjects in need of antithrombotic therapies but who are not responsive to aspirin.

Priority: US20040636744P Applic. Date: 2004-12-14

Inventor: PHILLIPS DAVID R [US]; ANDRE PATRICK [US]; STEPHENS GILLIAN [US]

Title: Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases

Applicant/Assignee:

Application No.: 10/534324   Filing Date: 13/Apr/2003

Abstract:Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agent is capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of MPD. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Priority: US20020424731P Applic. Date: 2002-11-06; WO2003US11325 Applic. Date: 2003-04-13

Inventor: ZELDIS JEROME B [US]

Title: Oral pharmaceutical formulation in the form of a plurality of microcapsules for prolonged release of active principle(s) with slow solubility

Applicant/Assignee:

Application No.: 10/522252   Filing Date: 28/Jul/2003

Abstract:The invention concerns microcapsules with prolonged release of active principles with low solubility, consisting of a core containing the active principle and coated with a polymer layer which controls the release of the active principle. The aim is that said oral microcapsules containing hardly soluble active principles should have a coating film of sufficient thickness to ensure controlled permeability and should be adapted to industrial reproduction. This is achieved by the inventive microcapsules of mean diameter less than 1000 microns, and whereof the coating film contains a film-forming polymer (P1) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA). Said microcapsules are characterized in that their coating films represents at least 3% p/p of dry matter, relative to their total weight and their core contains a hardly soluble active principle and a solubilizing agent (polyoxyethylene hydrogenated castor oil) which provides the core wherein it is contained with properties such that the behaviour of the exposed core (non-coated) in a given dissolving test (TD), is as follows: release of 80% of active principle in less than two hours. The invention also concerns the use of such microcapsules in galenic formulation.

Priority: FR20020009532 Applic. Date: 2002-07-26; WO2003FR02382 Applic. Date: 2003-07-28

Inventor: GUIMBERTEAU FLORENCE [FR]; CASTAN CATHERINE [FR]; MEYRUEIX REMI [FR]

Title: Genetic variants predicting warfarin sensitivity

Applicant/Assignee: ACADEMIA SINICA

Application No.: 11/316406   Filing Date: 21/Dec/2005

Abstract:We discovered that a polymorphism in the promoter of the VKORC1 gene is associated with warfarin sensitivity. This polymorphism can explain both the inter-individual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. Thus, the promoter sequence or activity of the VKORC1 gene of a subject can be used to predict how much warfarin should be prescribed for the subject. Relevant methods and compositions are provided.

Priority: US20040638837P Applic. Date: 2004-12-21; US20050679694P Applic. Date: 2005-05-10

Inventor: CHEN YUAN-TSONG [TW]; YUAN HSIANG-YU [TW]; CHEN JIN-JER [TW]

Title: Novel tissue factor targeted antibodies as anticoagulants

Applicant/Assignee: CPS COLOR EQUIPMENT S.P.A BAYER SCHERING PHARMA AG

Application No.: 10/512215   Filing Date: 12/Jan/2005

Abstract:This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Priority: US20020376566P Applic. Date: 2002-05-01; WO2003US13521 Applic. Date: 2003-04-30

Inventor: LIGHT DAVID [US]; MCLEAN KIRK [US]

Title: Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione

Applicant/Assignee: CELGENE CORPORATION

Application No.: 11/371777   Filing Date: 08/Mar/2006

Abstract:Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Priority: US2003-411656 Applic. Date: 2003-04-11; US20020424730P Applic. Date: 2002-11-06

Inventor: ZELDIS JEROME B [US]

Title: Heparin-binding peptides and uses thereof

Applicant/Assignee: THOMAS JEFFERSON UNIVERSITY

Application No.: 10/551005   Filing Date: 29/Mar/2004

Abstract:Heparin-binding peptides are provided of the formula R1(X1B1B2X2B3X3Y1R2)nR3, R1(X1B1B2B3X2X3B4X4Y1R2)nR3, and C(X1B1B2B3X2X3B4X4)nC

wherein X1, X2, X3, and X4 are independently selected from the group consisting of hydropathic amino acids

B1, B2, B3, and B4 are independently selected from the group consisting of basic amino acids

C is cysteine

Y1 is zero or one to ten amino acid residues, wherein at least one amino acid residue is proline

n is an integer from one to ten

and R1, R2, and R3 are independently selected segments containing from zero to twenty amino acid residues, provided, at least one of the segments R1, R2, and R3 comprises at least one hydrophobic amino acid residue. The peptide C(X1B1B2B3X2X3B4X4)nC is optionally cyclized via a disulfide bond formed between cysteine residues.

The peptides are administered to reduce plasma LMWH and heparin levels and to reduce the anticoagulant effects of heparin and LMWH. The peptides are also administered to inhibit microbial growth and to inhibit mast cell serine proteases involved in various diseases and disorders. The peptides are also administered as carriers to deliver active agents.

Priority: US20030458241P Applic. Date: 2003-03-28; WO2004US09668 Applic. Date: 2004-03-29

Inventor: SAN ANTONIO JAMES D [US]; SCHICK BARBARA P [US]; VERRECCHIO ANGELA [US]

Title: Automatic blood sampling device

Applicant/Assignee:

Application No.: 11/341865   Filing Date: 30/Jan/2006

Abstract:The present invention relates to an automatic blood sampling device comprising a catheter part being operatively connected to a penetration member, the operatively connection between the catheter part and the penetration member being provided via one or more tube sections. The device further comprises pump means being adapted to pump blood through the catheter part and the penetration member and into a storage container, the storage container being adapted to contain a blood sample. The penetration member, typically a needle or a canulla, is adapted to penetrate a flexible member, typically a seal in the form of a rubber membrane, of the storage container. The blood sampling device can be preprogrammed to perform a series of preprogrammed events, such as taking independent blood samples on animals with certain time intervals.

Priority: US20050647778P Applic. Date: 2005-01-31

Inventor: FONSS ANDERS [DK]

Title: Drug-eluting biodegradable stent

Applicant/Assignee:

Application No.: 11/130787   Filing Date: 17/May/2005

Abstract:The present invention relates to a biodegradable stent comprising a luminal surface portion with a second degree of crosslink, an outer surface portion with a first degree of crosslink, and a wall between the luminal and outer surface portions, wherein the wall comprises a crosslinked material characterized by the first degree of crosslink not less than the second degree of crosslink.

Priority: US2005-906239 Applic. Date: 2005-02-10

Inventor: SUNG HSING-WEN [TW]; CHEN MEI-CHIN [TW]; TU HOSHENG [US]

Title: Composition for preserving platelets and method of using the same

Applicant/Assignee:

Application No.: 11/330132   Filing Date: 12/Jan/2006

Abstract:The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Priority: US20050643107P Applic. Date: 2005-01-12

Inventor: SEHGAL LAKSHMAN R [US]; MOUSA SHAKER [US]

Title: Clotting cascade initiating apparatus and methods of use and methods of closing wounds

Applicant/Assignee:

Application No.: 11/337278   Filing Date: 23/Jan/2006

Abstract:Wound closure methods and apparata are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. Methods and apparata for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.

Priority: US2002-291278 Applic. Date: 2002-11-08; US2000-732423 Applic. Date: 2000-12-07; US1998-212080 Applic. Date: 1998-12-15; US19970069834P Applic. Date: 1997-12-16

Inventor: NOWAKOWSKI KAROL L [US]

Title: Hollow fiber technique for in vivo study of cell populations

Applicant/Assignee:

Application No.: 11/221294   Filing Date: 06/Sep/2005

Abstract:The present invention relates to a method of using hollow fibers to evaluate cellular changes in vivo. A method for evaluating cellular changes in vivo in response to administration of a drug or drugs of interest is provided. The hollow fiber technique is also used to evaluate cellular changes in a microorganism in vivo. The technique is further used to evaluate cellular changes in a microorganism in vivo in response to administration of a drug or drugs of interest. A vaccine and method of vaccination are also provided.

Priority: US20040606939P Applic. Date: 2004-09-04

Inventor: BISHAI WILLIAM R [US]; KARAKOUSIS PETROS C [US]

Title: Method for expansion of stem cells

Applicant/Assignee:

Application No.: 11/353692   Filing Date: 14/Feb/2006

Abstract:A method of increasing the growth of stem cells by mixing the stem cells with a growth medium that has been conditioned by an incubation with placental tissue. The method increases the expansion of the stem cell population.

Priority: US20050653390P Applic. Date: 2005-02-15

Inventor: RIORDAN NEIL H [US]

Title: Diagnostic assay for thrombin-activatable fibrinolysis inhibitor (fafi)

Applicant/Assignee: AMERICAN DIAGNOSTICA, INC

Application No.: 10/526167   Filing Date: 29/Aug/2003

Abstract:The invention relates to a diagnostic assay for selectively measuring levels of the 35kD form of thrombin-activatable fibrinolysis inhibitor (TAFla or TAFlai), or a derivative or variant thereof, but not the TAFI proenzyme (TAFI) or the N-terminal activation peptide of TAFI.

Priority: US20020406756P Applic. Date: 2002-08-29; WO2003US27061 Applic. Date: 2003-08-29

Inventor: GREENFIELD ROBERT S [US]; AN SEOUNG S [US]

Title: Quantitative contrast enhanced black-blood imaging using quadruple-inversion recovery

Applicant/Assignee: UNIVERSITY OF WASHINGTON

Application No.: 11/385201   Filing Date: 21/Mar/2006

Abstract:A reduced field-of-view (FOV) imaging technique combines suppression of signals from outer volume and inflowing blood. Both outer volume and blood suppression are achieved using an SFQIR (Small-FOV Quadruple-inversion-Recovery) preparative pulse sequence including two double-inversion pulse pairs separated by appropriate delays. Within each pair, inversion pulses are successively applied to the imaged slice and the slab orthogonal to the imaging plane, with the thickness equal to the FOV size in the phase-encoding direction. Each double-inversion results in a reinversion of the magnetization in a central part of the FOV, while outer areas of the FOV and inflowing blood remain inverted. The SFQIR module was implemented for single-slice and multislice acquisition with a fast spin-echo readout sequence.

Timing parameters of the sequence corresponding to the maximal suppression efficiency can be found by niiziig variation of the normalized signal over the entire range of T1 occurring in tissues.

Priority: US2003-740354 Applic. Date: 2003-12-18; US20020435835P Applic. Date: 2002-12-19

Inventor: YARNYKH VASILY L [US]; YUAN CHUN [US]

Title: Medical fluid therapy flow balancing and synchronization method and apparatus

Applicant/Assignee: BAXTER INTERNATIONAL INC BAXTER HEALTHCARE S.A

Application No.: 11/356661   Filing Date: 16/Feb/2006

Abstract:A medical fluid therapy method includes: (a) establishing a communication link between a kidney dialysis/blood treatment machine and at least one remote pump controller

(b) using the link to synchronize operation of at least one pump housed integrally with the machine with at least one pump located remotely from the machine

(c) enabling an operator to enter a net fluid transfer amount

and (d) controlling the pumps to at least substantially achieve the entered amount.

Priority: US2003-685724 Applic. Date: 2003-10-15

Inventor: WARE LEE C [US]; BOEHNLEIN ARNOLD F [US]

Title: Process, composition and kit for providing a stable whole blood calibrator/control

Applicant/Assignee:

Application No.: 11/066620   Filing Date: 24/Feb/2005

Abstract:The present invention is directed toward a stable calibrator and/or control, kit and process for using in a glucose monitoring instrumentation. Principally, the instant invention teaches a glycolyzed red blood cell component, which has been treated with a glycolysis stabilizing effective amount of at least one non-crosslinking aldehyde compound. The glycolyzed red blood cell component may be added to fresh plasma along with an amount of glucose to form a simulated whole blood glucose control product, effective for maintaining a particular and essentially stable glucose concentration over a period of time sufficient for accurate measurement and calibration of a glucose measuring instrument.

Priority:

Inventor: RYAN WAYNE L [US]; HUNSLEY BRADFORD A [US]

Title: Analyte monitoring device and methods of use

Applicant/Assignee: ABBOTT DIABETES CARE, INC

Application No.: 11/265787   Filing Date: 01/Nov/2005

Abstract:An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.

Priority: US2003-420057 Applic. Date: 2003-04-18

Inventor: PEYSER THOMAS [US]; HELLER ADAM [US]

Title: NANOPARTICULATE COMPOSITIONS OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE INHIBITORS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/275069   Filing Date: 07/Dec/2005

Abstract:Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US2002-323736 Applic. Date: 2002-12-20; US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21; US2003-392303 Applic. Date: 2003-03-20; US20020365524P Applic. Date: 2002-03-20

Inventor: BOSCH H W [US]; CARY GRETA G [US]; HOVEY DOUGLAS C [US]; JAIN RAJEEV A [US]; KLINE LAURA J [US]; MERISKO-LIVERSIDGE ELAINE [US]; OSTRANDER KEVIN D [US]

Title: Biointerface membranes incorporating bioactive agents

Applicant/Assignee:

Application No.: 11/416825   Filing Date: 03/May/2006

Abstract:A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.

Priority: US2004-842716 Applic. Date: 2004-05-10; US2003-647065 Applic. Date: 2003-08-22; US20030472673P Applic. Date: 2003-05-21; US20040544722P Applic. Date: 2004-02-12

Inventor: SHULTS MARK [US]; BRAUKER JAMES H [US]; CARR-BRENDEL VICTORIA [US]; TAPSAK MARK [US]; MARKOVIC DUBRAVKA [US]

Title: Drug Delivery Systems and Methods for Modulating the Fetal Environment and Pregnancy Process

Applicant/Assignee:

Application No.: 11/160949   Filing Date: 15/Jul/2005

Abstract:Systems and Methods are described for treatment of fetal disorders, promotion of fetal health, and extension of the pregnancy period. A drug delivery system (DDS) can perform both bolus and continuous delivery of substances in accordance with sensed data reflecting the current state of a fetus. The methods and systems for promotion of healthy pregnancy and treatment of a developing fetus can alter the drug delivery, by evaluating the sensed data with respect to the age or physical characteristics of the fetus and/or mother.

Priority: US20040574195P Applic. Date: 2004-05-25; US20040587870P Applic. Date: 2004-07-15; US20030488133P Applic. Date: 2003-07-16

Inventor: JOHN MICHAEL S [US]

Title: Biointerface membranes incorporating bioactive agents

Applicant/Assignee:

Application No.: 11/416734   Filing Date: 03/May/2006

Abstract:A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.

Priority: US2004-842716 Applic. Date: 2004-05-10; US2003-647065 Applic. Date: 2003-08-22; US20030472673P Applic. Date: 2003-05-21; US20040544722P Applic. Date: 2004-02-12

Inventor: SHULTS MARK [US]; BRAUKER JAMES H [US]; CARR-BRENDEL VICTORIA [US]; TAPSAK MARK [US]; MARKOVIC DUBRAVKA [US]

Title: Formulation of a mixture of Free-B-Ring flavonoids and flavans as a therapeutic agent

Applicant/Assignee: UNIGEN PHARMACEUTICALS, INC

Application No.: 11/373576   Filing Date: 10/Mar/2006

Abstract:The present invention provides a composition of matter comprised of a mixture of two specific classes of compounds-Free-B-Ring flavonoids and flavans-referred to herein as UP736 for use in the prevention and treatment of diseases and conditions related to platelet aggregation and platelet-induced thrombosis. The invention further provides a novel composition of matter comprised of UP736 in combination with injectable or oral anticoagulants, antiplatelet agents, non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 selective inhibitors and a method for using said composition in the prevention and treatment of diseases and conditions related to platelet aggregation and platelet-induced thrombosis. Finally, this invention provides a method for using UP736 in combination with anti-platelet, anti-coagulant, prophylaxis agents and NSAIDs as a means for reducing the dosage of these agents, decreasing the side effects associated with acute or chronic administration of these agents

counteracting or antagonizing the risks of acute or chronic administration of these agents and for achieving additional and/or multiple clinical benefits.

Priority: US20050660564P Applic. Date: 2005-03-10

Inventor: JIA QI [US]; ZHAO YUAN [US]

Title: Apparatus and method for ablating deposits from blood vessel

Applicant/Assignee: QI YU

Application No.: 11/077942   Filing Date: 11/Mar/2005

Abstract:An apparatus for ablating deposits along the blood vessel of human and animals is disclosed. The apparatus has an extracting and pressurizing unit for extracting blood from a supply vessel and pressurizing it plus a downstream delivering and injecting unit for delivering and injecting the filtered and pressurized source blood into a blood vessel under treatment. Besides inducing a blood circulation and having ablation devices like ultrasound and RF heating, the apparatus ablates the deposits from a nearby portion of the vessel. The characteristics of selective ablation and self-termination make the proposed apparatus safe and effective in treating early-stage atherosclerosis. A DC discharging device can be included to neutralize excess surface charge generation on the wounded healthy tissues following ablation for disinfection and anti-inflammation. Placement of the blood extracting point just downstream of the blood injecting point insures thorough collection and removal of blood-clogging plaque and calcification fragments.

Priority:

Inventor: LEE YEE-CHUN [US]; YU QI [US]

Title: Ocular delivery of polymeric delivery formulations

Applicant/Assignee:

Application No.: 11/244438   Filing Date: 04/Oct/2005

Abstract:The present invention provides a flowable composition suitable for use as a controlled release implant. The flowable composition can be administered into the ocular region of a mammal. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid

(b) a biological agent, a metabolite thereof, a biological agently acceptable salt thereof, or a prodrug thereof

and (c) a biocompatible organic liquid, at standard temperature and pressure, in which the thermoplastic polymer is soluble. The present invention also provides methods of medical treatment that include administering the flowable composition into the ocular region of a mammal.

Priority: US20040615727P Applic. Date: 2004-10-04; US20040628630P Applic. Date: 2004-11-17; US20040629133P Applic. Date: 2004-11-18

Inventor: DADEY ERIC [US]; LINDEMANN CHRISTOPHER M [US]; WARREN STEPHEN L [US]; NORTON RICHARD L [US]

Title: Process, composition and kit for providing a stable whole blood calibrator/control

Applicant/Assignee: STRECK, INC

Application No.: 11/362362   Filing Date: 23/Feb/2006

Abstract:The present invention is directed toward a stable calibrator and/or control, kit and process for using in a glucose monitoring instrumentation. Principally, the instant invention teaches a glycolyzed red blood cell component which has been treated with a glycolysis stabilizing effective amount of at least one non-crosslinking aldehyde compound which may be added to fresh plasma along with an amount of glucose to form a simulated whole blood glucose control product, effective for maintaining a particular and essentially stable glucose concentration over a period of time sufficient for accurate measurement and calibration of a glucose measuring instrument.

Priority: US20050656154P Applic. Date: 2005-02-23

Inventor: RYAN WAYNE L [US]; HUNSLEY BRADFORD A [US]

Title: Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism

Applicant/Assignee: LEWIS S. COLEMAN, MD, INC

Application No.: 11/080709   Filing Date: 15/Mar/2005

Abstract:A theory has been presented that provides a simplified explanation of a cohesive mechanism of embryological development, hemostasis, coagulation, wound repair and tissue maintenance that operates continuously in the animal body to oppose the effects of stress. The theory endeavors to fit all known facts, and is based on the hypothesis that coagulation Factors VII and VIII are respectively local and systemic stress agents that regulate thrombin activity and synergize each other's effects. Stress Theory may explain the etiologies of several hitherto mysterious disease syndromes, and the stress mechanism lo and may play a more pervasive role in disease than is generally appreciated. The theory offers fresh avenues for research and clinical strategy.

Priority:

Inventor: COLEMAN LEWIS S [US]

Title: Sample collection system with caspase inhibitor

Applicant/Assignee:

Application No.: 10/530824   Filing Date: 19/Oct/2005

Abstract:A collection container and a method for collecting a biological sample, particularly whole blood, includes at least one stabilizing agent in an amount effective to inhibit apoptosis. The stabilizing agent comprises or consists of one or more caspase inhibitors.

Priority: US20020417531P Applic. Date: 2002-10-10; WO2003US32261 Applic. Date: 2003-10-10

Inventor: RAINEN LYNNE [US]; LIEBMANN-VINSON ANDRCA [US]

Title: Reconstitutable dried blood products

Applicant/Assignee:

Application No.: 10/540520   Filing Date: 24/Dec/2003

Abstract:The invention provides a process for the preparation of a dried particulate blood product the particles whereof comprise anuclear blood cells in a protective agent, said process comprising: obtaining a blood sample from a mammalian subject

adding an anticoagulant to said sample

concentrating the cells of said sample

recovering a concentrate containing anuclear blood cells from said sample

impregnating with said concentrate a particulate comprising a macromolecular protective material

drying the impregnated particulate at a temperature in the range of -20 to +120 DEG C.

and, optionally, packaging the dried particular in sealed containers.

Priority: GB20020030152 Applic. Date: 2002-12-24; WO2003GB05670 Applic. Date: 2003-12-24

Inventor: ALVES-FILHO ODILIO [NO]; BERGSLIEN OLA [NO]; BJORK PETER [NO]; EIKEVIK TRYGVE M [NO]; STROMMEN INGVALD [NO]

Title: Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same

Applicant/Assignee:

Application No.: 11/332776   Filing Date: 13/Jan/2006

Abstract:An erythrocyte sedimentation rate (ESR) measurement instrument having a Blood Collection Configuration and an ESR Measurement Configuration. The ESR measurement instrument comprises a sedimentation measurement tube having an hollow interior volume containing a predetermined quantity of blood sample diluting agent therewithin and being air/fluid sealed with respect to the ambient environment

and a blood collection tube having a hollow interior volume containing a predetermined quantity of anti-coagulant and being vacuum-sealed with respect to the ambient environment, and physically coupled to the air-sealed sedimentation measurement tube, by at least a portion of the sedimentation measurement tube being inserted within a portion of the hollow interior volume of the blood collection tube. The sedimentation measurement tube and the blood collection tube are maintained stationarily fixed relative to each other as a unitary assembly having a syringe-like form factor when the ESR measurement instrument is arranged in the Blood Collection Configuration. During this configuration, a needle-supporting connector can be connected to the blood collection tube and a sample of whole blood from a patient vacuum-drawn and injected into the blood collection tube. After the sample of anti-coagulated blood has been collected in the blood collection tube and the needle-supporting connector is disconnected therefrom, the air/fluid seal of the sedimentation measurement tube can be broken and then the sedimentation measurement tube can be manually plunged into and to the bottom of the hollow interior volume of said blood collection tube, using a single-handed operation to rearrange the ESR measurement instrument into the ESR Measurement Configuration. The anti-coagulated sample of blood fills up a substantially portion of the sedimentation measurement tube and mixes with the blood sample diluting agent to enable the blood plasma/erythrocyte cell (P/E) interface level within the sedimentation measurement tube to settle downwards toward the blood collection tube during a predetermined time period when said ESR measurement instrument is oriented in a gravity vertical position. By virtue of the present invention, the erythrocyte sedimentation rate (ESR) of the collected blood sample can be measured by determining how far the P/E interface level has moved against graduation markings formed along the length of the sedimentation measurement tube during the predetermined time period.

Priority: US2005-194056 Applic. Date: 2005-07-29; US2003-395860 Applic. Date: 2003-03-21

Inventor: BOUBOULIS DENIS [US]

Title: Control system for driving fluids through an extracorporeal blood circuit

Applicant/Assignee:

Application No.: 11/444745   Filing Date: 01/Jun/2006

Abstract:A control deck and system for controlling and driving blood fluids through an extracorporeal blood circuit kit. In one aspect, the invention is a deck having an improved mechanism for securing a cassette in place during treatment operations. The improved deck comprises catches for slidably receiving tabs of the cassette and one or more rotating clamps for locking and securing the cassette in a loaded position. In another aspect the invention is a system for controlling and driving blood fluids having infrared communication abilities to transmit and receive real time data. In still another aspect, the invention is a system for controlling and driving blood fluids having an upright tower design that reduces the footprint of the system. In this embodiment, a centrifuge chamber is positioned in an upper portion of the system while the control deck and photoactivation chamber are located in a base portion of the system.

Priority: US2003-654670 Applic. Date: 2003-09-03

Inventor: HUTCHINSON MICHAEL [US]; BRIGGS DENNIS [US]; GARA STEPHEN [US]; WATTERS TOM [US]

Title: Control system for driving fluids through an extracorporeal blood circuit

Applicant/Assignee: THERAKOS, INC

Application No.: 11/444721   Filing Date: 01/Jun/2006

Abstract:A control deck and system for controlling and driving blood fluids through an extracorporeal blood circuit kit. In one aspect, the invention is a deck having an improved mechanism for securing a cassette in place during treatment operations. The improved deck comprises catches for slidably receiving tabs of the cassette and one or more rotating clamps for locking and securing the cassette in a loaded position. In another aspect the invention is a system for controlling and driving blood fluids having infrared communication abilities to transmit and receive real time data. In still another aspect, the invention is a system for controlling and driving blood fluids having an upright tower design that reduces the footprint of the system.

In this embodiment, a centrifuge chamber is positioned in an upper portion of the system while the control deck and photoactivation chamber are located in a base portion of the system.

Priority: US2003-654670 Applic. Date: 2003-09-03

Inventor: HUTCHINSON MCHAEL [US]; BRIGGS DENNIS [US]; GARA STEPHEN [US]; WALTERS TOM [US]

Title: Centrifuge for blood processing systems

Applicant/Assignee:

Application No.: 11/102215   Filing Date: 08/Apr/2005

Abstract:Described herein is a continuous-flow centrifuge (CFC) which may be embodied in an automated system for collecting and separating whole blood into its components. The collection and separation system includes a console and a disposable set. Various blood processing procedures which produce specific blood products may be implemented by using a specific disposable set for each process. The disposable set may include a manifold, a CFC, and various components attached by tubing. These components may include one or more solution bags, blood product bags, bacterial filters, leukofilters, and a donor blood collection tube with access needle. The manifold and CFC disk may be included in a cassette that mounts onto the front panel of the console. The console may contain valve actuators, pressure transducers, ultrasonic sensors, a roller pump assembly, a CFC drive system, optical sensors, electronics, software, user interface components, a bar code reader and data acquisition components.

Priority:

Inventor: ROBINSON THOMAS C [US]; SAHINES THOMAS P [US]; D ELIA RICHARD R [US]; ZAMORA SALVADOR M [US]; LEWIS BRIAN D [US]; FERNANDEZ ROBERT K [US]; BRIONES VICTOR A [US]; NIER DAVID M [US]; MCNAMARA THOMAS N [US]

Title: Disposable set for separations of blood into its components

Applicant/Assignee: MISSION MEDICAL, INC

Application No.: 11/386441   Filing Date: 22/Mar/2006

Abstract:Described herein is a continuous-flow centrifuge (CFC) which may be embodied in an automated system for collecting and separating whole blood into its components. The collection and separation system includes a console and a disposable set. Various blood processing procedures which produce specific blood products may be implemented by using a specific disposable set for each process. The disposable set may include a manifold, a CFC, and various components attached by tubing. These components may include one or more solution bags, blood product bags, bacterial filters, leukofilters, and a donor blood collection tube with access needle. The manifold and CFC disk may be included in a cassette that mounts onto the front panel of the console. The console may contain valve actuators, pressure transducers, ultrasonic sensors, a roller pump assembly, a CFC drive system, optical sensors, electronics, software, user interface components, a bar code reader and data acquisition components.

Priority: US2005-102215 Applic. Date: 2005-04-08

Inventor: ROBINSON THOMAS C [US]; SAHINES THOMAS P [US]; D ELIA RICHARD R [US]; ZAMORA SALVADOR M [US]; LEWIS BRIAN D [US]; FERNANDEZ ROBERT K [US]; BRIONES VICTOR A [US]; NIER DAVID M [US]; MCNAMARA THOMAS N [US]

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee:

Application No.: 11/386469   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US2004-769243 Applic. Date: 2004-01-30; US2004-796243 Applic. Date: 2004-03-09; US1998-159945 Applic. Date: 1998-09-24; US20030453555P Applic. Date: 2003-03-10; US20050664328P Applic. Date: 2005-03-23; US20050727080P Applic. Date: 2005-10-14; US20050726878P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20050727196P Applic. Date: 2005-10-14; US2004-977288 Applic. Date: 2004-10-29; US2002-235572 Applic. Date: 2002-09-06; US2001-950307 Applic. Date: 2001-09-10; US1999-433001 Applic. Date: 1999-11-02

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee:

Application No.: 11/386498   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US20050727196P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20050726878P Applic. Date: 2005-10-14; US20050727080P Applic. Date: 2005-10-14; US20050664328P Applic. Date: 2005-03-23; US19970060015P Applic. Date: 1997-09-25; US20030453555P Applic. Date: 2003-03-10; US1998-159945 Applic. Date: 1998-09-24; US1999-433001 Applic. Date: 1999-11-02; US2001-950307 Applic. Date: 2001-09-10; US2002-235572 Applic. Date: 2002-09-06; US2004-977288 Applic. Date: 2004-10-29; US2004-769243 Applic. Date: 2004-01-30

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]

Title: Method for detecting procoagulant phospholipid

Applicant/Assignee: HAEMATEX RESEARCH PTY LIMITED

Application No.: 11/384258   Filing Date: 21/Mar/2006

Abstract:The present invention relates to a method for determining the amount of procoagulant phospholipid in a sample, said method comprising steps (i) to (iii) performed in the following order: (i) forming an admixture of the sample and a substrate plasma which has been rendered free or substantially free of procoagulant phospholipid sufficient to at least reduce the capacity of the substrate plasma to coagulate, wherein said substrate plasma has been rendered free or substantially free of procoagulant phospholipid by treatment with a phospholipase

(ii) contacting the admixture with a reagent for activating coagulation of plasma in conditions were procoagulant phospholipids is the rate limiting component of the mixture

and (iii) determining the clotting time of the admixture.

Priority: AU20030905172 Applic. Date: 2003-09-22; WO2004AU01291 Applic. Date: 2004-09-22

Inventor: EXNER THOMAS [AU]

Title: Device for building up muscle

Applicant/Assignee:

Application No.: 10/552991   Filing Date: 13/Oct/2005

Abstract:To provide a muscle development device wherein a sufficient pressure can be applied to every part of the limb intended to be compressed, even under the influence of muscle movements. To provide a muscle development device comprising a hollow tight fitting band 1 having a tube 5 and a wire-like piece 6 provided therein

and fastening means for use in keeping a length of the tight fitting band 1 in a loop having a desired size, the muscle development device being used to develop muscles of a limb while restricting the blood flow therethrough by means of applying, with the tight fitting band 1 being wrapped around a predetermined compressed range of the limb and the tight fitting band 1 being fastened with the fastening means to have a desired size, a predetermined pressure to the limb around which the tight fitting band 1 is wrapped, the pressure being produced by introducing air to the tube 5 . The wire-like piece 6 is designed to limit the direction towards which the tube 5 is allowed to inflate as the tube 5 is filled with air, to against the muscles as determined with the tight fitting band 1 being rest on the muscles.

Priority: JP20030110903 Applic. Date: 2003-04-15; WO2004JP05249 Applic. Date: 2004-04-13

Inventor: SATO YOSHIAKI [JP]

Title: Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation

Applicant/Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA

Application No.: 10/513491   Filing Date: 05/Nov/2004

Abstract:Formulations for neutralizing the anticoagulant action of a human tissue factor inhibitor, comprising a blood coagulation factor complex product or an activated blood coagulation factor VII product as an active ingredient

and formulations for neutralizing the blood coagulation-promoting action of an activated blood coagulation factor VII product, comprising a human tissue factor inhibitor as an active ingredient.

Priority: JP20020149494 Applic. Date: 2002-05-23; WO2003JP06469 Applic. Date: 2003-05-23

Inventor: KITAZAWA TAKEHISA [JP]; HATTORI KUNIHIRO [JP]

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee:

Application No.: 11/386587   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US2004-769243 Applic. Date: 2004-01-30; US2004-796243 Applic. Date: 2004-03-09; US2004-977288 Applic. Date: 2004-10-29; US2002-235572 Applic. Date: 2002-09-06; US2001-950307 Applic. Date: 2001-09-10; US1999-433001 Applic. Date: 1999-11-02; US1998-159945 Applic. Date: 1998-09-24; US20030453555P Applic. Date: 2003-03-10; US20050664328P Applic. Date: 2005-03-23; US20050727080P Applic. Date: 2005-10-14; US20050726878P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20050727196P Applic. Date: 2005-10-14

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]

Title: Novel compounds with high therapeutic index

Applicant/Assignee:

Application No.: 11/343557   Filing Date: 30/Jan/2006

Abstract:The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

Priority: WO2004US24901 Applic. Date: 2004-07-29; US20030491331P Applic. Date: 2003-07-29

Inventor: CHANDRAN V R [US]

Title: Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls

Applicant/Assignee: JANSSEN PHARMACEUTICA N.V

Application No.: 11/385056   Filing Date: 21/Mar/2006

Abstract:The present invention describes compounds of Formula I or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal. The present invention also relates to a novel method of N-oxidation of nitrogen containing heteroaryls.

Priority: US20050673131P Applic. Date: 2005-04-20

Inventor: KREUTTER KEVIN [US]; LU TIANBAO [US]; LEE YU K [US]; TELEHA CHRISTOPHER [US]; PLAYER MARK [US]; ZHU XIZHEN [US]

Title: Intravascular ultrasound catheter device and method for ablating atheroma

Applicant/Assignee:

Application No.: 11/134983   Filing Date: 23/May/2005

Abstract:An intravascular catheter device having a catheter and an ultrasound ablation manifold is proposed for generating cavitations and acoustic jet streams in the blood to ablate atheroma. The ablation manifold has a power transducer and a coupled leaky acoustic cavity. The leaky acoustic cavity contains a first portion of ultrasonic power emission for intra-cavity ablation while allowing a second portion of ultrasonic power emission to leak outside for an extra-cavity ablation. The power transducer and the leaky acoustic cavity are configured to form a confocal resonant cavity. An intervening bird cage is coupled to the resonant cavity for stronger resonance while maintaining ultrasound leakage. A protective shield is mounted around the waist of bird cage to strengthen resonance and to prevent damaging the intima from an otherwise normal incidence of high intensity ultrasound. A microbubble releasing device and micro pump are also included to further increase the ablation efficacy.

Priority: US2005-077942 Applic. Date: 2005-03-11

Inventor: LEE YEE-CHUN [US]; CHIO SHIU-SHIN [US]; YU QI [US]

Title: Modified tridegins, production and use thereof as transglutaminase inihibitors

Applicant/Assignee:

Application No.: 10/498752   Filing Date: 10/Feb/2005

Abstract:The invention relates to modified tridegins, polypeptides derived from SEQ ID No. 1, in which the modification is replacement of a cysteine residue and/or one of the following amino acids-Lys2, Lys7, His10, Gly12, Leu24, Tyr31, Phe34, Arg39, Ile45, Met48, Asp50, Pro55, Phe58, Asn60, Pro65, Arg66, by another amino acid and/or N- or C-terminal deletion, whereby the remaining polypeptide comprises at least the amino acid sequence DDIYQRXVXFPXLPL (SEQ ID NO.89) and/or a covalent bonding to polyethylene glycol. Said polypeptides are novel inhibitors of transglutaminases, in particular of Factor XIIIa, of the terminal enzymes in the blood coagulation cascade. The invention further relates to methods for production of said inhibitors and the use thereof as transglutaminase inhibitors.

Priority: DE20011063333 Applic. Date: 2001-12-21; DE20021058159 Applic. Date: 2002-12-12; WO2002EP14684 Applic. Date: 2002-12-20

Inventor: GIERSIEFEN HELMUT [DE]; STOCKEL JOHANNES [DE]; PAMP TANJA [DE]; OHLMANN MARION [DE]

Title: Diamine derivatives

Applicant/Assignee: DAIICHI PHARMACEUTICAL CO., LTD

Application No.: 10/540259   Filing Date: 25/Dec/2003

Abstract:A compound represented by formula (1): Q<1>-Q<2>-T-N(R<1>)-Q<3>-N(R<2>)-T<1>-Q<4> ( 1 ) [wherein R<1 >and R<2 >are hydrogen atoms or the like

Q<1 >is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like

Q<2 >is a single bond or the like

Q<3 >represents the following group: (wherein Q<5 >is an alkylene group having 1 to 8 carbon atoms, or the like)

and T<0 >and T<1 >are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof.

The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Priority: JP20020373787 Applic. Date: 2002-12-25; JP20030379163 Applic. Date: 2003-11-07; WO2003JP16783 Applic. Date: 2003-12-25

Inventor: OHTA TOSHIHARU [JP]; KOMORIYA SATOSHI [JP]; YOSHINO TOSHIHARU [JP]; UOTO KOUICHI [JP]; NAKAMOTO YUMI [JP]; NAITO HIROYUKI [JP]; MOCHIZUKI AKIYOSHI [JP]; KANNO HIDEYUKI [JP]; HAGINOYA NORIYASU [JP]; YOSHIKAWA KENJI [JP]; NAGAMOCHI MASATOSHI [JP]; KOBAYASHI SYOZO [JP]; ONO MAKOTO [JP]

Title: Diagnostic whole blood and plasma apparatus

Applicant/Assignee: CHROMEDX INC

Application No.: 11/432616   Filing Date: 12/May/2006

Abstract:Some embodiments of the invention provide an apparatus suitable for measuring at least one plasma analyte in plasma extracted from a whole blood sample within the apparatus. The apparatus is adapted for insertion into a slot in a meter, which can preferably perform at least spectroscopic or biosensor measurement. The apparatus comprises a whole blood flow path, which begins at the inlet opening of the apparatus, and terminates at a vent or a suction chamber. Included in the blood flow path is a flow-through filtration chamber. The apparatus further comprises a plasma flow path, which begins at the filtration chamber, and terminates at a vent or a suction chamber. The plasma flow path includes a plasma analyte signal providing means. The signal is transmitted to a processor in the meter for preparing analyte measurements.

Priority: CA20052507323 Applic. Date: 2005-05-13

Inventor: SAMSOONDAR JAMES [CA]

Title: Detection and measurement of hematological parameters characterizing cellular blood components

Applicant/Assignee:

Application No.: 11/125937   Filing Date: 10/May/2005

Abstract:Systems and methods for the diagnostic analysis of blood samples. The present invention uses sensor technology useful in the analysis of headspace sample from blood to provide an efficient and accurate means for identifying the presence of a volatile marker associated with hematological diseases or conditions. In a preferred embodiment, the sensor technology of the present invention includes detecting means such as RNA oligonucleotide chains or aptamers.

Priority:

Inventor: BJORAKER DAVID G [US]; MELKER RICHARD J [US]; DENNIS DONN M [US]

Title: Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibdies and other binding agents

Applicant/Assignee:

Application No.: 10/525610   Filing Date: 20/Aug/2003

Abstract:The invention relates to thrombospondin fragments found in plasma, their use or use of portions thereof in diagnostic methods, as method calibrators, method indicators, and as immunogens, and as analytes for methods with substantial clinical utility

and their detection in plasma or other bodily fluids for purpose of diagnostic methods, especially for cancer.

Priority: US2003-419462 Applic. Date: 2003-04-21; US20020405495P Applic. Date: 2002-08-23; WO2003US26023 Applic. Date: 2003-08-20

Inventor: WILLIAMS KEVIN J [US]

Title: Methods to measure immunosuppressive tacrolimus, sirolimus, and cyclosporin a complexes in a blood sample

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 11/398997   Filing Date: 06/Apr/2006

Abstract:The present invention provides methods, diagnostic assays, and diagnostic kits based on said methods, to determine levels of immunosuppressive complexes containing immunosuppressive drugs tacrolimus, sirolimus and cyclosporine A separately and in combination, formed in the blood of a drug-treated patient or in a patient candidate to immunosuppressive drug therapy. These methods, assays and kits are especially useful when using automated systems.

Priority: US20050668714P Applic. Date: 2005-04-06

Inventor: DRENGLER SUSAN M [US]; BAUGHER BENNETT W [US]

Title: Methods and systems for delivering substances into luminal walls

Applicant/Assignee: ANGIOSCORE, INC

Application No.: 11/411635   Filing Date: 26/Apr/2006

Abstract:Angioplasty and other dilatation devices are provided with scoring elements which incorporate a drug to be delivered to a body lumen, typically a blood vessel. The scoring elements have drugs and other active substances coated over a portion thereof or incorporated within internal structure of the element so that the drug is released into the luminal wall closely associated diseased regions of the body lumen as the scoring structure is radially expanded into the wall.

Priority: US20050680450P Applic. Date: 2005-05-11

Inventor: KONSTANTINO EITAN [US]; KONSTANTINO MICHAL [US]

Title: Porous spun polymeric structures and method of making same

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 11/496187   Filing Date: 31/Jul/2006

Abstract:A non-woven polymeric matrix for separating leukocytes from a blood sample includes a non-woven three dimensional matrix formed from polymeric fibers having a predetermined pore volume fraction including a defined channel configuration, a predetermined pore size in the range of from about 10 mum to about 250 mum, and a plurality of connections between the plurality of fibers. The matrix is configured so as to remove at least about 98% of leukocytes from at least one unit of packed red blood cells. Methods of making and using the matrix are also provided.

Priority: US2002-331213 Applic. Date: 2002-12-30

Inventor: DAO KINH-LUAN LENNY D [US]; CHIN YEM [US]; ZHONG SHENG-PING SAMUEL [US]; MOHAN KSHITIJ [US]; VU LIEM [US]

Title: Drug-eluting stent cover and method of use

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 11/497652   Filing Date: 01/Aug/2006

Abstract:An intravascular stent includes an eluting sheath fabricated from a mesh for controlled release of therapeutic drugs and for delivery of the therapeutic drugs in localized drug therapy in a blood vessel. The eluting sheath is attached to at least a portion of an outside surface area of the stent structure and is fabricated from a mesh designed to neck down in response to a radially outward directed force resulting in the uniform expansion of the stent. The eluting sheath can be loaded with at least one therapeutic drug for the release thereof at a treatment site to facilitate repair of a damaged vessel. The stent has a high degree of flexibility in the longitudinal direction, yet has adequate vessel wall coverage and radial strength sufficient to hold open an artery or other body lumen.

Priority: US2002-334034 Applic. Date: 2002-12-30

Inventor: YIP PHILIP S [US]; JACOBS JAMES [US]; HOSSAINY SYED [US]; BECKER JON [US]; LIMON TIMOTHY A [US]

Title: Vascular prosthesis

Applicant/Assignee: UNIVERSITY OF SOUTH FLORIDA

Application No.: 10/561929   Filing Date: 28/Jun/2004

Abstract:The subject invention concerns vascular prosthetic devices and methods for ascending aorta and/or valve replacement in humans and animals. In one embodiment, a device of the invention includes a vessel-like structure having a first end adapted for surgical attachment to a left ventricle, a second end adapted for surgical attachment to an aorta, and, interposed between the first and second ends, a sinus portion configured in the shape of the sinuses of Valsalva in a human aortic valve.

Priority: US20030483035P Applic. Date: 2003-06-27; WO2004US21046 Applic. Date: 2004-06-28

Inventor: KNIGHT JOSEPH A [US]

Title: PLASMA-DEPLETED, NON-RED BLOOD CELL-DEPLETED CORD BLOOD COMPOSITIONS AND METHODS OF USE

Applicant/Assignee: STEMCYTE, INC

Application No.: 11/422017   Filing Date: 02/Jun/2006

Abstract:The umbilical cord blood (UCB) compositions of the present invention possess the unique features of having plasma that is substantially depleted from the UCB unit and red blood cells (RBC) that are not depleted from the UCB unit. Such UCB units can be prepared by a process that combines plasma depletion with cryopreservation, selection, thawing, and/or transplantation of hematopoietic stem cells to provide superior clinical outcome by maximizing post-processing cell recovery and post-thaw infusion cell dose. Methods for treating a wide variety of malignant diseases and benign diseases associated with the hematopoietic system by administering the UCB compositions of the present invention are also provided.

Priority: US2003-367339 Applic. Date: 2003-02-13; US20050733956P Applic. Date: 2005-11-03; US20050687127P Applic. Date: 2005-06-02; US20020357308P Applic. Date: 2002-02-14

Inventor: CHOW ROBERT [US]

Title: Microcapsules with modified release of active principles with low solubility for oral delivery

Applicant/Assignee:

Application No.: 10/522234   Filing Date: 28/Jul/2003

Abstract:The invention concerns microcapsules for reliably modified release and adapted to industrial reproduction of an active principle hardly water-soluble, other than anti-hyperglycemia agents Each of said microcapsules comprises a core of hardly soluble active principle and a coating film applied on the core. Their mean diameter is less than 1000 microns. The coating film contains a film-forming polymer (P1) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA). Said coating film represents at least 4% p/p of dry mraner of their total weight. and its components P1, P2. PL satisfy the following characteristics: dry weight mass fraction of PI relative to the total coating weight ranging between 40 and 90%

dry matter weight fraction of PL/P1+P2 ranging between 15 and 60%: dry matter weight fraction of PL/P1+P2 ranging between 1 and 30%. The invention also concerns the uses of said microcapsules in galenic formulation.

Priority: FR20020009530 Applic. Date: 2002-07-26; WO2003FR02384 Applic. Date: 2003-07-28

Inventor: GUIMBERTEAU FLORENCE [FR]; CASTAN CATHERINE [FR]; MEYRUEIX REMI [FR]; SOULA GERARD [FR]

Title: Vascular puncture sealing method, apparatus, and system

Applicant/Assignee:

Application No.: 11/354225   Filing Date: 13/Feb/2006

Abstract:Some embodiments of the invention provide a guidewire directed vascular sealing device for securing hemostasis within a vascular puncture and puncture tract extending from the epidermis into a blood vessel in a living being. In some instances, the puncture tract is created by a percutaneous access apparatus used in the performance of medical catheter based diagnostic and therapeutic techniques. In some embodiments, the apparatus includes a hemostatic compound or material designed to facilitate clot formation within the tract.

Priority: US20050688510P Applic. Date: 2005-06-07; US20050693706P Applic. Date: 2005-06-24; US20050723878P Applic. Date: 2005-10-05

Inventor: WENSEL JEFFREY P [US]; BERGIN PATRICK J [US]

Title: PRESSURE MEASURING LINE, PARTICULARLY FOR INVASIVE BLOOD PRESSURE MEASUREMENT

Applicant/Assignee: SMITHS MEDICAL DEUTSCHLAND GMBH

Application No.: 11/423858   Filing Date: 13/Jun/2006

Abstract:The invention relates to a pressure measuring line, particularly for invasive blood pressure measurement, which presents a wall made of a flexible material, which surrounds a passageway. The wall consists particularly of at least one inner hose and an outer hose enveloping the former, where the material of the inner hose is harder than the material of the outer hose, and the wall thickness of the inner hose is less than the wall thickness of the outer hose. The inner side of the outer hose is in full-surface contact with the outer side of the inner hose.

Priority: DE200520009293U Applic. Date: 2005-06-13

Inventor: WEBER JORG [DE]; BECK BERND [DE]

Title: Apparatus and method for separating and concentrating fluids containing multiple components

Applicant/Assignee:

Application No.: 11/442631   Filing Date: 26/May/2006

Abstract:An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.

Priority: US2004-932882 Applic. Date: 2004-09-02; US2003-445381 Applic. Date: 2003-05-23; US20020383013P Applic. Date: 2002-05-24

Inventor: WOODELL-MAY JENNIFER E [US]

Title: Intravascular diagnostic and therapeutic sampling device

Applicant/Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY

Application No.: 11/450862   Filing Date: 08/Jun/2006

Abstract:A device and methods for continuous precision blood sampling from a patient with a micro impedance pump as the driver in a microfluidic system. Depending on the needs of medical technologies, the micro impedance pump in the intravascular diagnostic and therapeutic sampling system serves in a forward pumping function for blood sampling, in a backward infusing for therapeutic treatment, and in a valving function for controlling fluid flow.

Priority: US20050688436P Applic. Date: 2005-06-08

Inventor: GHARIB MORTEZA [US]; RINDERKNECHT DEREK [US]; PETRASEK DANNY [US]

Title: Meniscal repair device and method

Applicant/Assignee:

Application No.: 11/151615   Filing Date: 13/Jun/2005

Abstract:Methods and apparatus for treating meniscal tissue damage are disclosed, including a biocompatible meniscal repair device comprising a stent. The tissue repair device is adapted to be placed in contact with a defect in the meniscus and can preferably provide a structure for supporting meniscal tissue and/or encouraging tissue growth through contact with vascularized portions of the meniscus or as a conduit for introduction of exogenous healing therapies.

Priority:

Inventor: HWANG JULIA [US]; KLADAKIS STEPHANIE [US]; KADIYALA SUDHAKAR [US]; BOWMAN STEVEN [US]

Title: Specific time-delayed burst profile delivery system

Applicant/Assignee: DEXCEL PHARMA TECHNOLOGIES, LTD

Application No.: 11/147388   Filing Date: 08/Jun/2005

Abstract:The invention provides a delivery device for the delayed release of an active agent in the gastrointestinal tract comprising a core, comprising an active agent

a first outer coating, comprising a relatively hydrophobic substantially water insoluble polymer having substantially water insoluble hydrophilic particles embedded therein

and a first inner coating layer, comprising an agent that can cause the dissolution of at least one of the water insoluble components of the outer coating, and optionally a water soluble polymer, such that the insoluble particles in the outer coating, upon absorption of liquid, form channels leading to the inner coating layer, thus enabling the dissolution thereof, whereby the agents contained therein are released to cause the dissolution and/or degradation (destruction) of the outer coating, and the release of the pharmaceutically acceptable active agent from the core of the device.

Priority:

Inventor: PENHASI ADEL [IL]; GOMBERG MILA [IL]; GOMBERG MAXIM [IL]

Title: Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation

Applicant/Assignee:

Application No.: 11/440749   Filing Date: 24/May/2006

Abstract:Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity obtained by a process comprising the preparation of the K5 polysaccharide from Escherichia coli, N-deacetilation/N-sulfation, C-5 epimerization, supersulfation, selective O-desulfation, selective 6-O sulfation and N-sulfation, wherein said epimerization is carried out using the glucuronosyl C-5 epimerase enzyme in solution or in immobilized form in presence of specific divalent cations.

Priority: IT2000MI00665 Applic. Date: 2000-03-30; US2002-240606 Applic. Date: 2002-12-21; WO2001EP03461 Applic. Date: 2001-03-27

Inventor: ZOPPETTI GIORGIO [IT]; ORESTE PASQUA [IT]; CIPOLLETTI GIOVANNI [IT]

Title: Systems for gel-based medical implants

Applicant/Assignee:

Application No.: 10/587580   Filing Date: 28/Jul/2006

Abstract:Systems, including methods and apparatus, for medical implants including a gel.

Priority: US20030529470P Applic. Date: 2003-12-15; US20030529479P Applic. Date: 2003-12-15; US20030529489P Applic. Date: 2003-12-15; US20030529534P Applic. Date: 2003-12-15; WO2004US42474 Applic. Date: 2004-12-15

Inventor: CAMPBELL TODD D [US]

Title: METHOD FOR MONITORING COAGULABILITY AND HYPERCOAGULABLE STATES

Applicant/Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION

Application No.: 10/028741   Filing Date: 20/Dec/2001

Abstract:The assay of soluble endothelial protein C receptor (sEPCR) is useful to monitor effective thrombin levels and a hypercoagulable state. An assay for sEPCR is therefore useful to monitor ongoing effectiveness of anticoagulant therapy. A sEPCR ELISA assay is particularly useful for this purpose. A state of hypercoagulability in patients or normal individuals can also be identified by such an assay.

Priority: US20010270066P Applic. Date: 2001-02-20

Inventor: KUROSAWA SHINICHIRO [US]; STEARNS-KUROSAWA DEBORAH J [US]

Title: L-Threonine derivatives of high therapeutic index

Applicant/Assignee: SIGNATURE R&D HOLDINGS, LLC

Application No.: 11/442027   Filing Date: 26/May/2006

Abstract:The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the derivatives of the present invention enhance at least one or more therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

Priority: US2006-343557 Applic. Date: 2006-01-30; WO2004US24901 Applic. Date: 2004-07-29; US20030491331P Applic. Date: 2003-07-29

Inventor: CHANDRAN V R [US]

Title: Pyrazinedicarboxamides and their use

Applicant/Assignee: BAYER HEALTHCARE AG

Application No.: 11/299342   Filing Date: 08/Dec/2005

Abstract:The present invention relates to novel pyridinedicarboxamides, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.

Priority: DE200410059219 Applic. Date: 2004-12-09

Inventor: ROHRIG SUSANNE [DE]; JESKE MARIO [DE]; AKBABA METIN [DE]; ROSENTRETER ULRICH [DE]; BOYER STEPHEN [US]; FISCHER KARIN [DE]; POHLMANN JENS [CH]; TUCH AROUNARITH [FR]; PERZBORN ELISABETH [DE]; GERDES CHRISTOPH [DE]; SCHLEMMER KARL-HEINZ [DE]; BURKHARDT NILS [DE]; ALLERHEILIGEN SWEN [DE]; NELL PETER [DE]; ARNDT SABINE [DE]; LOBELL MARIO [DE]

Title: Blood component collection apparatus and method

Applicant/Assignee: TERUMO KABUSHIKI KAISHA

Application No.: 11/453840   Filing Date: 16/Jun/2006

Abstract:A blood component collection apparatus comprises a blood component collecting circuit which includes an anticoagulant line for feeding an anticoagulant and a line for collecting an initial flow of collected blood. In the blood component collection apparatus, air is intermediately present between the anticoagulant and the blood in the passage of a blood collection needle side line, after a priming operation is performed in which anticoagulant is supplied from the anticoagulant line toward the side of a centrifugal separator in the blood collection needle side line through a branch connector and after an initial flow collecting operation is performed in which the initial flow of blood is collected.

Priority: JP20050178316 Applic. Date: 2005-06-17

Inventor: HIRABUKI MAKOTO [JP]

Title: Drug-eluting stent and methods of making the same

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 11/510431   Filing Date: 25/Aug/2006

Abstract:An intravascular stent having a prefabricated, patterned polymeric sleeve for controlled release of therapeutic drugs and for delivery of the therapeutic drugs in localized drug therapy in a blood vessel is disclosed. The polymeric sleeve is attached to at least a portion of an outside surface area of the stent structure. Alternatively, a plurality of individual microfilament strands are longitudinally attached to an outer surface of a stent structure in a spaced apart orientation and loaded with at least one therapeutic drug for the release thereof at a treatment site. The stent has a high degree of flexibility in the longitudinal direction, yet has adequate vessel wall coverage and radial strength sufficient to hold open an artery or other body lumen. Methods for making the same are also disclosed.

Priority: US2002-293108 Applic. Date: 2002-11-13

Inventor: RAO K T V [US]

Title: Method of making selective organ cooling catheter

Applicant/Assignee:

Application No.: 11/389879   Filing Date: 27/Mar/2006

Abstract:A heat transfer device has first and second elongated, articulated segments, each having a turbulence-inducing exterior surface. A flexible joint connects the first and second elongated, articulated segments. An inner coaxial lumen is disposed within the first and second elongated, articulated segments. The inner coaxial lumen is capable of transporting a pressurized working fluid to a distal end of the first elongated, articulated segment.

Priority: US2003-749140 Applic. Date: 2003-12-29; US2001-836585 Applic. Date: 2001-04-16; US2000-566531 Applic. Date: 2000-05-08; US1998-103342 Applic. Date: 1998-06-23

Inventor: DOBAK JOHN D III [US]; LASHERAS JUAN C [US]

Title: Imidazole derivative, process for producing the same, and use

Applicant/Assignee:

Application No.: 10/535268   Filing Date: 20/Nov/2003

Abstract:There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents -CO-, -S(O)-, -S(O)2- or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z<1 >and Z<3 >independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z<2 >represents -N(R<1>)-, -O-, -S(O)-, -S(O)2-, -CO-, -CH(R<1>)- or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R<1 >to form an optionally substituted ring, and a represents 0, 1 or 2.

Priority: JP20020338939 Applic. Date: 2002-11-22; WO2003JP14793 Applic. Date: 2003-11-20

Inventor: KUBO KEIJI [JP]; KUROITA TAKANOBU [JP]; IMAEDA YASUHIRO [JP]; KAWAMURA MASAKI [JP]

Title: Central nervous system cooling catheter

Applicant/Assignee:

Application No.: 11/418849   Filing Date: 05/May/2006

Abstract:The invention provides a method and apparatus for performing selective hypothermia to the brain and spinal cord for injury protection without the need for systemic cooling. A flexible catheter is inserted into the cerebral lateral ventricle or spinal subdural space. The catheter has lumens with a heat transfer element. The lumens of the catheter circulate a coolant and communicate at the distal heat transfer element for transfer of heat from the cerebrospinal fluid. Furthermore a method of maintaining catheter patency and providing blood clot hemolysis and drainage is also provided through the use of ultrasonic and/or laser energy delivered through the catheter.

Priority: US2002-136003 Applic. Date: 2002-04-29

Inventor: KHANNA ROHIT [US]

Title: Topical/on-the-skin estrogen cream, lotion, ointment, hair tonic, shampoo and wound healing powder

Applicant/Assignee:

Application No.: 11/475797   Filing Date: 27/Jun/2006

Abstract:The Claimed Invention is the topical-to-skin use of generic estradiol, estriol, conjugated estrogens, or any other synthetic estrogen within a non-absorbable generic vehicle of cream, lotion, ointment, shampoo, hair tonic, and wound-healing powder, having no absorbents or deconstructors in their formulas. This invention causes skin basal cells to produce increased quantities of collagen and to retain skin-water resulting in increased skin-thickness. This increased thickness results in improved resilience, resistance to injury, trauma and infection. The target of this invention is the skin and skin only. Specifically, there is no intended absorption of hormone into the circulation to result in side effects or risk. Any possible unintended and minimal quantity of hormone absorbed would be metabolized normally by the liver and excreted in the urine without risk or awareness to the user. Improving skin health and healing existing injuries/disease can save individuals from mid 30's and older, and society in general millions of dollars annually in skin-related health care costs.

Priority: US20050595451P Applic. Date: 2005-07-06

Inventor: JUNG KIN [US]

Title: Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer

Applicant/Assignee:

Application No.: 11/416470   Filing Date: 02/May/2006

Abstract:This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

Priority: WO1997US03479 Applic. Date: 1997-03-14; US2004-912367 Applic. Date: 2004-07-23; US2001-013294 Applic. Date: 2001-12-10; US2001-013868 Applic. Date: 2001-10-30; US1998-155152 Applic. Date: 1998-09-22

Inventor: KOPRESKI MICHAEL S [US]

Title: Thiazoline derivative and use of the same

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 10/574048   Filing Date: 12/May/2006

Abstract:A thiazoline derivative represented by Formula (I): wherein R is a cyclic hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted

X is a bond or a divalent chain hydrocarbon group which may be substituted

X' is a bond or -N(R<5>)-

Y is a divalent hydrocarbon group which may be substituted

Y' is a bond or -C(-O)-

ring A is a nitrogen-containing heterocycle which may be substituted

Z<1 >and Z<3 >are each independently a bond or a divalent chain hydrocarbon group which may be substituted

Z<2 >is a bond or -N(R<6>)-

and B is a group represented by the formula: which is useful as a therapeutic drug for thrombosis, is provided.

Priority: JP20030341430 Applic. Date: 2003-09-30; WO2004JP14685 Applic. Date: 2004-09-29

Inventor: KUBO KEIJI [JP]; KUROITA TAKANOBU [JP]; KAWAMURA MASAKI [JP]; SAKAMOTO HIROKI [JP]

Title: Compositions and methods for treating a damaged cardiovascular element

Applicant/Assignee:

Application No.: 11/443594   Filing Date: 31/May/2006

Abstract:In the present invention, the applicants describe methods and compositions of treating damaged cardiovascular elements and cardiovascular conditions including hypotension, atherosclerotic lesions, vulnerable plaque, and acute myocardial infarct. The applicants demonstrate the ability of a biomembrane sealing agent to accumulate on the walls of damaged blood vessels and help improving mean arterial pressure following tissue injury. The applicants describe the use of formulations comprising at least one biomembrane sealing agent and one bioactive agent for prophylactic treatment such as they could be administered concurrently to an invasive therapeutic intervention or after the insult (i.e. post-injury or post-surgery). Alternatively, these methods and compositions could be used to reduce the severity of cardiovascular diseases after onset.

Priority: US20050685831P Applic. Date: 2005-05-31

Inventor: ROY JOSEE [US]; AYALA HEZI-YAMIT [US]; SULLIVAN CAROL [US]; CHEN MINGFEI [US]

Title: Hydroxylated nebivolol metabolites

Applicant/Assignee:

Application No.: 11/342497   Filing Date: 30/Jan/2006

Abstract:Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6'difluoro-, 4-hydroxy-5-phenol-6,6'difluoro-, and 4-hydroxy-8-pheno-6,6'difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

Priority: US20050648551P Applic. Date: 2005-01-31; US20060755856P Applic. Date: 2006-01-03

Inventor: O'DONNELL JOHN P [US]; OWENS WALTER [US]; DUNCAN JOSEPH [US]; SHAW ANDREW [US]; WU JINN [US]

Title: Glucuronidated nebivolol metabolites

Applicant/Assignee:

Application No.: 11/342889   Filing Date: 30/Jan/2006

Abstract:This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol and/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also provides methods of treating and/or preventing vascular diseases, by administering at least one glucuronidated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one glucuronidated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

Priority: US20050648552P Applic. Date: 2005-01-31; US20060755755P Applic. Date: 2006-01-03

Inventor: O'DONNELL JOHN P [US]; OWENS WALTER [US]; DUNCAN JOSEPH [US]; SHAW ANDREW [US]

Title: PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS

Applicant/Assignee: GENENTECH, INC

Application No.: 11/533305   Filing Date: 19/Sep/2006

Abstract:A solution is provided comprising about 0.01-0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline. Such solution is useful for delivery from a catheter and for treating a thrombotic disorder by exposing fibrin-rich fluid from the disorder to an effective amount thereof, as well as in kits. In a preferred embodiment, peripheral thrombosis is treated in a mammal comprising delivering to the mammal via a catheter an effective amount of this solution.

Priority: US2003-697142 Applic. Date: 2003-10-30; US20020426616P Applic. Date: 2002-11-14

Inventor: SEMBA CHARLES P [US]

Title: Implantable device for vital signs monitoring

Applicant/Assignee:

Application No.: 11/181969   Filing Date: 15/Jul/2005

Abstract:An implantable medical device is provided for subcutaneous implantation within a human being. The implantable medical device includes a pair of electrodes for sensing electrical signals from the human being's heart. Electronic circuitry having digital memory is provided with the electronic circuitry designed to record the electrical signals from the heart. The electronics of the electronic circuitry are housed in a case having a tapered shape to facilitate implantation and removal of the implantable medical device.

Priority:

Inventor: FISCHELL DAVID R [US]; FISCHELL TIM A [US]; HARWOOD JONATHAN [US]; JOHNSON STEVEN R [US]; TURI GREGG [US]

Title: Methods for the storage and deglycerolization of red blood cells

Applicant/Assignee: MISSION MEDICAL, INC

Application No.: 11/187521   Filing Date: 22/Jul/2005

Abstract:The present invention relates to improved methods for the anticoagulation of whole blood and the subsequent refrigerated storage of red blood cells and to improved methods for removing glycerol from frozen-thawed red blood cells.

Priority:

Inventor: MERYMAN HAROLD T [US]; HOGMAN CLAES F [SE]

Title: Stabilised compositions of Factor VII

Applicant/Assignee: NOVO NORDISK HEALTHCARE A/G

Application No.: 11/450783   Filing Date: 09/Jun/2006

Abstract:The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.

Priority: DK20030001901 Applic. Date: 2003-12-19; WO2004EP53587 Applic. Date: 2004-12-17

Inventor: HANSEN BIRTHE L [DK]; JENSEN MICHAEL B [DK]; KORNFELT TROELS [DK]

Title: Selective resonance of bodily agents

Applicant/Assignee: SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE

Application No.: 11/441786   Filing Date: 26/May/2006

Abstract:Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs.

Priority: US2005-186633 Applic. Date: 2005-07-21

Inventor: ISHIKAWA MURIEL Y [US]; JUNG EDWARD K [US]; LEUTHARDT ERIC C [US]; MYHRVOLD NATHAN P [US]; WOOD LOWELL L JR [US]

Title: Analyte sensor

Applicant/Assignee:

Application No.: 11/503367   Filing Date: 10/Aug/2006

Abstract:Biointerface membranes are provided which can be utilized with implantable devices, such as devices for the detection of analyte concentrations in a biological sample. More particularly, methods for monitoring glucose levels in a biological fluid sample using an implantable analyte detection device incorporating such membranes are provided.

Priority: US2006-439630 Applic. Date: 2006-05-23; US2005-077715 Applic. Date: 2005-03-10; US20040587787P Applic. Date: 2004-07-13; US20040587800P Applic. Date: 2004-07-13; US20040614683P Applic. Date: 2004-09-30; US20040614764P Applic. Date: 2004-09-30; US20050683923P Applic. Date: 2005-05-23

Inventor: BRAUKER JAMES H [US]; BOOCK ROBERT [US]; RIXMAN MONICA [US]; SIMPSON PETER C [US]; BRISTER MARK [US]

Title: Biological artificial blood vessel and method of making

Applicant/Assignee:

Application No.: 11/494817   Filing Date: 28/Jul/2006

Abstract:A prosthetic device for implantation into a human body is made by a method that includes the steps of providing a natural animal tissue that has a substrate, crosslinking and fixing the substrate, minimizing the antigens from the substrate, tanning the substrate to improve its mechanical properties, and coupling an anticoagulant to an inner surface of the substrate to form an anticoagulant surface layer.

Priority: CN20051036175 Applic. Date: 2005-07-29

Inventor: XU GUO-FENG [CN]

Title: Multiple laminar flow-based particle and cellular separation with laser steering

Applicant/Assignee: ARRYX, INC

Application No.: 11/543773   Filing Date: 06/Oct/2006

Abstract:The invention provides a method, apparatus and system for separating blood and other types of cellular components, and can be combined with holographic optical trapping manipulation or other forms of optical tweezing. One of the exemplary methods includes providing a first flow having a plurality of blood components

providing a second flow

contacting the first flow with the second flow to provide a first separation region

and differentially sedimenting a first blood cellular component of the plurality of blood components into the second flow while concurrently maintaining a second blood cellular component of the plurality of blood components in the first flow. The second flow having the first blood cellular component is then differentially removed from the first flow having the second blood cellular component.

Holographic optical traps may also be utilized in conjunction with the various flows to move selected components from one flow to another, as part of or in addition to a separation stage.

Priority: US2004-934597 Applic. Date: 2004-09-03; US2004-867328 Applic. Date: 2004-06-13; US20040571141P Applic. Date: 2004-05-14; US20030499957P Applic. Date: 2003-09-04; US20030511458P Applic. Date: 2003-10-15

Inventor: MUETH DANIEL [US]; PLEWA JOSEPH [US]; SHIREMAN JESSICA [US]; ANDERSON AMY [US]; GRUBER LEWIS [US]; ROSENBAUM NEIL H [US]

Title: Stimulators of Factor X activated (FXa) as new topical antihemorrhagic agents

Applicant/Assignee: THROMBOTARGETS CORPORATION

Application No.: 11/498590   Filing Date: 03/Aug/2006

Abstract:The activated coagulation Factor X (FXa) stimulating agents may be used in the treatment of hemorrhages in a subject. Compounds and combinations are described which are particularly useful for the topical treatment of hemorrhaging in healthy subjects or in patients with hemorrhagic diathesis.

Priority: EP20050380179 Applic. Date: 2005-08-03; US20050719643P Applic. Date: 2005-09-21

Inventor: EGEA JAVIER P [ES]; CATASUS LUIS C [US]

Title: Tissue graft composition comprising autologous bone marrow and purified autologous thrombin

Applicant/Assignee:

Application No.: 11/200535   Filing Date: 09/Aug/2005

Abstract:A method for the preparation of an autologous tissue graft composition is disclosed. Bone marrow is harvested from the patient. In one embodiment, the nucleated cells of the bone marrow are subsequently concentrated. Autologous thrombin is purified from a volume of whole blood also taken from the patient. The bone marrow aspirate or bone marrow concentrate is then combined with the purified autologous thrombin to form a coagulated tissue graft material that may be used alone or in conjunction with other graft materials.

Priority:

Inventor: KEVY SHERWIN [US]; JACOBSON MAY [US]; ELLSWORTH JAMES [US]; BENOIT KEVIN [US]

Title: Composition and method for the repair and regeneration of cartilage and other tissues

Applicant/Assignee:

Application No.: 11/584870   Filing Date: 23/Oct/2006

Abstract:The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention.

Priority: US2005-031325 Applic. Date: 2005-01-07; US2001-896912 Applic. Date: 2001-06-29; US20000214717P Applic. Date: 2000-06-29

Inventor: HOEMANN CAROLINE D [CA]; BUSCHMANN MICHAEL D [CA]; MCKEE MARC D [CA]

Title: Inhibition of platelet activation, aggregation and/or adhesion by hypothermia

Applicant/Assignee: RADIANT MEDICAL, INC ZOLL CIRCULATION, INC

Application No.: 11/501442   Filing Date: 08/Aug/2006

Abstract:A method for treating acute coronary syndromes (i.e., unstable angina or non-Q-wave MI) or transient ischemic attacks in a human or animal patient by placing a heat exchange apparatus in the patient's vasculature and using that heat exchange apparatus to cool the patient to a temperature (e.g. 30-36 DEG C.) at which platelet inhibition (i.e., inhibition of platelet activation and/or aggregation and/or adhesion) occurs. Anti-shivering drugs or anesthesia may be administered to patients whose body temperature is cooled below that patient's shivering threshold (typically approximately 35.5 C).

If it is determined that platelet inhibition is no longer desirable, such as when the patient is about to undergo a surgical or interventional procedure wherein bleeding could be problematic, the hypothermia-induced platelet inhibition may be rapidly reversed by using the intravascular heat exchange apparatus to re-warm the patient's body to normothermia or near normothermia.

Priority: US2003-408617 Applic. Date: 2003-04-07; US2001-790249 Applic. Date: 2001-02-21

Inventor: DAE MICHAEL W [US]; MACHOLD TIMOTHY R [US]; KELLER WADE A [US]

Title: Nanoparticulate benidipine compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LIMITED

Application No.: 11/446589   Filing Date: 05/Jun/2006

Abstract:The present invention relates to nanoparticulate benidipine compositions having improved bioavailability. The compositions comprise benidipine particles having an effective average particle size of less than about 2000 nm and may be useful in the prevention and treatment of hypertension, renal parenchymal hypertension and angina pectoris.

Priority: US20050687145P Applic. Date: 2005-06-03

Inventor: LIVERSIDGE GARY G [US]; JENKINS SCOTT [US]

Title: Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity

Applicant/Assignee:

Application No.: 11/589371   Filing Date: 30/Oct/2006

Abstract:Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Three examples of such recombinant APC mutants are KKK191-193AAA-APC, RR229/230AA-APC, and RR229/230AA plus KKK191-193AAA-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of APC's anticoagulant activity. These subjects include patients at risk of damage to blood vessels or tissue in various organs caused, at least in part, by apoptosis. At risk patients include, for example, those suffering (severe) sepsis, ischemia/reperfusion injury, ischemic stroke, acute myocardial infarction, acute or chronic neurodegenerative diseases, or those undergoing organ transplantation or chemotherapy, among other conditions. Methods of screening for variants of recombinant protein C or APC that are useful in accordance with the invention are also provided.

Priority: US2004-886766 Applic. Date: 2004-07-08; US20030485792P Applic. Date: 2003-07-08

Inventor: GRIFFIN JOHN H [US]; MOSNIER LAURENT O [US]; GALE ANDREW J [US]

Title: Cord blood and placenta collection kit

Applicant/Assignee:

Application No.: 11/589018   Filing Date: 27/Oct/2006

Abstract:The present invention provides an improved kit for the collection of umbilical cord blood and placental blood, and collection of the placenta from which such blood is obtained. The kit improves upon existing kits in that it provides for improved user convenience, provides for the collection of the placenta itself, and better maintains the internal temperature of the container in which the collected blood and placenta are shipped to a blood bank or registry. The invention further provides a method of collecting umbilical cord and placental blood, and the placenta from which such blood is obtained, comprising using the kit described herein.

Priority: US2005-230760 Applic. Date: 2005-09-20; US20040612408P Applic. Date: 2004-09-23

Inventor: GOODMAN CHRIS B [US]; ROBINSON WAYNE M [US]; FEINGOLD BARNETT D [US]

Title: Method and system for extracting blood-derived growth factors

Applicant/Assignee: BIOMET MANUFACTURING CORP

Application No.: 11/214661   Filing Date: 30/Aug/2005

Abstract:Methods for extracting heparin-binding growth factors from whole blood comprising contacting whole blood with a heparin-conjugated system to immobilize a conjugated fraction comprising the heparin-binding growth factors

separating a non-conjugated fraction from the system

and releasing the heparin-binding growth factors are provided. Kits include a heparin-conjugate immobilized to the surface of a substrate

and a device to withdraw whole blood from a human or animal subject. Methods of promoting tissue health with the growth factors are also provided.

Priority:

Inventor: TROXEL KAREN S [US]; PALACIOS FELIPE [US]

Title: Method for treatment of ischaemic tissue

Applicant/Assignee:

Application No.: 10/554427   Filing Date: 03/Nov/2003

Abstract:A method for treating ischaemic tissue comprising cutting the tissue to form a wound, and locating a sponge-like element ( 1 ) structured to receive blood and to comply with the movement of the tissue, in contact with a source of blood whereby the element ( 1 ) receives blood from the source of blood to thereby promote tissue growth and angiogenesis throughout and beyond the element ( 1 ).

Priority: AU20030902037 Applic. Date: 2003-04-24; WO2003AU01449 Applic. Date: 2003-11-03

Inventor: MCLACHLAN CRAIG [AU]

Title: Citrate anticoagulation system for extracorporeal blood treatments

Applicant/Assignee:

Application No.: 11/602827   Filing Date: 21/Nov/2006

Abstract:A hemofiltration system and method for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.

Priority: EP19990201302 Applic. Date: 1999-04-26; US2003-742137 Applic. Date: 2003-12-19; US2001-959543 Applic. Date: 2001-10-23; WO2000EP03583 Applic. Date: 2000-04-20; US20050739086P Applic. Date: 2005-11-22

Inventor: LANNOY JEAN-MICHEL [FR]

Title: Method and apparatus for fractionating blood

Applicant/Assignee:

Application No.: 10/554565   Filing Date: 28/Apr/2004

Abstract:A method and an apparatus for processing blood in a closed system in order to obtain fractionation of the corpusculate part and preferably the separation of the white cells from the red cells according to their sedimentation rate and maintain a high degree of vitality of the cells. The white blood cells are sequestered from the remaining cell population of the blood by placing the blood in a container, preventing its coagulation and separating the blood by means of a sedimentation agent in at least two compartments, one of which is extremely rich in white cells.

Priority: IT2003MI00897 Applic. Date: 2003-04-30; WO2004EP04474 Applic. Date: 2004-04-28

Inventor: STRISINO CESARE [IT]

Title: Nucleic acid preparation from whole blood for use in diagnosis of transmissible spongiform encephalopathy

Applicant/Assignee: ROCHE DIAGNOSTICS OPERATIONS, INC

Application No.: 11/514776   Filing Date: 01/Sep/2006

Abstract:The present invention deals with a method of preparing nucleic acids, particularly RNA, from a whole blood sample. The nucleic acids purified by the method of the invention are particularly suited for detection of nucleic acid marker molecules. Preferred are markers for the diagnosis of transmissible spongiform encephalopathy (TSE). Such diagnosis is based on the detection, by means of real-time PCR, of certain mRNAs of the TSE-infected organism. Said mRNAs specifically originate as splicing variants and are isolated from whole blood by the method of the invention.

Priority: EP20050019479 Applic. Date: 2005-09-07

Inventor: KNOLL MICHAEL [DE]; EBERLE WALTER [DE]; KIRSCHBAUM THOMAS [DE]

Title: Heterocyclic compounds

Applicant/Assignee: BAYER HEATHCARE AG

Application No.: 10/557168   Filing Date: 06/May/2004

Abstract:The present invention relates to the area of blood clotting. The invention relates in particular to certain heterocyclic compounds, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases.

Priority: DE20031022469 Applic. Date: 2003-05-19; WO2004EP04836 Applic. Date: 2004-05-06

Inventor: GERDES CHRISTOPH [DE]; PERZBORN ELISABETH [DE]; POHLMANN JENS [CH]; ROHRIG SUSANNE [DE]; STRAUB ALEXANDER [DE]; THOMAS CHRISTIAN R [DE]; TUCH AROUNARITH [FR]; SCHLEMMER KARL-HEINZ [DE]

Title: Automation and optimization of CRRT treatment using regional citrate anticoagulation

Applicant/Assignee:

Application No.: 11/525800   Filing Date: 21/Sep/2006

Abstract:A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.

Priority: US20050719718P Applic. Date: 2005-09-22

Inventor: LANNOY JEAN-MICHEL [FR]

Title: Production of human glycosylated proteins in transgenic insects

Applicant/Assignee: CHESAPEAKE PERL, INC

Application No.: 10/577528   Filing Date: 28/Oct/2004

Abstract:This invention relates, e.g., to transgenic insects, or progeny thereof, whose cells contain at least one genomically integrated, expressible, nucleic acid encoding two or more of a set of Nglycosylation enzymes that can glycosylate a heterologous protein with a mammalianized (e.g., humanized) glycosylation pattern. The glycosylation genes are preferably expressed in the insect cells in catalytic amounts. Also described are methods to use such a transgenic insect to produce heterologous, mammalianized polypeptides of interest.

Priority: US20030514741P Applic. Date: 2003-10-28; WO2004US35553 Applic. Date: 2004-10-28

Inventor: JARVIS DONALD [US]; BEEK NIKOLAI V [US]; FRASER MALCOLM [US]

Title: Peptides that inhibit viral infections

Applicant/Assignee:

Application No.: 11/541488   Filing Date: 29/Sep/2006

Abstract:The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides.

Priority: US20050722502P Applic. Date: 2005-09-29; US20060840328P Applic. Date: 2006-08-25

Inventor: CHISARI FRANCIS V [US]

Title: Integrated Infusion and Aspiration System and Method

Applicant/Assignee:

Application No.: 11/560754   Filing Date: 16/Nov/2006

Abstract:An integrated infusion and aspiration system includes of a flow control system and a catheter assembly. The catheter assembly includes an infusion catheter and an aspiration catheter, each having ports located at the distal end of thereof. The distal ends of the catheters are separated so that the aspiration catheter ports can be positioned on an opposing side of a surgical wound site from the infusion catheter ports. Methods of operation of the integrated infusion and aspiration system provides for uninterrupted aspiration with concurrent controlled delivery of an infusion solution such that the infusion solution is substantially evenly dispersed of over the wound site.

Priority: US2004-896515 Applic. Date: 2004-07-22; US2002-218106 Applic. Date: 2002-08-12

Inventor: GOBLE E M [US]; HOWARD MARK E [US]; MASON JEFFREY T [US]; FALLIN T W [US]

Title: Drug-eluting stent cover and method of use

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 11/497706   Filing Date: 01/Aug/2006

Abstract:An intravascular stent includes an eluting sheath fabricated from a mesh for controlled release of therapeutic drugs and for delivery of the therapeutic drugs in localized drug therapy in a blood vessel. The eluting sheath is attached to at least a portion of an outside surface area of the stent structure and is fabricated from a mesh designed to neck down in response to a radially outward directed force resulting in the uniform expansion of the stent. The eluting sheath can be loaded with at least one therapeutic drug for the release thereof at a treatment site to facilitate repair of a damaged vessel. The stent has a high degree of flexibility in the longitudinal direction, yet has adequate vessel wall coverage and radial strength sufficient to hold open an artery or other body lumen.

Priority: US2002-334034 Applic. Date: 2002-12-30

Inventor: YIP PHILIP S [US]; JACOBS JAMES [US]; HOSSAINY SYED [US]; BECKER JON [US]; LIMON TIMOTHY A [US]

Title: Solid active ingredient formulation

Applicant/Assignee: BAYER TECHNOLOGY SERVICE GMBH

Application No.: 10/577608   Filing Date: 19/Oct/2004

Abstract:The present invention relates to novel solid active substance formulations comprising solid active substances, dispersants, and polymers which together result in a fine-particle, predominantly amorphous mixture, to a process for the preparation thereof and to the use thereof for application of the contained bioactive active substances.

Priority: DE20031051087 Applic. Date: 2003-10-31; WO2004EP11807 Applic. Date: 2004-10-19

Inventor: EBLE AXEL [DE]; BAUR PETER [DE]; REIZLEIN KARL [DE]

Title: Treatment of B cell diseases using anti-germline antibody binding agents

Applicant/Assignee:

Application No.: 11/524531   Filing Date: 19/Sep/2006

Abstract:Methods for reducing the number of pathologic antibody producing B cells in a patient suffering from an autoimmune disease by administration of an anti-germline antibody are described. Methods for removing pathologic antibodies and B cells and plasma cells producing pathologic antibodies from the body of a patient suffering from autoimmune disease are provided, comprising contacting the blood or plasma of the patient with an immunoadsorbent having specific binding for an epitope present on germline antibodies, particularly VH4-34 antibodies, wherein said contacting results in the reduction in the amount of germline antibodies present in the blood or bone marrow or lymphoid tissue of the patient or the amount of germline antibody producing B cells present in the blood, lymphoid tissues or bone marrow of the patient. Methods for treating a patient suffering from a B cell cancer expressing cell surface germline antibodies by similar methods are also provided. Methods for ex vivo purging bone marrow of pathologic antibody producing B-cells and cancerous B-cells expressing germline antibodies are provided. Methods for monitoring the efficacy of a therapeutic treatment in a patient suffering from an autoimmune disease or B cell cancer are also provided. Kits and uses in preparation of a medicament are also described.

Priority: US20050718796P Applic. Date: 2005-09-19

Inventor: SANDERS MARTIN E [US]

Title: Blood clot filter having coating

Applicant/Assignee:

Application No.: 11/248024   Filing Date: 11/Oct/2005

Abstract:The present invention is directed to a blood clot filter for implantation in a patient comprising a blood clot filter having a coating comprising one or more pharmaceutically active compounds.

Priority:

Inventor: PICCONE VINCENT A JR [US]

Title: Surgical device and method for performing combination revascularization and therapeutic substance delivery to tissue

Applicant/Assignee:

Application No.: 11/543505   Filing Date: 05/Oct/2006

Abstract:The present invention contemplates a surgical device for both ablating a channel in a patient's tissue and also delivering a therapeutic agent. The device includes an elongated multi-lumen tube, an elongated tissue ablating assembly, and a therapeutic agent delivery assembly. The therapeutic agent is capable of being delivered into the channel and/or to the surrounding tissue. The device may further include a second multi-lumen tube also capable of delivering therapeutic agents. Although suitable for many operations, the device is particularly well suited for transmyocardial revascularization operations. The present invention also contemplates a procedure for using such a surgical device to ablate a channel in a patient's tissue and also deliver a therapeutic agent.

Priority: US20050727325P Applic. Date: 2005-10-17

Inventor: MCINTYRE JOHN [US]; TZENG ELBERT [US]

Title: Medical assembly with transducer for local delivery of a therapeutic substance and method of using same

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 11/636097   Filing Date: 08/Dec/2006

Abstract:A medical Assembly is used to delivery a therapeutic substance to a treatment area. The medical assembly comprises a catheter having a distal end and a proximal end, a transducer supported by at least a portion of the distal end of the catheter assembly, and a delivery lumen mounted on the catheter for delivery of a therapeutic substance. Support for the transducer is provided at a preselected number of anchoring points, wherein an inner surface of the transducer is positioned at a preselected distance from an outer surface of the catheter. The preselected distance defines a gap that is occupied by a low density material such as a gas which reflects acoustic pressure waves directed toward the gap by a transducer when a voltage is applied to the transducer. The reflected pressure wave increases the energy in the system, enhancing transport of therapeutic substances from the delivery lumen to the surrounding tissues and/or cells to be treated. The medical assembly may optionally be used in conjunction with both macroporous and microporous balloons. The medical assembly may optionally be modified so that a plurality of transducers are used, wherein the distal end of a transducer is positioned at a preselected distance from the proximal end of an adjacent transducer.

Priority: US1999-475548 Applic. Date: 1999-12-30

Inventor: STEWARD JEFFREY A [US]; GOSIENGFIAO BRANDON [US]

Title: Orally bioavailable compounds and methods for inhibiting platelet aggregation

Applicant/Assignee: INSPIRE PHARMACEUTICALS, INC

Application No.: 11/595837   Filing Date: 09/Nov/2006

Abstract:This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae III, IIIa, and IIIb, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae IIIa and IIIb, which are potent and have a good oral bioavailability.

Priority: WO2006US17781 Applic. Date: 2006-05-05; US2005-124619 Applic. Date: 2005-05-05; US2004-971766 Applic. Date: 2004-10-21; US20030513845P Applic. Date: 2003-10-21

Inventor: DOUGLASS JAMES G III [US]; WATSON PAUL S [US]; SAMUELSON CARL A [US]; CREAN CHRISTOPHER S [US]

Title: Urea derivative, process for producing the same, and use

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 10/583046   Filing Date: 15/Dec/2004

Abstract:The present invention provides a urea derivative or a salt thereof, which is useful as a therapeutic agent for thrombosis. The derivative is represented by Formula (I): wherein Cy is an aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted

R<1 >is a hydrogen atom or a hydrocarbon group which may be substituted

V is -C(O)-, -S(O)-, or -S(O)2-

W is -N(R<2>)-, -O-, or a bond (wherein R<2 >is a hydrogen atom or a hydrocarbon group which may be substituted)

X is alkylene which may be substituted

Y is -C(O)-, -S(O)-, or -S(O)2-

Z is a bond, a chain hydrocarbon group which may be substituted, or -N-

ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted

ring B is a nitrogen-containing heterocyclic ring which may be substituted

and [Chemical formula 2] , are each independently a single bond or a double bond

provided that R<1 >may be bonded to R<2 >to form a non-aromatic nitrogen-containing heterocyclic ring and that R<2 >may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted.

Priority: JP20030420031 Applic. Date: 2003-12-17; WO2004JP18717 Applic. Date: 2004-12-15

Inventor: KUBO KEIJI [JP]; IMAEDA YASUHIRO [JP]

Title: Methods of making and using novel griseofulvin compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LIMITED

Application No.: 11/546378   Filing Date: 12/Oct/2006

Abstract:The present invention is directed to nanoparticulate compositions comprising griseofulvin. The griseofulvin particles of the composition preferably have an effective average particle size of less than about 2 microns.

Priority: US2003-683154 Applic. Date: 2003-10-14; US2002-175851 Applic. Date: 2002-06-21; US1997-815346 Applic. Date: 1997-03-11

Inventor: LIVERSIDGE GARY G [US]

Title: METHOD FOR COLLECTING A DESIRED BLOOD COMPONENT AND PERFORMING A PHOTOPHERESIS TREATMENT

Applicant/Assignee:

Application No.: 11/613021   Filing Date: 19/Dec/2006

Abstract:An improved method for separating whole blood into components and collecting a desired blood component. The method allows a desired blood component to be subjected to centrifugal forces within a separator for prolonged periods of time, yielding a cleaner cut and higher yield of the desired blood component. Whole blood is drawn from a source and pumped into a separator, the undesired blood components are removed from the separator at rates so as to build up the desired blood component in the separator. The desired blood component is only removed after a predetermined amount of the desired blood component has built up in the separator. It is preferred that the desired blood component be buffy coat and that the method be used to perform photopheresis treatments. In another aspect, the invention is a method of performing a full photopheresis treatment to treat diseases in a reduced time, preferably less than about 70 minutes, and more preferably less than about 45 minutes.

Priority: US2003-654803 Applic. Date: 2003-09-03; US2003-375629 Applic. Date: 2003-02-27; US20020361287P Applic. Date: 2002-03-04

Inventor: BRIGGS DENNIS [US]

Title: Dietary monitoring system for comprehensive patient management

Applicant/Assignee: CARDIAC PACEMAKERS, INC

Application No.: 11/269771   Filing Date: 07/Nov/2005

Abstract:A patient management system includes a device, an interactive display, a repeater unit, and a host. The device assesses at least one dietary condition of a patient. The interactive display receives patient input related to the patient's dietary conditions and communicates dietary feedback to the patient. The system may also include at least one sensor configured to assess at least one dietary condition of the patient. The repeater unit collects information from the device, the interactive display and the sensors. The host communicates with the repeater through a network. The patient's own input of dietary information into the system can be useful for verifying sources of measured data and enhancing feedback given to the patient. The system is configured to perform accurately even in the absence of patient input or the input of incorrect information by the patient.

Priority:

Inventor: SRIVATHSA MURALIDHARAN [US]; JOHNSON DAVID C [US]; GOSCHA DONALD L [US]; BROCKWAY MARINA [US]; KADHIRESAN VEERICHETTY A [US]

Title: Systems and methods for securing cardiovascular tissue, including via asymmetric inflatable members

Applicant/Assignee: COAPTUS MEDICAL CORPORATION

Application No.: 11/582205   Filing Date: 16/Oct/2006

Abstract:Systems and methods for securing cardiovascular tissue, including via asymmetric inflatable members, are disclosed. A device in accordance with one embodiment includes a catheter having a proximal end and a distal end, with a working portion positioned toward the distal end and being elongated along a terminal axis. An energy transmitter and an inflatable member are positioned at the working portion, with the inflatable member being inflatable under fluid pressure from a generally collapsed configuration to an inflated configuration. In the inflated configuration, the inflatable member can be asymmetric relative to the terminal axis.

Priority: US20050727678P Applic. Date: 2005-10-17; US20060811866P Applic. Date: 2006-06-07; US20060811993P Applic. Date: 2006-06-07; US20060811864P Applic. Date: 2006-06-07; US20060811999P Applic. Date: 2006-06-07; US20060812002P Applic. Date: 2006-06-07; US2006-581848 Applic. Date: 2006-10-16; US2006-581869 Applic. Date: 2006-10-16; US2006-582210 Applic. Date: 2006-10-16; US2006-582253 Applic. Date: 2006-10-16

Inventor: GRAY WILLIAM [US]; GENAU CHRISTOPHER C [US]

Title: Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia

Applicant/Assignee: MERCATOR MEDSYSTEMS INC

Application No.: 11/607168   Filing Date: 01/Dec/2006

Abstract:Methods and kits for delivering pharmaceutical agents to the adventitia surrounding a blood vessel utilize a catheter having a microneedle. The microneedle is positioned in the perivascular space and delivers an amount of pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally along the blood vessel and in some cases to the adventitia surrounding other blood vessels.

Priority: US2003-350314 Applic. Date: 2003-01-22; US20020430993P Applic. Date: 2002-12-03; US20020370602P Applic. Date: 2002-04-05; US20020356670P Applic. Date: 2002-02-13; US20020350564P Applic. Date: 2002-01-22

Inventor: SEWARD KIRK P [US]; BARR LYNN M [US]; WILBER JUDITH C [US]; CAFFERATA ROBERT [US]

Title: Fibrin targeted therapeutics

Applicant/Assignee:

Application No.: 11/581677   Filing Date: 16/Oct/2006

Abstract:Fibrin targeted therapeutic agents for the treatment of thromboembolism, infection, and cancer are provided.

Priority: US20060800152P Applic. Date: 2006-05-12; US20050726632P Applic. Date: 2005-10-14

Inventor: MCMURRY THOMAS J [US]; KOLODZIEJ ANDREW [US]; CARPENTER ALAN P JR [US]; JONES SIMON [US]; GRAHAM PHILIP [US]; LOOBY RICHARD [US]; NAIR SHRIKUMAR A [US]; WANG XIFANG [US]; OVEROYE-CHAN KIRSTEN [US]; BARRETT JOHN A [US]

Title: Multiple laminar flow-based rate zonal or isopycnic separation with holographic optical trapping of blood cells and other static components

Applicant/Assignee: ARRYX, INC

Application No.: 11/594094   Filing Date: 08/Nov/2006

Abstract:The invention provides a method and apparatus for separating blood into components, may be expanded to include other types of cellular components, and can be combined with holographic optical manipulation or other forms of optical tweezing. One of the exemplary methods includes providing a first flow having a plurality of blood components

providing a second flow

contacting the first flow with the second flow to provide a first separation region

and differentially sedimenting a first blood cellular component of the plurality of blood components into the second flow while concurrently maintaining a second blood cellular component of the plurality of blood components in the first flow. The second flow having the first blood cellular component is then differentially removed from the first flow having the second blood cellular component.

Holographic optical traps may also be utilized in conjunction with the various flows to move selected components from one flow to another, as part of or in addition to a separation stage.

Priority: US2004-867328 Applic. Date: 2004-06-13; US2003-630904 Applic. Date: 2003-07-31

Inventor: MUETH DANIEL M [US]; SHIREMAN JESSICA [US]; ANDERSON AMY [US]

Title: Methods of treating hemolytic anemia

Applicant/Assignee:

Application No.: 11/595118   Filing Date: 08/Nov/2006

Abstract:Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.

Priority: US2005-050543 Applic. Date: 2005-02-03; US2004-771552 Applic. Date: 2004-02-03; US20060783070P Applic. Date: 2006-03-15

Inventor: BELL LEONARD [US]; ROTHER RUSSELL P [US]

Title: Device with anchoring elements for transdermal delivery or sampling of agents

Applicant/Assignee:

Application No.: 11/668157   Filing Date: 29/Jan/2007

Abstract:A percutaneous agent delivery or sampling device comprising a sheet having a plurality of microblades for piercing and anchoring to the skin for increasing transdermal flux of an agent and for improving the attachment of the device to the skin.

Priority: US1997-877155 Applic. Date: 1997-06-17; US19960019990P Applic. Date: 1996-06-18

Inventor: CORMIER MICHEL J [US]; NEUKERMANS ARMAND P [US]; BLOCK BARRY [US]; THEEUWES FELIX T [US]; AMKRAUT ALFRED A [US]

Title: Methods for producing nanoparticles

Applicant/Assignee:

Application No.: 11/486620   Filing Date: 14/Jul/2006

Abstract:The present invention relates to methods of preparing nanoparticles from reactively formed block and/or graft copolymers and nanoparticles derived therefrom

Priority: US20050700855P Applic. Date: 2005-07-20

Inventor: MACOSKO CHRISTOPHER W [US]; HOYE THOMAS R [US]; ANACKER JESSICA [US]; PRUD HOMME ROBERT K [US]

Title: Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime

Applicant/Assignee:

Application No.: 11/530826   Filing Date: 11/Sep/2006

Abstract:A method of determining a personalised therapeutic regime, comprising: receiving genetic information relating to a patient

determining genetic criteria relevant to a personalised therapeutic regime for the patient using the genetic information

receiving personal information relating to the patient

determining personal criteria relevant to the personalised therapeutic regime using the personal information

and combining the genetic criteria and the personal criteria to determine the personalised therapeutic regime for the patient.

Priority: US20050715936P Applic. Date: 2005-09-09

Inventor: TUCKER MARK R [GB]; WALTON ROBERT [GB]; MATTHEWS HUBERT [GB]; MISKIN ANTHONY [GB]

Title: Factor VII glycoforms

Applicant/Assignee: NOVO NORDISK HEALTHCARE A/G

Application No.: 11/643607   Filing Date: 21/Dec/2006

Abstract:The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.

Priority: DK20010000751 Applic. Date: 2001-05-14; DK20010000430 Applic. Date: 2001-03-14; DK20010000262 Applic. Date: 2001-02-16; DK20000001456 Applic. Date: 2000-10-02; US2003-725843 Applic. Date: 2003-12-02; US2001-969357 Applic. Date: 2001-10-02; US20010276322P Applic. Date: 2001-03-16; US20010271581P Applic. Date: 2001-02-26; US20000238944P Applic. Date: 2000-10-10

Inventor: PINGEL HANS K [DK]; KLAUSEN NIELS K [DK]

Title: [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 11/556490   Filing Date: 03/Nov/2006

Abstract:The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.

Priority: US20050733650P Applic. Date: 2005-11-03

Inventor: SCARBOROUGH ROBERT [US]; HUANG WOLIN [US]; MEHROTRA MUKUND [US]; ZHANG XIAOMING [US]; CANNON HILARY [GB]; GRANT CRAIG M [GB]; SCARBOROUGH CARROLL A C [US]

Title: MAGNETICALLY GUIDABLE ENERGY DELIVERY APPARATUS AND METHOD OF USING SAME

Applicant/Assignee: BAYLIS MEDICAL COMPANY

Application No.: 11/627406   Filing Date: 26/Jan/2007

Abstract:An energy delivery apparatus for delivering electrical energy at a target location, the energy delivery apparatus being usable in combination with a magnetic field. The energy delivery apparatus includes an electrical conductor, the electrical conductor having a substantially elongated configuration

an electrode for delivering the electrical energy at the target location, the electrode being electrically coupled to the electrical conductor and located at a predetermined location therealong

and a guiding element mounted to the electrical conductor in a substantially spaced apart relationship relative to the electrode, the guiding element including a magnetically responsive material. The energy delivery apparatus is constructed such that a movement of the guiding element causes a corresponding movement of the electrode. The magnetic field is used to move the guiding element in order to position the electrode substantially adjacent to the target location.

Priority: US2006-520754 Applic. Date: 2006-09-14; US2005-265304 Applic. Date: 2005-11-03; US2003-666301 Applic. Date: 2003-09-19; US2004-760479 Applic. Date: 2004-01-21; US2003-666288 Applic. Date: 2003-09-19; US2003-347366 Applic. Date: 2003-01-21; US20050596297P Applic. Date: 2005-09-14; US20060743181P Applic. Date: 2006-01-27; US20060827458P Applic. Date: 2006-09-29

Inventor: DAVIES GARETH [CA]; ALBERT KELLY [CA]; MUNGER GARETH T [US]; PANDEY ASHWINI [US]; VISWANATHAN RAJU [US]

Title: Methods of Preventing Morbidity and Mortality by Perioperative Administration of a Blood Clotting Inhibitor

Applicant/Assignee:

Application No.: 11/462282   Filing Date: 03/Aug/2006

Abstract:The present invention provides methods of using a blood clotting inhibitor to reduce post-surgical morbidity and mortality. In particular, perioperative use of a blood clotting inhibitor decreases surgical complications without significant adverse effects and is cost effective.

Priority: US2002-272187 Applic. Date: 2002-10-15

Inventor: MANGANO DENNIS T [US]

Title: Novel ethylenediamine derivatives

Applicant/Assignee: DAIICHI PHARMACEUTICAL CO., LTD

Application No.: 10/539995   Filing Date: 24/Dec/2003

Abstract:A compound represented by the following formula (1): Q<1>-Q<2>-T-N(R<1>)-Q<3>-N(R<2>)-T<1>-Q<4> ( 1 ) [wherein, R<1 >and R<2 >are hydrogen atoms or the like

Q<1 >is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may have a substituent, or the like

Q<2 >is a single bond or the like

Q<3 >represents the following group: -C(R<3a>)(R<4a>)-{C(R<3b>)(R<4b>)}m<1>-{C(R<3c>)(R<4c>)}m<2>-{C(R<3d>)(R<4d>)}m<3>-{C(R<3e>)(R<4e>)}m<4>-C (R<3f>)(R<4f>)- (in which, R<3a >to R<4e >represent hydrogen or the like)

T<0 >represents a carbonyl group or the like

and T<1 >represents -COCONR- or the like]

or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Priority: JP20020373025 Applic. Date: 2002-12-24; WO2003JP16556 Applic. Date: 2003-12-24

Inventor: NAKAMOTO YUMI [JP]; YOSHINO TOSHIHARU [JP]; NAITO HIROYUKI [JP]; NAGATA TSUTOMU [JP]; YOSHIKAWA KENJI [JP]; SUZUKI MAKOTO [JP]

Title: MULTI-PART SUBSTITUTION INFUSION FLUIDS AND MATCHING ANTICOAGULANTS

Applicant/Assignee: BAXTER INTERNATIONAL INC BAXTER HEALTHCARE S.A

Application No.: 11/678525   Filing Date: 23/Feb/2007

Abstract:A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Priority: EP19990201302 Applic. Date: 1999-04-26; US2003-742137 Applic. Date: 2003-12-19; US2001-959543 Applic. Date: 2001-10-23; WO2000EP03583 Applic. Date: 2000-04-20

Inventor: CHANG PETER C [NL]; LANNOY JEAN-MICHEL [FR]

Title: Use of peroxisome proliferator-activated receptor gamma (ppary) and/or retinoic acid receptor (rxr) agonists to inhibit platelet functions

Applicant/Assignee:

Application No.: 10/576824   Filing Date: 22/Oct/2004

Abstract:Methods of inhibiting mammalian platelet release of CD40 ligand, thromboxanes, or prostaglandin E2, or surface expression of CD40 ligand that involve contacting mammalian platelets with an effective amount of a PPARgamma agonist, an RXR agonist, or a combination thereof. As a consequence of inhibiting CD40 ligand and thromboxane release, the present invention allows for inhibition of thrombus fon-nation by (or clotting activities of) activated platelets, as well as treating or preventing CD40 ligand-mediated conditions and/or thromboxane-mediated conditions. Use of PPARgamma agonist, RXR agonist, and/or inducers of PPARgamma agonist in preparing a stored blood product, and for diagnostic testing of patient samples is also disclosed.

Priority: US20030513372P Applic. Date: 2003-10-22; US20040553657P Applic. Date: 2004-03-16; US20040567397P Applic. Date: 2004-04-30; WO2004US35065 Applic. Date: 2004-10-22

Inventor: PHIPPS RICHARD P [US]; SIME PATRICIA J [US]; BLUMBERG NEIL [US]

Title: Wrap

Applicant/Assignee: SUNSHINE HEART COMPANY PTY LTD

Application No.: 10/595602   Filing Date: 28/Oct/2004

Abstract:A wrap ( 20 ) for securing about a blood vessel ( 36 ) by encasing a section of the vessel. The wrap ( 20 ) being of thin flexible construction having two ends ( 22, 24 ) and two sides ( 26, 28 ). The wrap ( 20 ) is more elastic or stretchable at, near, or along at least some of its sides ( 22, 24 ) compared to at, near, or along its centre, to provide strain relief from wrapped to unwrapped aorta. The wrap ( 20 ) is not inelastic, so that loss of aortic compliance is minimised or enhanced. The wrap ( 20 ) is adapted to apply, in use, less compressive force at, near, or along at least some of its sides ( 22, 24 ) compared to at, near, or along its centre.

Priority: AU20030905992 Applic. Date: 2003-10-30; WO2004AU01484 Applic. Date: 2004-10-28

Inventor: MILLER SCOTT H [AU]; PETERS WILLIAM S [NZ]; DE PLATER GEMMA L [AU]

Title: METHODS OF MAKING NANOPARTICULATE DRUG COMPOSITIONS COMPRISING COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABILIZERS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/213765   Filing Date: 30/Aug/2005

Abstract:The present invention is directed to nanoparticulate compositions comprising a poorly soluble drug and at least one copolymer of vinyl pyrrolidone and vinyl acetate as a surface stabilizer adsorbed to the surface of the drug. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate composition of the invention, methods of making and using such nanoparticulate and pharmaceutical compositions.

Priority: US2003-345312 Applic. Date: 2003-01-16; US2000-715117 Applic. Date: 2000-11-20; US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21

Inventor: BOSCH H W [US]; RYDE NIELS P [US]

Title: Factor VII or VIIa-like molecules

Applicant/Assignee:

Application No.: 11/448143   Filing Date: 07/Jun/2006

Abstract:Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Priority: DK20000000218 Applic. Date: 2000-02-11; US2004-950747 Applic. Date: 2004-09-27; US2001-782578 Applic. Date: 2001-02-12; US20000241916P Applic. Date: 2000-10-18; US20000184036P Applic. Date: 2000-02-22; DK20000001558 Applic. Date: 2000-10-18

Inventor: PEDERSEN ANDERS H [DK]; ANDERSEN KIM V [DK]; BORNAES CLAUS [DK]

Title: Stabilized pharmaceutical solid compositions of low-solubility drugs and poloxamers, and stabilizing polymers

Applicant/Assignee: PFIZER INC

Application No.: 10/596885   Filing Date: 20/Dec/2004

Abstract:Solid compositions with improved physical stability comprise an amorphous, low-solubility drug, a poloxamer, and a stabilizing polymer. The compositions provide good physical stability during storage and concentration enhancement of dissolved drug when administered to an aqueous environment of use.

Priority: US20030533848P Applic. Date: 2003-12-31; WO2004IB04260 Applic. Date: 2004-12-20

Inventor: CREW MARSHALL D [US]; FRIESEN DWAYNE T [US]; MILLER WARREN K [US]; SHANKER RAVI M [US]; SMITHEY DANIEL T [US]

Title: Coumarin analog compounds for safer anticoagulant treatment

Applicant/Assignee: NEW CENTURY PHARMACEUTICALS, INC

Application No.: 11/708004   Filing Date: 20/Feb/2007

Abstract:The present invention relates to the albumin-guided development of coumarin analogs and the analogs developed thereby. The coumarin analogs of the present invention are identified and isolated by the fact that they have binding sites to albumin which are different than the binding sites of conventional coumarin analogs such as sodium warfarin, and as a result will be less prone to be displaced since the binding site of sodium warfarin is shared by numerous drugs such as aspirin. The coumarin analogs of the invention are advantageous because they can achieve the effects of the prior coumarin analogs with a minimum of metabolic complications and undesirable side effects.

Priority: US2003-629858 Applic. Date: 2003-07-30; US20020399126P Applic. Date: 2002-07-30

Inventor: CARTER DANIEL C [US]

Title: Microcapsules with modified release of active principles with low solubility for oral delivery

Applicant/Assignee:

Application No.: 11/583940   Filing Date: 20/Oct/2006

Abstract:The present invention is directed to microcapsules for reliably modified release and adapted to industrial reproduction of an active principle hardly water-soluble, other than anti-hyperglycemia agents. Each of said microcapsules comprises a core of hardly soluble active principle and a coating film applied on the core. Their mean diameter is less than 1000 microns. The coating film contains a film-forming polymer (PI) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA). Said coating film represents at least 4% p/p of dry matter of their total weight, and its components P1, P2, PL satisfy the following characteristics: dry weight mass fraction of PI relative to the total coating weight ranging between 40 and 90%

dry matter weight fraction of PL/P1 +P2 ranging between 15 and 60%

dry matter weight fraction of PL/P1+P2 ranging between 1 and 30%. The present invention is also directed to the uses of said microcapsules in galenic formulation.

Priority: FR20020009530 Applic. Date: 2002-07-26; US2006-358047 Applic. Date: 2006-02-22; WO2003FR02384 Applic. Date: 2003-07-28

Inventor: GUIMBERTEAU FLORENCE [FR]; CASTAN CATHERINE [FR]; MEYRUIEX REMI [FR]; SOULA GERARD [FR]

Title: Methods and systems for sampling, screening, and diagnosis

Applicant/Assignee: THE JOHNS HOPKINS UNIVERSITY

Application No.: 10/587927   Filing Date: 04/Feb/2005

Abstract:Apparatus, systems, and methods for detecting, screening and sampling of cells are disclosed.

Priority: US20040541781P Applic. Date: 2004-02-04; US20040577790P Applic. Date: 2004-06-08; US20040619621P Applic. Date: 2004-10-18; WO2005US03369 Applic. Date: 2005-02-04

Inventor: HALDEN ROLF U [US]

Title: Blood cell sorting methods and systems

Applicant/Assignee:

Application No.: 11/646985   Filing Date: 28/Dec/2006

Abstract:The invention relates to methods of isolating white blood cells (WBCs) from a sample, e.g., whole blood, using magnetic particles that specifically bind to WBCs and a series of specific steps and conditions. The methods can include one or more of decreasing the viscosity of the sample prior to WBC isolation, agitating the sample at specified frequencies, and/or using a sample container arranged such that all of the sample is placed in close proximity (e.g., within 5, 2, 1, or 0.5 mm) to the source of the magnetic field. The new methods provide for isolation of WBC preparations with high yield, purity, and viability. The methods are designed for compatibility with automation protocols for rapid processing of multiple samples.

Priority: US20050754426P Applic. Date: 2005-12-28

Inventor: FAUSTMAN DENISE L [US]; BURGER DOUGLAS E [US]

Title: System and method for monitoring health using exhaled breath

Applicant/Assignee:

Application No.: 11/301911   Filing Date: 13/Dec/2005

Abstract:The present invention includes systems and methods for monitoring endogenous compound concentration in blood by detecting markers, such as odors, upon exhalation by a patient, wherein such markers are the endogenous compound itself or result from the endogenous compound. In the case of olfactory markers, the invention preferably utilizes electronic sensor technology, such as the commercial devices referred to as "artificial" or "electronic" noses or tongues, to non-invasively monitor endogenous compound levels in blood. The invention further includes a reporting system capable of tracking endogenous compound concentrations in blood (remote or proximate locations) and providing the necessary alerts with regard to emergent or harmful conditions in a patient.

Priority: WO2005US06355 Applic. Date: 2005-02-28; US2004-788501 Applic. Date: 2004-02-26; US2002-178877 Applic. Date: 2002-06-24; US2002-054619 Applic. Date: 2002-01-22

Inventor: MELKER RICHARD J [US]; DENNIS DONN M [US]; BJORAKER DAVID G [US]; GOLD MARK S [US]

Title: Medical device package

Applicant/Assignee:

Application No.: 11/340912   Filing Date: 26/Jan/2006

Abstract:The present disclosure provides a package containing a sealable pouch for a medical device and a sealed port positioned adjacent a periphery of the sealable pouch for permitting the passage of at least one agent to the medical device contained therein from outside the sealable pouch.

Priority:

Inventor: STOPEK JOSHUA [US]; HOTTER JOSEPH [US]; COHEN MATTHEW D [US]

Title: Compositions capable of facilitation penetration across a biological barrier

Applicant/Assignee:

Application No.: 10/572249   Filing Date: 17/Sep/2004

Abstract:This invention relates to novel pharmaceutical compositions capable of facilitating penetration of at least one effector across biological barriers. The invention also relates to methods of treating or preventing diseases by administering these compositions to affected subjects.

Priority: US2003-665184 Applic. Date: 2003-09-17; US2003-664989 Applic. Date: 2003-09-17; US20030503615P Applic. Date: 2003-09-17; WO2004IB04452 Applic. Date: 2004-09-17

Inventor: BEN-SASSON SHMUEL A [IL]; GALAMIDI-COHEN EINAT [IL]

Title: Compositions and methods for preventing infection

Applicant/Assignee: LA JOLLA BIOSCIENCES LLC

Application No.: 11/637960   Filing Date: 11/Dec/2006

Abstract:This invention relates to cholesterol-sequestering agents and methods of using cholesterol-sequestering agents to prevent infection. The compositions of the invention can be used to reduce or prevent maternal to fetal transmission of a microorganism and/or to reduce or eliminate a microorganism present in a blood sample or a blood product.

Priority: US2003-667727 Applic. Date: 2003-09-22; US20020412399P Applic. Date: 2002-09-20

Inventor: SCHEELE GEORGE A [US]; HILDRETH JAMES E [US]

Title: Methods and means for treating solid tumors

Applicant/Assignee:

Application No.: 11/399281   Filing Date: 06/Apr/2006

Abstract:The present invention relates to method and means for treating a vascularized solid tumor using a number of, in vitro prepared, anticellular agent(s)-carrying blood platelets to induce a thrombus formation within the tumor vasculature, and at the same time to deliver a high concentration of an anticellular agent within the tumor. The blood platelets are targeted and attached to the tumor vasculature using in vivo assembled binding complexes, each having at least one binding site specifically binding to tumor cells or to tumor-associated vasculature, and at least one binding site specifically binding to a blood platelet surface. The platelet-mediated thrombus formed within the tumor vasculature leads to occlusion of the tumor vasculature, with ultimate destruction of the centrally located tumor cells. This is followed by destruction or suppressing the growth or cell division of the peripherally located tumor cells, by the anticellular agent(s) carried by the blood platelets.

Priority: US2006-343694 Applic. Date: 2006-01-31

Inventor: AWDALLA ESSAM T [US]

Title: Method of inactivating virus in circular blood and its applications in treating viral diseases

Applicant/Assignee: BEIJING JINGJING MEDICAL EQUIPMENT CO., LTD

Application No.: 10/551334   Filing Date: 21/May/2004

Abstract:The present invention relates to a method for illuminating the viruses in a circulatory blood, comprising the following steps of: 1) Adding an anticoagulant into a whole blood source and establishing a circulation system for the whole blood source

2) Withdrawing the whole blood with the anticoagulant into a plasma-separating device for a separation, when finished, directly pumping the red-blood cells back into the whole blood source and transporting the plasma into a mixing transport pump after the separation

3) Meanwhile, pumping a photosensitizer methylene blue into the mixing transport pump so that the methylene blue is mixed with the plasma and pumped together into a plasma container

4) Using an illumination device to illuminate the plasma in the plasma container for virus illumination, and pumping the virus-illuminated plasma into a removing device for removing off the photosensitizer

5) The methylene blue being absorbed by the removing device and the plasma illuminated being transfused back into the whole blood system

6) Repeating the step 2 to the step 5 until the virus content in the whole blood source is reduced by 99.99%. The present invention can process blood in a batch, as a pipeline, and can utilize aseptic and disposable sealed systems isolated from the outside environment for processing. The processed plasma flows back into the whole blood source and can be directly transfused into the human body. Still, the invention may be further used to treat virus-diseases such as Hepatitis B, Hepatitis C, AIDS and etc., and to eliminate the viruses of organ transplantation recipient.

Priority: CN20031036647 Applic. Date: 2003-05-22; WO2004CN00516 Applic. Date: 2004-05-21

Inventor: WU WEIXING [CN]; KAM YUEN [CN]

Title: ADJUSTING PH IN A METHOD OF SEPARATING WHOLE BLOOD

Applicant/Assignee: GAMBRO BCT, INC

Application No.: 11/668715   Filing Date: 30/Jan/2007

Abstract:This invention is directed to a method of collecting and separating whole blood into components. The method includes the steps of adding an anticoagulant having an acidic pH to a bag for collecting and/or separating whole blood, collecting whole blood in the bag, loading the bag containing anticoagulated whole blood on a rotor, spinning the bag on the rotor to separate the whole blood into at least one component

and squeezing the bag on the rotor to push the component from the separation bag into at least one satellite bag.

Priority: US20060766586P Applic. Date: 2006-01-30

Inventor: FELT THOMAS [US]; GIBBS BRUCE [US]; PIHLSTEDT PETER [SE]

Title: High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjunction therewith

Applicant/Assignee:

Application No.: 11/640138   Filing Date: 15/Dec/2006

Abstract:A therapeutic product formed from a high concentration of white blood cells having a high degree of cell viability. The white blood cells are sequestered from their normal population presence in whole blood by placing the blood into a container and preventing coagulation of the blood, separating the blood into two components, one of which is extremely rich in white blood cells through the use of a reagent and centrifugation, sequestering the white cell concentration, and freezing the white cells.

Priority: US2001-855789 Applic. Date: 2001-05-15; US1999-313816 Applic. Date: 1999-05-18; US1998-128208 Applic. Date: 1998-08-03; US1994-349747 Applic. Date: 1994-12-05

Inventor: RUBINSTEIN PABLO [US]; COELHO PHILIP H [US]; STEVENS CLADD E [US]

Title: MONOCYTE ACTIVATION TEST BETTER ABLE TO DETECT NON-ENDOTOXIN PYROGENIC CONTAMINANTS IN MEDICAL PRODUCTS

Applicant/Assignee: NATIONAL BIOLOGICAL STANDARDS BOARD

Application No.: 11/613866   Filing Date: 20/Dec/2006

Abstract:An improved monocyte activation test is described that is better able to detect non-endotoxin pyrogens in medical products, in which a sample is incubated with a monocyte-containing reagent in an assay system comprising at least one surface comprising polypropylene. The invention also concerns assay systems for use in these tests that include at least one microtiter well having at least one interior surface comprising polypropylene and having a shape such that monocyte-containing reagent is concentrated in the well to provide greater cell to cell contact. The invention also relates to a diagnostic kit that can be used to test for the presence of non-endotoxin pyrogens in a sample.

Priority: US20050752970P Applic. Date: 2005-12-22

Inventor: POOLE STEPHEN [GB]; PATEL MEHUL [US]

Title: Method for the production of emulsion-based micro particles

Applicant/Assignee: PR PHAMACEUTICALS

Application No.: 10/553003   Filing Date: 12/Apr/2004

Abstract:The apparatus and methods of the present invention are of use for the production of emulsion-based microparticles containing a biological or chemical agent. In particular, the apparatus provides a vessel

packing material situated inside such vessel and may further provide material capable of insertion into both ends of said vessel for enclosure of the packing material. In a particular embodiment, the apparatus is a packed bed apparatus. The methods include production of emulsion based microparticles containing a biological or chemical agent. The usefulness of the present invention is that the apparatus and methods of the present invention provide for a low-shear, non-turbulent, production of emulsion-based microparticles that provides a narrow, reproducible, particle size distribution, capable of use with both large and small volumes that is capable of being conveniently scaled up while providing predictable emulsion properties.

Priority: US20030461860P Applic. Date: 2003-04-10; WO2004US11485 Applic. Date: 2004-04-12

Inventor: ZEIGERSON EHUD [US]

Title: Nanoparticles for drug-delivery

Applicant/Assignee:

Application No.: 10/570461   Filing Date: 02/Sep/2004

Abstract:This invention relates to polymeric nanoparticles useful for drug delivery with target molecules bonded to the surface of the particles and having sizes of up to 1000 nm, preferably 1 nm to 400 nm, more preferably 1 nm to 200 nm, that are dispersed homogeneously in aqueous solution. The target drug/target substance is covalently bonded to the novel polymeric nanoparticles to secure them from outer intervention in vivo or cell culture in vitro until they are exposed at the target site within the cell. This invention also relates to microemulsion polymerization techniques useful for preparing the novel nanoparticles.

Priority: US20030499904P Applic. Date: 2003-09-02; US20030500750P Applic. Date: 2003-09-04; US20040568746P Applic. Date: 2004-05-06; WO2004US28995 Applic. Date: 2004-09-02

Inventor: TUROS EDWARD [US]; SHIM JEUNG-YEOP [US]

Title: New mandelic acid derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 11/520063   Filing Date: 13/Sep/2006

Abstract:There is provided a compound of formula (I) wherein R, R<1>, R<2>, Y and R<3 >have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g., thrombosis) or as anticoagulants.

Priority: SE20000004458 Applic. Date: 2000-12-01; SE20010000965 Applic. Date: 2001-03-19; SE20010001239 Applic. Date: 2001-04-06; SE20010002921 Applic. Date: 2001-08-30; US2003-432411 Applic. Date: 2003-05-21; WO2001SE02657 Applic. Date: 2001-11-30

Inventor: INGHARDT TORD [SE]; JOHANSSON ANDERS [SE]; SVENSSON ARNE [SE]

Title: Acellular bioabsorbable tissue regeneration matrices

Applicant/Assignee:

Application No.: 11/588840   Filing Date: 26/Oct/2006

Abstract:The present invention provides methods and compositions useful in the regeneration of damaged, lost and/or degenerated tissue in humans and animals. In certain embodiments, the present invention provides an acellular bioabsorbable tissue regeneration matrix, methods of making such a matrix, and methods of using such a matrix for the regeneration of damaged, lost and/or degenerated tissue. In certain embodiments, methods and compositions of the present invention are useful in the treatment of damaged, lost and/or degenerated nerve tissue.

Priority: US20050730614P Applic. Date: 2005-10-26

Inventor: AHLFORS JAN-ERIC [US]

Title: System, method and apparatus for use in blood testing through luminescence

Applicant/Assignee: GEMOSCAN CANADA, INC

Application No.: 11/364273   Filing Date: 01/Mar/2006

Abstract:The present invention seeks to provide an express-control system for analysing the compatibility of blood with other substances. The present invention relates to a system, method and apparatus for use in blood testing and more specifically, food intolerance testing through analysis of blood using luminescence. The present invention utilises a blood testing system and apparatus, which includes a displacement assembly, a blood divider assembly, a reagent divider assembly, an electro-optical multiplier assembly and a central controller. A sample of blood is added to a corresponding one of a plurality of canisters containing a test substance. Thereafter a luminescent reagent is added and the plurality of canisters are moved in the blood testing apparatus until the canisters begin to luminese.

The amount of luminescence is measured and analysed an indicator of compatibility of the blood with the test substance and more specifically as an indicator of the presence and activity of neutrophil in the blood and more specifically the granulacy of the blood.

Priority:

Inventor: OSTROVSKY ALEKSANDR [CA]; LEIBOVSKI MIKHAIL [CA]

Title: Compressible resilient granules and formulations prepared therefrom

Applicant/Assignee:

Application No.: 11/715821   Filing Date: 07/Mar/2007

Abstract:Methods and compositions having resilient, self-adhered granules are disclosed and described. In one embodiment, a resilient, self-adhering granule, which includes a combination of a polysaccharide in an amount of about 10 wt % to about 30 wt %

a sugar alcohol in an amount of about 15 wt % to about 35 wt %

and a binder having a viscosity from about 5000 mPa.s to about 250,000 mPa.s in an amount of from about 10 wt % to about 35 wt %, is capable of low-pressure, reversible agglomeration. In other embodiments, an oral dosage form of such granules and methods of administering said forms are provided.

Priority: US20060780304P Applic. Date: 2006-03-07

Inventor: CHERUKURI S R [US]

Title: Blood Co-Processing For Contingent Autologous Leukocyte Transplantation

Applicant/Assignee: LIFEFORCE GROUP PLC

Application No.: 10/573872   Filing Date: 28/Sep/2004

Abstract:A process for producing a leukocyte bank suitable for CAT therapy comprising the steps of providing a blood sample from a healthy donor individual

selectively separating and collecting leukocytes from the sample

selectively separating and collecting red blood cells and/or platelets and/or plasma from the sample

and cryogenically preserving the leukocytes (and optionally the red blood cells and/or platelets and/or plasma)

wherein steps are conducted with an automated leukapheresis device comprising a separation device (e.g. a centrifuge rotor or filter), a leukapheresis tubing set and one or more pumps for conveying the sample through the tubing set and the separated leukocytes into a collection vessel.

Priority: GB20030022791 Applic. Date: 2003-09-30; WO2004GB04173 Applic. Date: 2004-09-28

Inventor: SPIERS WILLIAM A [GB]

Title: Assays for Determining Anticoagulant Cofactor Activity

Applicant/Assignee:

Application No.: 11/560502   Filing Date: 16/Nov/2006

Abstract:Methods are disclosed for determining, in a sample derived from a human, the functional activity of a component of the human blood coagulation system, which activity can be correlated to conversion of a substrate specific for activated Protein C (APC), by measuring in an assay medium containing the sample and a substrate for APC, the conversion of the substrate by APC and correlating the conversion to the functional activity of the component. When the component is anticoagulant Factor V, at least one of exogenous APC, Protein S or an inhibitor of Protein S activity is added to the medium. When the component is Protein C, APC, or Protein S, exogenous anticoagulant Factor V or an inhibitor of anticoagulant activity of Factor V is added to the medium. Methods are also disclosed for diagnosing a blood coagulation/anticoagulation disorder or for determining a predisposition thereto in a human by determining anticoagulant Factor V activity in an assay medium containing a sample derived from the human.

Priority: SE19930000300 Applic. Date: 1993-01-29; SE19930002457 Applic. Date: 1993-07-20; US1995-500917 Applic. Date: 1995-10-20; WO1994SE00070 Applic. Date: 1994-01-28

Inventor: DAHLBAECK BJOERN [SE]

Title: METHODS AND COMPOSITIONS FOR INDUCING TORPOR IN A SUBJECT

Applicant/Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Application No.: 11/623625   Filing Date: 16/Jan/2007

Abstract:The present invention relates to the discovery the 5'-AMP and analogues thereof can be used to induce a state of torpor or suspended animation in subjects, as exemplified by studies carried out in laboratory mice. In these studies, mice were injected with high doses of 5'-AMP, which was found to result in a decoupling of the animals' body temperature regulation mechanism accompanied by a reduction in the animals' core body temperature, which tended to lower towards the ambient environmental temperature. It was further discovered that the introduction of high levels of 5'-AMP resulted in an induction of fat regulation genes such as procolipase (Clps) in tissues and organs that do not normally express Clps, this in turn was accompanied by a shift in metabolism from a primarily glycolytic energy metabolism (which is inhibited at lower temperatures) to one that relied primarily on the liberation and metabolism of free fatty acids. Substantial medical and other applications that arise out of this discovery are also disclosed.

Priority: US20060821521P Applic. Date: 2006-08-04; US20060759480P Applic. Date: 2006-01-16

Inventor: LEE CHENG C [US]; ZHANG JIANFA [US]

Title: New mandelic acid derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 11/520052   Filing Date: 13/Sep/2006

Abstract:There is provided a compound of formula (I) wherein R, R<1>, R<2>, Y and R<3 >have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g., thrombosis) or as anticoagulants.

Priority: SE20000004458 Applic. Date: 2000-12-01; SE20010000965 Applic. Date: 2001-03-19; SE20010001239 Applic. Date: 2001-04-06; SE20010002921 Applic. Date: 2001-08-30; US2003-432411 Applic. Date: 2003-05-21; WO2001SE02657 Applic. Date: 2001-11-30

Inventor: INGHARDT TORD [SE]; JOHANSSON ANDERS [SE]; SVENSSON ARNE [SE]

Title: TROPHOBLAST PRESERVATION/PRETREATMENT MEDIUM AND METHOD

Applicant/Assignee: BIOCEPT, INC

Application No.: 11/277218   Filing Date: 22/Mar/2006

Abstract:An aqueous preservation medium for the selective preservation of trophoblasts obtained in a sample of cervical mucus which permits transportation of such sample to a laboratory facility for analysis and selectively preserves fetal trophoblasts in said sample while presenting conditions that are antagonistic to many maternal cells.

Priority:

Inventor: PIRCHER TONY [US]

Title: Device and method for high-throughput quantification of mRNA from whole blood

Applicant/Assignee:

Application No.: 11/803593   Filing Date: 15/May/2007

Abstract:Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.

Priority: US2004-796298 Applic. Date: 2004-03-09; US2003-698967 Applic. Date: 2003-10-30; WO2003US12895 Applic. Date: 2003-04-24; US20020375472P Applic. Date: 2002-04-24

Inventor: MITSUHASHI MASATO [US]

Title: PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN

Applicant/Assignee: JANSSEN PHARMACEUTICA NV

Application No.: 11/685544   Filing Date: 13/Mar/2007

Abstract:The present invention describes compounds of Formula I: wherein W, X, Y, Z, and Q are defined herein, or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal.

Priority: US20060784361P Applic. Date: 2006-03-21

Inventor: PLAYER MARK R [US]; LU TIANBAO [US]; HU HUAPING [US]; ZHU XIZHEN [US]; TELEHA CHRISTOPHER [US]; KREUTTER KEVIN [US]

Title: Methods and apparatus for regional and whole body temperature modification

Applicant/Assignee: RADIANT MEDICAL INC ZOLL CIRCULATION, INC

Application No.: 11/724075   Filing Date: 13/Mar/2007

Abstract:Methods and apparatus for temperature modification of selected body regions including an induced state of local hypothermia of the brain region for neuroprotection. A heat exchange catheter is provided with heat transfer fins projecting or extending outward from the catheter which may be inserted into selected blood vessels or body regions to transfer heat with blood or fluid in the selected blood vessels or body regions. Another aspect of the invention further provides methods and apparatus for controlling the internal body temperature of a patient. By selectively heating or cooling a portion of the catheter lying within a blood vessel, heat may be transferred to or from blood flowing within the vessel to increase or decrease whole body temperature or the temperature of a target region.

Feed back from temperature sensors located within the patient's body allow for control of the heat transfer from the catheter to automatically control the temperature of the patient or of the target region within the patient. The apparatus may include a blood channeling sleeve that directs body fluid over a heat exchanger where the body fluid's temperature is altered, and then is discharged out the distal end of the sleeve to a desired location, for example, cooled blood to the brain for neuroprotection. The catheter may be used alone or in conjunction with other heat exchangers to cool one region of a patient's body while heating another.

Priority: US2003-626007 Applic. Date: 2003-07-24; US1998-138830 Applic. Date: 1998-08-24; US1996-584013 Applic. Date: 1996-01-08; US1994-324853 Applic. Date: 1994-10-18; US1993-015714 Applic. Date: 1993-02-09

Inventor: GINSBURG ROBERT [US]; GINSBURG ARLENE S [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]

Title: ANTI-CLOTTING APPARATUS AND METHODS FOR FLUID HANDLING SYSTEM

Applicant/Assignee: OPTISCAN BIOMEDICAL CORPORATION

Application No.: 11/734242   Filing Date: 11/Apr/2007

Abstract:Methods and apparatus are provided for determining the concentration of an analyte in a sample, such as an analyte in a sample of bodily fluid. In some embodiments, a method for maintaining clear passageways in an extracorporeal blood flow system includes intermittently providing one or more anti-clotting agents to a passageway of the extracorporeal blood flow system. In some embodiments, an extracorporeal blood flow system includes a passageway and a device operatively connected to provide one or more anti-clotting agents to a least a portion of said passageway.

Priority: US20060791621P Applic. Date: 2006-04-11

Inventor: KEENAN RICHARD [US]; CHIOU JEFF [US]

Title: Methods for measuring platelet reactivity of patients that have received drug eluting stents

Applicant/Assignee:

Application No.: 11/742684   Filing Date: 01/May/2007

Abstract:A method is providing for measuring platelet reactivity of a PCI patient that has a (DES). A blood sample is obtained from the patient. The blood sample is mixed in combination with 1) an anticoagulant

2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation

3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface

4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the mixture. The absence of agglutination indicates that the patient has reduced ability to form platelet thrombi.

Priority: US20030485703P Applic. Date: 2003-07-08; US2004-886155 Applic. Date: 2004-07-06

Inventor: COLLER BARRY S [US]; DURBIN DENNIS [US]

Title: Cyclic Amide Derivative, and Its Production and Use

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 11/596089   Filing Date: 20/May/2005

Abstract:The present invention provides a cyclic amide derivative useful as a drug for treating thrombosis, which is represented by the formula (I)-: wherein R<1 >represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent chain hydrocarbon group, a represents 0, 1, or 2, X<1 >represents an optionally substituted lower alkylene or an optionally substituted lower alkenylene, Y<1 >represents -C(O)-, -S(O)- or -S(O)2-, A represents a piperazine ring which may be further substituted or a piperidine ring which may be further substituted, X<2 >represents a bond or an optionally substituted lower alkylene, Y<2 >represents -C(O)-, -S(O)-, -S(O)2- or -C(-NR<7>)-, X<3 >represents an optionally substituted C1-4 alkylene or an optionally substituted C2-4 alkenylene, Z<3 >represents -N(R<4>)-,

-O- or a bond, Z<1 >represents -C(R<2>)(R<2'>)-, -N(R<2>)-, etc., and Z<2 >represents -C(R<3>)(R<3'>)-, -N(R<3>)-, etc., or a salt thereof.

Priority: JP20040152000 Applic. Date: 2004-05-21; WO2005JP09711 Applic. Date: 2005-05-20

Inventor: KUBO KEIJI [JP]; IMAEDA YASUHIRO [JP]

Title: Use of nitric oxide adducts

Applicant/Assignee: NITROMED, INC

Application No.: 11/819513   Filing Date: 27/Jun/2007

Abstract:The invention provides a method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device

coated per se on a surface of the medical device

directly or indirectly bound to reactive sites on a surface of the medical device

or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.

Priority: US2003-646713 Applic. Date: 2003-08-25; US2002-253977 Applic. Date: 2002-09-25; US2000-621610 Applic. Date: 2000-07-21; US1999-433550 Applic. Date: 1999-11-04; US1995-460465 Applic. Date: 1995-06-02; US1993-123331 Applic. Date: 1993-09-17

Inventor: STAMLER JONATHAN [US]; LOSCALZO JOSEPH [US]; FOLTS JOHN D [US]

Title: METHOD FOR SELECTIVELY REMOVING VIRUS AND LEUKOCYTES, REMOVING MATERIAL AND REMOVING APPARATUS

Applicant/Assignee: ASAHI MEDICAL CO., LTD ASAHI KASEI KURARAY MEDICAL CO., LTD

Application No.: 11/772448   Filing Date: 02/Jul/2007

Abstract:It is intended to provide a method whereby a virus and leukocytes can be simultaneously eliminated from virus-containing blood and platelets can be recovered at a high yield, and a material and an apparatus therefor. A water-soluble carrier having surface which is capable of capturing a virus and leukocytes in blood but allows the permeation of platelets therethrough is brought into contact with virus-containing blood. Thus the virus and leukocytes can be simultaneously removed from the blood while platelets can be recovered at a high yield.

Priority: JP20010318512 Applic. Date: 2001-10-16; US2004-492652 Applic. Date: 2004-09-03; WO2002JP10766 Applic. Date: 2002-10-16

Inventor: ONODERA HIROKAZU [JP]; YOSHIDA MAKOTO [JP]

Title: New amidino derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 11/808122   Filing Date: 06/Jun/2007

Abstract:There is provided compounds of formula I wherein R<1>, Rx, Y, R, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: SE19980004313 Applic. Date: 1998-12-14; WO1999SE02316 Applic. Date: 1999-12-10; US2004-815954 Applic. Date: 2004-04-02; US2000-509032 Applic. Date: 2000-03-21

Inventor: INGHARDT TORD [SE]; KARLSSON OLLE [SE]; LINSCHOTEN MARCEL [SE]; NYSTROM JAN-ERIK [SE]

Title: SELF-FLUSHING MEDICAL APPARATUS

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 11/379884   Filing Date: 24/Apr/2006

Abstract:An apparatus for use in a therapeutic medical procedure that may include an elongate sheath having a longitudinal axis, an outer surface a distal end and a proximal end, the elongate sheath having a first lumen having a first cross-sectional area running from an first opening at the distal end to a first point proximal the distal end and a second lumen fluidly connected to the first lumen, the second lumen having a distal end at or proximal the first point and a second cross-sectional area less than the first cross-sectional area, the second lumen having a portion running generally along the elongate axis

and an elongate member having a first portion having a third cross-sectional area, a proximal end and a distal end and having a therapeutic device disposed on the elongate member proximate the distal end, the therapeutic device having a first configuration having a fourth cross-sectional area, wherein the elongate member is disposed in the first and second lumens and the distal protection device is disposed in the first lumen, wherein when the distal protection device is disposed in the first lumen, the elongate sheath has a second opening proximate and proximal the distal protection device and a third opening proximal the second opening in which the elongate member is partially disposed, and wherein the second opening is in fluid communication with the third opening when the distal protection device is disposed in the first lumen.

Priority:

Inventor: KIM ELIOT T [US]

Title: Method of Treatment for Undesired Effect Following Transdermal or Topical Drug Delivery

Applicant/Assignee: ACRUX DDS PTY LTD

Application No.: 10/581991   Filing Date: 09/Dec/2004

Abstract:This invention relates to a method for inhibiting the percutaneous absorption of a physiologically active agent topically applied to a transdermal administration site of a subject, the method including the step of applying to skin of the subject at the transdermal administration site, a device ( 1, 7 ) comprising a membrane ( 8 ) for contacting the skin of the subject coated on the skin contacting side thereof ( 11 ) with a layer of an adhesive ( 10 ).

Priority: AU20030906842 Applic. Date: 2003-12-10; WO2004AU01738 Applic. Date: 2004-12-09

Inventor: HUMBERSTONE ANDREW J [AU]; WILKINS NINA F [AU]; GONDA IGOR [AU]

Title: System and Method for Real-Time Diagnosis, Treatment, and Therapeutic Drug Monitoring

Applicant/Assignee:

Application No.: 10/588749   Filing Date: 28/Feb/2005

Abstract:Systems and methods for diagnosing and/or treating diseases as well as monitoring disease treatment. For diagnosis, the present invention uses nanoparticle-based assemblies, which comprise a nanoparticle

a surrogate marker

and a means for detecting a specific chemical entity. In certain embodiments, nanoparticle-based assemblies include a payload for simultaneous diagnosis and treatment of disease. In further embodiments, a therapeutic drug and therapeutic drug marker are administered to a patient to monitor disease treatment. Bodily fluid samples are analyzed using sensor technology to detect the presence of surrogate and/or therapeutic drug markers to provide an efficient and accurate means for diagnosing a disease and/or monitoring disease treatment.

Priority: US2000-708789 Applic. Date: 2000-11-08; WO2005US06355 Applic. Date: 2005-02-28

Inventor: MELKER RICHARD J [US]; SACKELLARES JAMES C [US]; GOLD MARK S [US]; DENNIS DONN M [US]

Title: Methods of Using High Affinity Atiii Variants

Applicant/Assignee:

Application No.: 10/584640   Filing Date: 10/Jan/2005

Abstract:Disclosed are compositions and methods related to binding of ATIII under low and high shear rate conditions.

Priority: US20040535360P Applic. Date: 2004-01-09; US20040618746P Applic. Date: 2004-10-14; WO2005US00843 Applic. Date: 2005-01-10

Inventor: BOCK SUSAN C [US]

Title: Peptides That Bind To Atherosclerotic Lesions

Applicant/Assignee: THE SCRIPPS RESEARCH INSTITUTE

Application No.: 10/486318   Filing Date: 09/Aug/2002

Abstract:The present invention provides peptides that selectively bind to mammalian atherosclerotic lesions. The present invention also provides methods for in vivo identification of peptides capable of binding to biomolecules as well as methods for identifying the targets of such binding moieties. Methods to diagnose or treat pathologic conditions that involve atherosclerotic lesions are also provided by the invention that involve administering to a mammal a peptide attached to a reporter molecule or a therapeutic agent, respectively.

Priority: US20010311507P Applic. Date: 2001-08-10; WO2002EP08942 Applic. Date: 2002-08-09

Inventor: LIU CHENG [US]; EDGINGTON THOMAS S [US]; PRESCOTT MARGARET F [US]

Title: Electrosurgical instrument with suction, irrigation and means to collect blood

Applicant/Assignee:

Application No.: 11/473103   Filing Date: 23/Jun/2006

Abstract:An electrosurgical instrument with electrode, suction, optional irrigation and means to bend the distal part of the surrounding suction tube is described. A distal part of the suction tube (around the electrode) has two members, whereas one member can be engaged inside the other-to various degrees-in order to control the length of the suction tube and its relation to the tip of the electrode. Means to fixate the electrode within the suction tube are described. Also described are means to evacuate smoke, blood, irrigation anticoagulant fluid and debris via a suction tube to a separation chamber and evacuation of the gaseous portions by a vacuum machine. The separation chamber serves as a blood collection container (the blood could then be re-infused to the patient!). Irrigation means of isotonic fluid with blood-anticoagulant combined with the suction are described. Combination of the various functions and options could be utilized for building various useful surgical instruments.

Priority: IL20060175493 Applic. Date: 2006-05-09

Inventor: BEN-SIMHON HAIM [IL]

Title: Drug Delivery Device

Applicant/Assignee: TAYSIDE FLOW TECHNOLOGIES LTD

Application No.: 10/597677   Filing Date: 04/Feb/2005

Abstract:A drug delivery device ( 1 ) is disclosed. The device comprises a vascular implant having a helical formation ( 4 ) that is capable of inducing helical flow of blood passing it. A drug is releasably associated with the helical formation.

Priority: GB20040002736 Applic. Date: 2004-02-06; WO2005GB00379 Applic. Date: 2005-02-04

Inventor: HOOD ROBERT G [GB]; DUFF CRAIG M [GB]

Title: Gene Expression Technique

Applicant/Assignee: DELTA BIOTECHNOLOGY LIMITED

Application No.: 10/584424   Filing Date: 23/Dec/2004

Abstract:The present invention provides a method for producing heterologous protein comprising: (a) providing a host cell comprising a 2 mum-family plasmid, the plasmid comprising a gene encoding a protein comprising the sequence of a chaperone protein and a gene encoding a heterologous protein

(b) culturing the host cell in a culture medium under conditions that allow the expression of the gene encoding the chaperone protein and the gene encoding a heterologous protein

(c) purifying the thus expressed heterologous protein from the cultured host cell or the culture medium.

Priority: GB20030029681 Applic. Date: 2003-12-23; WO2004GB05462 Applic. Date: 2004-12-23

Inventor: SLEEP DARRELL [GB]; SHUTTLEWORTH GILLIAN [GB]; FINNIS CHRISTOPHER JOHN A [GB]

Title: Intravascular Line and Port Cleaning Methods, Methods of Administering an Agent Intravascularly, Methods of Obtaining/Testing Blood, and Devices for Performing Such Methods

Applicant/Assignee: HYPROTEK, INC

Application No.: 11/745843   Filing Date: 08/May/2007

Abstract:An intravascular port access device includes a first component having a chamber configured to attach reversibly to an intravenous line port. A second component reversibly attaches to the first component and contains a disinfecting agent and an applicator material. The second component is configured to be reversibly received over external surfaces of the intravenous line port. A method of cleansing an intravenous line port includes providing a port cleaning device having a first component with a chamber containing a first cleaning agent. A second component includes a second cleaning agent. A third component has a microbiocidal agent and is reversibly attached to the first component. The second component is removed from the device, the external surfaces of the port are contacted with the second cleaning agent, the first cleaning agent is ejected from the chamber into the port, and the third component is used to cap the port.

Priority: US20060842194P Applic. Date: 2006-08-31; US20060747606P Applic. Date: 2006-05-18; US20070895621P Applic. Date: 2007-03-19

Inventor: TENNICAN PATRICK O [US]

Title: PLASMA EXTRACTION APPARATUS

Applicant/Assignee: CHROMEDX INC

Application No.: 11/835631   Filing Date: 08/Aug/2007

Abstract:Some analyzers cannot measure blood analytes from a sample of whole blood, but can measure the analytes in plasma extracted from the whole blood. Some embodiments of the invention provide a disposable apparatus that is suitable for extracting plasma from whole blood received from a blood supply. The blood supply includes one of a tube containing blood, a syringe containing blood, a drop of blood on the skin resulting from a pin prick, a vein, an artery, and an arterial line. The apparatus includes a housing, and arranged within the housing is a porous membrane, a filtration chamber, and a plasma collection chamber. The porous membrane forms a barrier between the whole blood and the plasma extracted from the whole blood. The filtration chamber receives the whole blood for plasma extraction, and the plasma collection chamber collects the plasma extracted from the whole blood.

The apparatus also includes a blood flow path within the housing, and the blood flow path includes the filtration chamber. Means for enabling blood flow in the blood flow path are provided, and means for enabling plasma extraction and plasma removal from the housing are also provided.

Priority: CA20052507323 Applic. Date: 2005-05-13; US2006-432616 Applic. Date: 2006-05-12

Inventor: SAMSOONDAR JAMES [CA]

Title: Production of tissue factor in plants

Applicant/Assignee:

Application No.: 11/165590   Filing Date: 22/Jun/2005

Abstract:The instant invention provides transgenic plants that express mammalian, e.g., human, recombinant tissue factor (rhTF) as well as methods for making rhTF. The invention further provides rhTF or functional fragment thereof that are obtained from a transgenic plant. The invention also provides methods of treating a subject using the rhTF or a fragment thereof.

Priority: US20040583187P Applic. Date: 2004-06-25

Inventor: NEGROUK VALENTIN [US]; WONG HING C [US]; TAYLOR DEAN [US]; HAN KAI-PING [US]

Title: Methods and Compositions for the Treatment or Prevention of Secondary Ischemic Injury

Applicant/Assignee: INDEX PHARMACEUTICALS AB

Application No.: 10/589842   Filing Date: 21/Feb/2005

Abstract:After a primary ischemic injury, which predominantly results in necrosis, there is a secondary injury in the neighbouring tissue, due at least to some extent to apoptosis. This secondary damage is usually not evident until several days after the initial ischemic event. The present invention provides methods of preventing, treating and/or alleviating secondary ischemic damage in a mammalian organ or tissue, comprising a step of administering an effective amount of an NF-kappaB inhibitor to said organ or tissue. Compositions for this purpose are also disclosed.

Priority: SE20040000399 Applic. Date: 2004-02-20; US20040546723P Applic. Date: 2004-02-20; WO2005SE00231 Applic. Date: 2005-02-21

Inventor: VON STEIN OLIVER [SE]; PETTERSSON SVEN [SE]; LIM SAI K [SG]

Title: Apparatus for vascular and nerve tissue histogenesis and enhancement

Applicant/Assignee:

Application No.: 11/477175   Filing Date: 28/Jun/2006

Abstract:An apparatus for delivering decompressive energy to soft tissues to stimulate cellular expansion through deep penetration of said applied decompressive energy to said soft tissues to stimulate a predetermined reaction to application of said decompressive energy comprising a vessel having an open end and adapted to encompass the soft tissue to be stimulated. A source of decompressive energy in communication with said vessel and a flexible mass affixed to said open end of said vessel to absorb the pressure exerted by delivery of said decompressive energy to said soft tissue, thereby acting as a seal and force diffuser between said vessel and the soft tissue adjacent the periphery of said vessel.

Priority:

Inventor: KAISER DANIEL E [US]

Title: Automated system, method, and kit for immediate treatment of acute medical condition

Applicant/Assignee:

Application No.: 11/300104   Filing Date: 13/Dec/2005

Abstract:A system, method, and kit for immediate and initial treatment of an acute medical condition. The system, method, and kit may be self-administered in the event of an acute medical condition.

Priority: US20040635800P Applic. Date: 2004-12-13

Inventor: MACKIE ROBERT W JR [US]

Title: Medicaments Comprising Carbonyl Compounds, And The Use Thereof

Applicant/Assignee:

Application No.: 11/575711   Filing Date: 24/Aug/2005

Abstract:Use of compounds of the formula (I) in which D, E, G, W, X, Y, T, R<1 >and R<2 >have the meaning indicated in Patent Claim 1 , for the prophylaxis and/or therapy of thromboembolic diseases

Priority: DE200410045796 Applic. Date: 2004-09-22; WO2005EP09124 Applic. Date: 2005-08-24

Inventor: CEZANNE BERTRAM [DE]; DORSCH DIETER [DE]; MEDERSKI WERNER [DE]; TSAKLAKIDIS CHRISTOS [DE]; GLEITZ JOHANNES [DE]

Title: Method of medically treating an individual

Applicant/Assignee:

Application No.: 11/478070   Filing Date: 29/Jun/2006

Abstract:A method immunizing an individual that minimizes the amount of antigen or attenuated organism needed and the number of doses and clinic visits required, while making possible polyvalent simultaneous immunizations. The method comprises the steps of obtaining a sample of blood. Exposing at least a portion of this sample to at least one immunogenic antigen, attenuant or other immunogen. Incubating the exposed sample under specified optimal conditions and introducing this exposed sample into the individual to effect immunization thereof. The method of the invention also provides a method of delivery of materials, other than antigens, throughout an individual's body such as therapeutic drugs, virus vectors, genes, DNA, RNA, isotopes, and other therapeutic substances. A method for the delivery of treatment material to an individual is also provided by this method.

Priority:

Inventor: NALIN DAVID R [US]

Title: SAMPLE PROCESSING

Applicant/Assignee: IQUUM, INC

Application No.: 11/674117   Filing Date: 12/Feb/2007

Abstract:A sample processing tubule may include at least three segments. Each segment may be defined by the tubule, may be fluidly isolated, at least in part by a breakable seal, may be so expandable as to receive a volume of fluid expelled from another segment, and may be so compressible as to contain substantially no fluid when so compressed. At least one segment may contain at least a control reagent. At least one segment may contain at least one of a nucleic acid amplification reagent and a detection reagent.

Priority: US20060743292P Applic. Date: 2006-02-14

Inventor: CHEN SHUQI [US]; CHEN LINGJUN [US]

Title: PLASMA-DEPLETED, NON-RED BLOOD CELL-DEPLETED CORD BLOOD COMPOSITIONS AND METHODS OF USE

Applicant/Assignee: STEMCYTE, INC

Application No.: 11/771942   Filing Date: 29/Jun/2007

Abstract:The umbilical cord blood (UCB) compositions of the present invention possess the unique features of having plasma that is substantially depleted from the UCB unit and red blood cells (RBC) that are not depleted from the UCB unit. Such UCB units can be prepared by a process that combines plasma depletion with cryopreservation, selection, thawing, and/or transplantation of hematopoietic stem cells to provide superior clinical outcome by maximizing post-processing cell recovery and post-thaw infusion cell dose. Methods for treating a wide variety of malignant diseases and benign diseases associated with the hematopoietic system by administering the UCB compositions of the present invention are also provided.

Priority: US2006-422017 Applic. Date: 2006-06-02; US20050733956P Applic. Date: 2005-11-03; US20050687127P Applic. Date: 2005-06-02

Inventor: CHOW ROBERT [US]

Title: Novel tissue support

Applicant/Assignee:

Application No.: 11/825478   Filing Date: 06/Jul/2007

Abstract:The present disclosure provides tissue supports which may be utilized by themselves or in combination with other tissue closure means to enhance wound closure and healing. The tissue supports are made of a material which shrinks upon application of heat or light to further support the tissue and/or wound to which it is applied.

Priority: US20060819152P Applic. Date: 2006-07-07

Inventor: PROMMERSBERGER MEGAN [US]

Title: Device and method for high-throughput quantification of mRNA from whole blood

Applicant/Assignee:

Application No.: 11/803663   Filing Date: 15/May/2007

Abstract:Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.

Priority: US2004-796298 Applic. Date: 2004-03-09; US2003-698967 Applic. Date: 2003-10-30; WO2003US12895 Applic. Date: 2003-04-24; US20020375472P Applic. Date: 2002-04-24

Inventor: MITSUHASHI MASATO [US]

Title: STENT DESIGN WITH SHEATH ATTACHMENT MEMBERS

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 11/857531   Filing Date: 19/Sep/2007

Abstract:A stent is provided having attachment members for allowing attachment of a sheath or sheaths. Accordingly, a practitioner is able to selectively choose a desirable sheath, such as a polymeric sleeve, a biomaterial, or a natural blood vessel, at a point-of-use and attach it to the sheath. The attachment members may be bendable tabs and/or secondary support stents.

Priority: US2001-974653 Applic. Date: 2001-10-10

Inventor: BICEK ANDREW D [US]; GIRTON TIMOTHY S [US]

Title: Perturbed membrane-binding compounds and methods of using the same

Applicant/Assignee: APOSENSE LTD

Application No.: 11/882490   Filing Date: 02/Aug/2007

Abstract:The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes.

Priority: US2004-799586 Applic. Date: 2004-03-15; US20040536493P Applic. Date: 2004-01-15; US20040537289P Applic. Date: 2004-01-20

Inventor: ZIV ILAN [IL]; SHIRVAN ANAT [IL]

Title: System and Method for Delivery of Regional Citrate Anticoagulation to Extracorporeal Blood Circuits

Applicant/Assignee: HENRY FORD HEALTH SYSTEM

Application No.: 11/829261   Filing Date: 27/Jul/2007

Abstract:The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.

Priority: WO2007US62589 Applic. Date: 2007-02-22; US20060775729P Applic. Date: 2006-02-22; US20060775728P Applic. Date: 2006-02-22; US20060790882P Applic. Date: 2006-04-11; US20060791055P Applic. Date: 2006-04-11; US20060845646P Applic. Date: 2006-09-19

Inventor: SZAMOSFALVI BALAZS [US]; FRINAK STANLEY [US]; YEE JERRY [US]

Title: Novel skin staples

Applicant/Assignee:

Application No.: 11/827278   Filing Date: 11/Jul/2007

Abstract:The present disclosure provides composite staples which include legs made of a bioabsorbable shape memory material capable of gripping tissue upon application in vivo and holding the staple in place.

Priority: US20060819965P Applic. Date: 2006-07-11

Inventor: PROMMERSBERGER MEGAN [US]

Title: Membrane-based Double-layer Tube for Sample Collections

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 11/459076   Filing Date: 21/Jul/2006

Abstract:The fluid sample collection device is adapted to collect and separate a fluid sample into constituent parts such as separating plasma or serum from a blood sample. The device includes an evacuated outer container and an inner container. The outer container has a first open end and a second closed end. A pierceable closure closes the first open end thereby defining a first interior chamber. The inner container is contained within the outer container and separates the first interior chamber into an upper chamber portion and lower chamber portion in fluid communication. The inner container defines a second interior chamber separated from the lower chamber portion through a porous membrane. A port is provided for placing the second interior chamber in fluid communication with the first interior chamber. Another aspect of the device relates to a method of using the device to separate plasma or serum from a blood sample.

Priority:

Inventor: YI JIZU [US]; LIN FU CHUNG [US]; MANOUSSAKIS DIMITRIOS [US]; GELFAND CRAIG [US]

Title: NOVEL TISSUE FACTOR TARGETED THROMBOMODULIN FUSION PROTEINS AS ANTICOAGULANTS

Applicant/Assignee: BAYER SCHERING AG BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Application No.: 11/766155   Filing Date: 21/Jun/2007

Abstract:This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Priority: US2003-427805 Applic. Date: 2003-04-30; US20020376566P Applic. Date: 2002-05-01

Inventor: LIGHT DAVID [US]; MCLEAN KIRK [US]

Title: NOVEL TISSUE FACTOR TARGETED THROMBOMODULIN FUSION PROTEINS AS ANTICOAGULANTS

Applicant/Assignee: BAYER SCHERING AG BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Application No.: 11/766160   Filing Date: 21/Jun/2007

Abstract:This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Priority: US2003-427805 Applic. Date: 2003-04-30; US20020376566P Applic. Date: 2002-05-01

Inventor: LIGHT DAVID [US]; MCLEAN KIRK [US]

Title: NOVEL BENZAMIDINE COMPOUND

Applicant/Assignee: AJINOMOTO CO. INC AJINOMOTO CO., INC

Application No.: 11/832895   Filing Date: 02/Aug/2007

Abstract:Compounds represented by formula (1) and pharmaceutically acceptable salt thereofs: wherein each symbol is as defined in the specification, are useful as inhibitors of an activated blood coagulation factor X. Compositions which contain, as an active ingredient, an FXa selective low-molecular weight FXa inhibitor having a short serum half-life are particularly useful as anticoagulants for an extracorporeal blood circuit.

Priority: JP20050026949 Applic. Date: 2005-02-02; WO2006JP302202 Applic. Date: 2006-02-02

Inventor: TAKAYANAGI MASARU [JP]; TAKEHANA SHUNJI [JP]; OTANI KAYO [JP]; SAITOU YUKI [JP]

Title: WEARABLE ULTRAFILTRATION DEVICE

Applicant/Assignee: NATIONAL QUALITY CARE, INC FRESENIUS MEDICAL CARE HOLDINGS, INC

Application No.: 11/830695   Filing Date: 30/Jul/2007

Abstract:An ultrafiltration device adapted to be worn on a portion of the body of a patient includes a blood inlet tube leading from a first blood vessel, a blood pump, an anticoagulant reservoir for infusing anticoagulants into the blood, a blood filter including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube leading to a second blood vessel.

Priority: US2002-251937 Applic. Date: 2002-09-19; US2001-085349 Applic. Date: 2001-11-16

Inventor: GURA VICTOR [US]; RAMBOD EDMOND [US]

Title: Apparatus and method for continuous particle separation

Applicant/Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY

Application No.: 11/809559   Filing Date: 31/May/2007

Abstract:The invention is directed to an apparatus and a method of separating particles, such as cells, from a heterogeneous fluid, such as blood, where the particles have a large range of sizes.

Priority: US20060809933P Applic. Date: 2006-06-01

Inventor: INGLIS DAVID W [AU]; DAVIS JOHN [US]; AUSTIN ROBERT [US]; STURM JAMES [US]

Title: Disposable Fluid Sample Collection Device

Applicant/Assignee:

Application No.: 10/578453   Filing Date: 05/Nov/2004

Abstract:A fluid sampling device ( 100 ) that operates by a combination of capillary action to collect a small fluid sample, and by pressure differential when inserted into an analyzer ( 200 ) to expose the fluid sample for testing by the analyzer ( 200 ). The device is especially suited for use as a disposable blood sampling unit designed to interface with a blood analyzer, albeit the concept of the invention may be employed for sampling and testing virtually any fluids.

Priority: US20030517573P Applic. Date: 2003-11-05; WO2004US36909 Applic. Date: 2004-11-05

Inventor: DYKES CHRIS [US]; LANE BEN [US]

Title: ASSAY FOR DIFFERENTIATING COMPOUNDS THAT MODULATE THE EXTRINSIC AND/OR INTRINSIC COAGULATION PATHWAYS

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 11/782660   Filing Date: 25/Jul/2007

Abstract:Methods for differentiating compounds that modulate the extrinsic and/or intrinsic coagulation pathways are provided. Also provided are methods for identifying a compound that modulates the extrinsic coagulation pathway. In addition, methods for determining an effective dosage of an anticoagulant in a patient are provided.

Priority: US20060833674P Applic. Date: 2006-07-27

Inventor: WANG XINKANG [US]; HSU MEI-YIN [US]; WONG PANCRAS C [US]

Title: Treatment of endotoxemia using endotoxin neutralizing agents

Applicant/Assignee:

Application No.: 11/703538   Filing Date: 06/Feb/2007

Abstract:Methods and compositions for selecting a patient suffering from endotoxemia for treatment with an endotoxin neutralizing agent are disclosed comprising: (a) determining the level of endotoxin in the patient's blood

and (b) comparing the endotoxin level in the patient's blood to a predetermined threshold endotoxin level to determine if the patient has elevated endotoxin levels. The methods can further comprise treating patients identified as having elevated levels of endotoxin with an endotoxin neutralizing therapy. The methods provide increased safety and a reduction in risk for critically ill patients.

Priority: US20060765996P Applic. Date: 2006-02-06

Inventor: SANDERS MARTIN E [US]

Title: Processes for the production of solid dressings for treating wounded tissue

Applicant/Assignee:

Application No.: 11/882872   Filing Date: 06/Aug/2007

Abstract:Disclosed are processes for preparing solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen and liquid compositions useful for preparing the haemostatic layer(s) of these dressings or for treating wounded tissue in a mammal.

Priority: US20060835423P Applic. Date: 2006-08-04

Inventor: MACPHEE MARTIN [US]; BEALL DAWSON [US]

Title: Solid dressing for treating wounded tissue

Applicant/Assignee:

Application No.: 11/882874   Filing Date: 06/Aug/2007

Abstract:Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.

Priority: US20060835423P Applic. Date: 2006-08-04

Inventor: MACPHEE MARTIN [US]; BEALL DAWSON [US]

Title: Solid dressing for treating wounded tissue

Applicant/Assignee:

Application No.: 11/882876   Filing Date: 06/Aug/2007

Abstract:Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of fibrinogen and a fibrinogen activator, wherein the fibrinogen is present in an amount between 3.0 mg/cm<2 >of the wound facing surface of the dressing and 13.0 mg/cm<2 >of the wound facing surface of the dressing. Also disclosed are methods for treating wounded tissue.

Priority: US20060835423P Applic. Date: 2006-08-04

Inventor: MACPHEE MARTIN [US]; BEALL DAWSON [US]

Title: Solid dressing for treating wounded tissue

Applicant/Assignee:

Application No.: 11/882879   Filing Date: 06/Aug/2007

Abstract:Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.

Priority: US20060835423P Applic. Date: 2006-08-04

Inventor: MACPHEE MARTIN [US]; BEALL DAWSON [US]

Title: Conveniently implantable sustained release drug compositions

Applicant/Assignee:

Application No.: 11/826833   Filing Date: 18/Jul/2007

Abstract:This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

Priority: US2005-236426 Applic. Date: 2005-09-27; US20050709665P Applic. Date: 2005-08-19; US20040614484P Applic. Date: 2004-10-01; US20060831991P Applic. Date: 2006-07-19

Inventor: WONG VERNON G [US]; WOOD LOUIS L [US]

Title: Flowable carrier matrix

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 11/504363   Filing Date: 14/Aug/2006

Abstract:A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Priority:

Inventor: BEALS NEAL [US]; SCIFERT JEFFREY L [US]; BODEN SCOTT D [US]

Title: COMPOSITIONS, KIT AND ONE-STEP METHOD FOR MONITORING COMPOUNDS HAVING ANTI-FACTOR Xa AND/OR ANTI FACTOR IIa ACTIVITIES

Applicant/Assignee:

Application No.: 11/841684   Filing Date: 20/Aug/2007

Abstract:Provided are compositions and methods for accurate determination of the concentration of anticoagulant in a sample such as a blood or plasma sample. The compositions can contain a Factor X compound and Factor V compound, and additional components as well. Methods for performing the assay include one-step methods in which a sample is added to a coagulation assay composition, and time is monitored from the point of adding the sample and coagulation assay composition to an endpoint, such as clot formation.

Priority: US2005-127540 Applic. Date: 2005-05-11; US20040570312P Applic. Date: 2004-05-11

Inventor: YIN THYE [US]

Title: Protocol for Monitoring Direct Thrombin Inhibition

Applicant/Assignee: HAEMOSCOPE CORPORATION

Application No.: 11/753071   Filing Date: 24/May/2007

Abstract:A hemostasis analyzer, such as the Thrombelastograph(R) (TEG(R)) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit evaluation of hemostasis therapies including anticoagulation therapies such as direct thrombin inhibition therapies.

Priority: US2006-608174 Applic. Date: 2006-12-07; US2003-384345 Applic. Date: 2003-03-07; US2000-591371 Applic. Date: 2000-06-09; US1999-255099 Applic. Date: 1999-02-22; US20060803184P Applic. Date: 2006-05-25

Inventor: COHEN ELI [US]; COHEN ROSLYN [US]

Title: Pegylated Factor VII Glycoforms

Applicant/Assignee: NOVO NORDISK A/S

Application No.: 11/845175   Filing Date: 27/Aug/2007

Abstract:The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked oligosaccharide chains, and wherein at least one oligosaccharide group is covalently attached to at least one polymeric group.

Priority: DK20020000964 Applic. Date: 2002-06-21; US2003-609701 Applic. Date: 2003-06-30; WO2003DK00420 Applic. Date: 2003-06-20; US20020394778P Applic. Date: 2002-07-01

Inventor: KLAUSEN NIELS K [DK]; BJORN SOREN [DK]; BEHRENS CARSTEN [DK]; GARIBAY PATRICK W [DK]

Title: DEVICES AND METHODS FOR REMOVING A MATTER FROM A BODY CAVITY OF A PATIENT

Applicant/Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA

Application No.: 11/829879   Filing Date: 27/Jul/2007

Abstract:Disclosed are systems and methods for removing a matter from a body cavity of a patient. Exemplary systems of the present invention generally comprise a delivery catheter device, a central matter retrieval device and a device retriever. The central matter retrieval device has an elongated body and shape memory foam attached thereon. In use, the central matter retrieval device is housed within a parking segment of the delivery catheter and delivered to a desired body cavity in a patient. The retriever device is separately deployed to securely remove the matter and the central matter retrieval device from the patient.

Priority: US2005-087780 Applic. Date: 2005-03-23; WO2005US09658 Applic. Date: 2005-03-24; US20040556993P Applic. Date: 2004-03-26; US20040611684P Applic. Date: 2004-09-20; US20060820671P Applic. Date: 2006-07-28

Inventor: TEITELBAUM GEORGE P [US]; LARSEN DONALD W [US]

Title: COMPOSITIONS AND METHODS FOR JOINING NON-CONJOINED LUMENS

Applicant/Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Application No.: 11/766779   Filing Date: 21/Jun/2007

Abstract:Disclosed are compositions, methods, and kits for joining together non-conjoined lumens in a patient's body including vascular lumens. More particularly, in various aspects, this invention provides compositions, methods, and kits for joining such non-conjoined lumens, including small lumens typically requiring microsurgical technique

Priority: US20060805425P Applic. Date: 2006-06-21; US20060806242P Applic. Date: 2006-06-29; US20070914635P Applic. Date: 2007-04-27

Inventor: GURTNER GEOFFREY C [US]; FULLER GERALD G [US]; LONGAKER MICHAEL T [US]; RAJADAS JAYAKUMAR [US]

Title: Sealed Sterile System and Method for Filtering Biological or Medical Fluids, in Particular Whole Blood

Applicant/Assignee: GERATEZENTRALE FUR BLUTTRANSFUSION DES OSTERREICHI

Application No.: 11/632823   Filing Date: 14/Jun/2005

Abstract:The invention relates to a sealed, sterile system for filtering fluids, in particular whole blood. The system comprises a first collapsible container for receiving the fluid to be filtered and a second collapsible container for receiving the filtered fluid, both containers interconnected by a fluid line, in which a filter and a third container, for deaeration, are located. The first collapsible container contains a predetermined quantity of air, which is sufficient to ensure that no blood remains in the filter and the adjacent tube line sections when the whole blood is transferred from the first container into the second container. The air that is present in the second container, after the whole blood has been filtered, is transferred to the deaeration container.

Priority: DE200410035352 Applic. Date: 2004-07-21; WO2005EP06338 Applic. Date: 2005-06-14

Inventor: SOMMER CHRISTIAN [AT]; KURZ MICHAEL [AT]; MAYER GUNTER [AT]

Title: Tool for Recovering Biological Samples and Method for Recovering Biological Samples

Applicant/Assignee: EIKEN KAGAKU KABUSHIKI KAISHA

Application No.: 11/597412   Filing Date: 25/May/2005

Abstract:This invention provides a tool for recovering biological samples for realizing more simple and accurate clinical testing with the use of a trace amount of the blood sample, a kit comprising the same, and a method for recovering and separating biological samples using the same. Such tool comprises: a recovery container body composed of an upper container portion having a medium-accommodating portion, provided with an upper opening, for accommodating and conserving an absorption medium to be impregnated with the recovered biological samples and a lower container portion for accommodating the biological samples separated from the medium

and a lid for closing the upper opening of the medium-accommodating portion, the bottom of such medium-accommodating portion being provided with an open area in communication with the lower container portion.

Priority: JP20040158290 Applic. Date: 2004-05-27; WO2005JP09534 Applic. Date: 2005-05-25

Inventor: SEKINE KAZUHITO [JP]; HIRAHARA SHIN [JP]; ICHIKAWA YOSHIHARU [JP]; TAKAHASHI TOMOYOSHI [JP]; OYAMA TAKAO [JP]; TAKAHASHI MASAMI [JP]

Title: Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots

Applicant/Assignee: TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Application No.: 11/640737   Filing Date: 18/Dec/2006

Abstract:Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.

Priority: US2002-253518 Applic. Date: 2002-09-23; US1999-454666 Applic. Date: 1999-12-03; WO1999US10547 Applic. Date: 1999-05-12; US19980086262P Applic. Date: 1998-05-21

Inventor: MUZYKANTOV VLADIMIR R [US]; HIGAZI ABD A [US]; MURCIANO JUAN C [ES]; CINES DOUGLAS [US]; TAYLOR RONALD P [US]

Title: System and device for medically treating an individual

Applicant/Assignee:

Application No.: 11/507876   Filing Date: 22/Aug/2006

Abstract:A system for medically treating/vaccinating an individual comprising a first syringe, containing an anticoagulant material therein, for drawing a sample of blood from the individual. A centrifuge means for centrifuging the sample of blood contained within the first syringe to obtain a buffy coat. A second syringe comprising a second plunger and at least one microtubule member containing one of a treatment agent and a vaccine antigen. At least one open end formed within the at least one microtubule member for drawing a portion of the buffy coat therein and exposing the buffy coat to one of the treatment agent and vaccine antigen. A second needle capable of being attached onto the second syringe for introducing the exposed sample into the individual to effect treatment/vaccination thereof.

This system is capable of allowing a plurality of treatment agents and/or vaccine antigens to be simultaneously applied to an individual.

Priority:

Inventor: NALIN DAVID R [US]

Title: NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/928250   Filing Date: 30/Oct/2007

Abstract:Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US2003-392403 Applic. Date: 2003-03-20; US20020365540P Applic. Date: 2002-03-20; US20020366542P Applic. Date: 2002-03-25

Inventor: MERISKO-LIVERSIDGE ELAINE [US]; BOSCH H WILLIAM [US]; CARY GRETA G [US]; PRUITT JOHN [US]; RYDE TUULA [US]; JAIN RAJEEV [US]; WALTERS AMY [US]

Title: WEARABLE ULTRAFILTRATION DEVICE

Applicant/Assignee: NATIONAL QUALITY CARE, INC

Application No.: 11/933569   Filing Date: 01/Nov/2007

Abstract:An ultrafiltration device adapted to be worn on a portion of the body of a patient includes a blood inlet tube leading from a first blood vessel, a blood pump, an anticoagulant reservoir for infusing anticoagulants into the blood, a blood filter including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube leading to a second blood vessel.

Priority: US2004-846618 Applic. Date: 2004-05-17; US2001-085349 Applic. Date: 2001-11-16

Inventor: GURA VICTOR [US]; RAMBOD EDMOND [US]

Title: Self-Propelled Sterilization Robot and Method

Applicant/Assignee:

Application No.: 11/468157   Filing Date: 29/Aug/2006

Abstract:A sterilization apparatus ( 200 ) comprises a robot ( 201 ), at least one germicidal energy source ( 202 ), and at least one motive capability ( 203 ). The sterilization apparatus may optionally further comprise numerous additional components, including a filtration unit ( 204 ), at least one power source ( 209 ), a power connector ( 210 ), an environmental sampling device ( 211 ), at least one sensor ( 212 ), a control system ( 213 ), an audio output device ( 214 ), a data transmitter ( 215 ), a global positioning satellite (GPS) receiver ( 216 ), a radio frequency identification (RFID) tag ( 217 ), a vacuum device ( 218 ), a floor washing device ( 219 ), an activator ( 220 ), a waterproof housing ( 221 ), and/or a padded housing ( 222 ).

Priority:

Inventor: MOORE BARRETT H [US]; BOTOS MATTHEW J [US]

Title: MEDICAL DEVICES FOR CONTROLLED DRUG RELEASE

Applicant/Assignee:

Application No.: 11/839093   Filing Date: 15/Aug/2007

Abstract:The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.

Priority: US20060823057P Applic. Date: 2006-08-21; US20060823061P Applic. Date: 2006-08-21; US20060823063P Applic. Date: 2006-08-21; US20060823067P Applic. Date: 2006-08-21; US20060823069P Applic. Date: 2006-08-21; US20060823071P Applic. Date: 2006-08-21

Inventor: ROORDA WOUTER [US]

Title: METHODS OF MANUFACTURING MEDICAL DEVICES FOR CONTROLLED DRUG RELEASE

Applicant/Assignee:

Application No.: 11/839104   Filing Date: 15/Aug/2007

Abstract:The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.

Priority: US20060823057P Applic. Date: 2006-08-21; US20060823061P Applic. Date: 2006-08-21; US20060823063P Applic. Date: 2006-08-21; US20060823067P Applic. Date: 2006-08-21; US20060823069P Applic. Date: 2006-08-21; US20060823071P Applic. Date: 2006-08-21; US2007-839093 Applic. Date: 2007-08-15; US2007-839121 Applic. Date: 2007-08-15

Inventor: ROORDA WOUTER [US]

Title: METHODS OF USING MEDICAL DEVICES FOR CONTROLLED DRUG RELEASE

Applicant/Assignee:

Application No.: 11/839121   Filing Date: 15/Aug/2007

Abstract:The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.

Priority: US20060823057P Applic. Date: 2006-08-21; US20060823061P Applic. Date: 2006-08-21; US20060823063P Applic. Date: 2006-08-21; US20060823067P Applic. Date: 2006-08-21; US20060823069P Applic. Date: 2006-08-21; US20060823071P Applic. Date: 2006-08-21; US2007-839093 Applic. Date: 2007-08-15; US2007-839104 Applic. Date: 2007-08-15

Inventor: ROORDA WOUTER [US]

Title: Autotransfusion Method and Autotransfusion Device with Phase Separation and Concentration, Comprising Removable Bags

Applicant/Assignee: DIRECTION ET PRIORITES SA

Application No.: 11/660323   Filing Date: 04/Aug/2005

Abstract:A process for treating the haemorrhage fluids of a patient at the time of a surgical procedure with the aim of carrying out an autotransfusion, includes a stage for recovering the haemorrhage fluids with simultaneous introduction of agents such as anticoagulant and/or diluting agents, at least one stage for the mechanical separation/concentration of this haemodiluted haemorrhage fluid in order to concentrate its content in red blood cells and partially purify it, this phase being collected in a sterile manner so as to be fit for injecting back to the patient. Also described is the related device.

Priority: WO2005FR50648 Applic. Date: 2005-08-04

Inventor: PEROVITCH PHILIPPE [FR]; GADRAT FRANCIS [FR]; CHASTENET BERTRAND [FR]

Title: WEARABLE CONTINUOUS RENAL REPLACEMENT THERAPY DEVICE

Applicant/Assignee: NATIONAL QUALITY CARE, INC

Application No.: 11/933533   Filing Date: 01/Nov/2007

Abstract:A continuous renal replacement therapy (CRRT) device adapted to be worn on a portion of the body of a patient. The CRRT device is worn by the patient and operates on rechargeable batteries for more than 5 hours. Dialysate is used to remove impurities from the blood. The dialysate is recycled and refreshed by a filter section. Less than one liter of dialysate is required to circulate through the wearable CRRT device.

Priority: US2004-940862 Applic. Date: 2004-09-14; US2001-085349 Applic. Date: 2001-11-16

Inventor: GURA VICTOR [US]; RAMBOD EDMOND [US]

Title: Thin film dressing

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 11/900301   Filing Date: 11/Sep/2007

Abstract:Multi-layer articles are provided which are suitable for use as medical dressings. The articles include a hydrophilic layer, a hydrophobic layer, a delivery layer, and a release layer. In embodiments, the articles may also include adhesive tapes, stabilizer layers, and absorbent materials which may be included in an existing layer or applied as a separate absorbent layer.

Priority: US20060844008P Applic. Date: 2006-09-12

Inventor: VITARIS RONALD F [US]

Title: Pharmaceutical Compositions of Amorphous Dispersions of Drugs and Lipophilic Microphase-Forming Materials

Applicant/Assignee:

Application No.: 11/924988   Filing Date: 26/Oct/2007

Abstract:A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material. Alternatively, a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer is co-administered with a lipophilic microphase-forming material to an in vivo use environment.

Priority: WO2003IB00335 Applic. Date: 2003-01-28; US2003-355747 Applic. Date: 2003-01-31; US20020354081P Applic. Date: 2002-02-01

Inventor: PERLMAN MICHAEL E [US]; SHANKER RAVI M [US]; BABCOCK WALTER C [US]; FRIESEN DWAYNE T [US]; RABENSTEIN MARK D [US]; SMITHEY DAN T [US]

Title: METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION

Applicant/Assignee:

Application No.: 11/689315   Filing Date: 21/Mar/2007

Abstract:Systems and methods for delivery of a drug to the respiratory system of a patient are provided, where the drug is supplied in purified air at a positive pressure relative to atmospheric pressure. With the systems and methods of the present disclosure, medication available in a variety of forms is introduced in a controlled fashion into the purified air stream in aerosol, nebulized, or vaporized form.

Priority: US2007-627692 Applic. Date: 2007-01-26; US2006-552871 Applic. Date: 2006-10-25; US20060826271P Applic. Date: 2006-09-20

Inventor: LEMAHIEU EDWARD [US]; JONES CHARLES [US]; STERN TOM [US]; HEBRANK JACK [US]; HUNTER CHARLES ERIC [US]; DUVALL LYNDELL [US]; HARTLEY CHRIS [US]; BALLOU BERNARD L [US]; HUNTER JOCELYN [US]; MCNEIL LAURIE [US]; WETZEL PAUL [US]; CRISS RON [US]

Title: Compressible resilient granules and formulations prepared therefrom

Applicant/Assignee:

Application No.: 11/899601   Filing Date: 05/Sep/2007

Abstract:The present invention provides resilient self-adhering granules which comprise a polysaccharide present in an amount from about 10 wt % to about 90 wt % and a binder having a viscosity from about 5,000 mPa.s to about 250,000 mPa.s present in an amount from about 90 wt % to about 10 wt %, wherein the granule is capable of reversible agglomeration at or below 6,500 kilonewtons/m<2>. The present invention also provides oral dosage compositions comprising the resilient self-adhering granules and methods for making and using the resilient self-adhering granules.

Priority: US2007-715821 Applic. Date: 2007-03-07; US20060780304P Applic. Date: 2006-03-07

Inventor: CHERUKURI S R [US]

Title: Permucosal Composition and Method of Improving Permucosal Absorption

Applicant/Assignee: OTSUKA PHARMACEUTICAL CO., LTD

Application No.: 11/662094   Filing Date: 12/Sep/2005

Abstract:An object of the invention is to provide a composition for transmucosal administration that enables pharmacologically active peptides and proteins to be efficiently absorbed through the mucosa such as the pulmonary mucosa, nasal mucosa, oral mucosa, vaginal mucosa, gastric mucosa, gastrointestinal mucosa or the like. A composition for transmucosal administration are prepared by adding (i) at least one member selected from the group consisting of peptides and proteins having pharmacological activity

and (ii) at least one member selected from the group consisting of chitosan oligosaccharides having a polymerization degree of from 2 to 20, derivatives thereof, glucosamine, and salts thereof.

Priority: JP20040268891 Applic. Date: 2004-09-15; WO2005JP16739 Applic. Date: 2005-09-12

Inventor: YAMAMOTO AKIRA [JP]; YAMADA KEIGO [JP]

Title: PHARMACEUTICAL COMPOSITIONS HAVING NOVEL SCORING PATTERNS AND METHODS OF USING THOSE COMPOSITIONS

Applicant/Assignee:

Application No.: 11/735268   Filing Date: 13/Apr/2007

Abstract:The invention provides novel scoring patterns for a wide variety of tablets that contain specific drugs or contain drugs in certain drug classes, and methods of treatment with layered tablets and fractional tablets derived from breaking said tablets.

Priority: US20060791834P Applic. Date: 2006-04-13; US20060792601P Applic. Date: 2006-04-17; US20060792933P Applic. Date: 2006-04-18; US20060861898P Applic. Date: 2006-11-30

Inventor: SOLOMON LAWRENCE [US]; KAPLAN ALLAN S [US]

Title: DIAMMONIUM PHOSPHATE AND OTHER AMMONIUM SALTS AND THEIR USE IN PREVENTING CLOTTING

Applicant/Assignee:

Application No.: 11/859291   Filing Date: 21/Sep/2007

Abstract:The present invention relates to products, methods, and processes of various ammonium salts and their use as anti-coagulants.

Priority: US20060846312P Applic. Date: 2006-09-21

Inventor: LEE SAMUEL [US]; LOUIE STEPHANIE [US]; SCHWARDT JEFFREY D [US]; SLATER THOMAS A [US]; WENZ ROBERT [DE]

Title: DEVICES FOR DELIVERING SUBSTANCES THROUGH AN EXTRA-ANATOMIC OPENING CREATED IN AN AIRWAY

Applicant/Assignee: BRONCUS TECHNOLOGIES, INC

Application No.: 11/538950   Filing Date: 05/Oct/2006

Abstract:Devices and methods for delivering substances to lung tissue through an extra-anatomic passage created in an airway.

Priority:

Inventor: ROSCHAK EDMUND J [US]

Title: Mandelic acid derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB ASTRAZENECA

Application No.: 11/797656   Filing Date: 04/May/2007

Abstract:There is provided a compound of formula (I) wherein R, R<1>, R<2>, Y and R<3 >have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g., thrombosis) or as anticoagulants.

Priority: SE20000004458 Applic. Date: 2000-12-01; SE20010000965 Applic. Date: 2001-03-19; SE20010001239 Applic. Date: 2001-04-06; SE20010002921 Applic. Date: 2001-08-30; US2006-520063 Applic. Date: 2006-09-13; US2003-432411 Applic. Date: 2003-05-21; WO2001SE02657 Applic. Date: 2001-11-30

Inventor: INGHARDT TORD [SE]; JOHANSSON ANDERS [SE]; SVENSSON ARNE [SE]

Title: LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY BRISTOL-MEYERS SQUIBB COMPANY

Application No.: 11/955678   Filing Date: 13/Dec/2007

Abstract:The present application describes lactam-containing compounds and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Priority: US2005-198801 Applic. Date: 2005-08-05; US2004-850587 Applic. Date: 2004-05-20; US2002-245122 Applic. Date: 2002-09-17; US20010324165P Applic. Date: 2001-09-21; US20020402317P Applic. Date: 2002-08-09

Inventor: PINTO DONALD J P [US]; QUAN MIMI L [US]; ORWAT MICHAEL J [US]; LI YUN-LONG [US]; HAN WEI [US]; QIAO JENNIFER X [US]; LAM PATRICK Y S [US]; KOCH STEPHANIE L [US]

Title: Crystal Comprising (2R)-2-Propyloctanoic Acid and Amine

Applicant/Assignee: ONO PHARMACEUTICAL CO., LTD

Application No.: 11/579071   Filing Date: 27/Apr/2005

Abstract:Crystals comprising (2R)-2-propyloctoic acid and an amine which retain the pharmacological effect of (2R)-2-propyloctoic acid and can be safely used as a medicinal raw drug for peroral solid preparations. Of these crystals, the crystals especially with dibenzylamine are advantageous because not only the crystals themselves are useful as a medicinal raw drug but also use of the crystals as an intermediate can yield (2R)-2-propyloctoic acid having an optical purity exceeding 99.5% e.e., which has not been obtained hitherto.

Priority: JP20040134655 Applic. Date: 2004-04-28; WO2005JP08462 Applic. Date: 2005-04-27

Inventor: HASEGAWA TOMOYUKI [JP]; KAWANAKA YASUFUMI [JP]; KASAMATSU EIJI [JP]

Title: SAMPLING DEVICE

Applicant/Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY

Application No.: 11/874830   Filing Date: 18/Oct/2007

Abstract:This invention provides devices and methods for obtaining a sample.

Priority: US20060852830P Applic. Date: 2006-10-18

Inventor: MALTEZOS GEORGE [US]; SCHERER AXEL [US]

Title: Disposable Blood Sampling Device

Applicant/Assignee: KUN SHAN MEDSAFE MEDICAL TECH CO., LTD

Application No.: 11/781237   Filing Date: 21/Jul/2007

Abstract:A disposable blood sampling device is disclosed herein, which includes a plunger, a rubber stopper, a barrel, a sealing member, a needle holder, a protection sleeve, an anticoagulant storing tube and a needle sheath. In use, the disposable blood sampling device is deconstructed by removing each component therefrom and is unable to be assembled again for recycling. Furthermore, the needle can be hidden in the protection sleeve before it is detached from the blood sampling device, which effectively prevents a medical operator from being hurt or even infected by the needle.

Priority: TW20060218599U Applic. Date: 2006-10-20

Inventor: CAI JIAN [CN]

Title: HOLLOW NEEDLE ASSEMBLY

Applicant/Assignee:

Application No.: 11/466588   Filing Date: 23/Aug/2006

Abstract:Some embodiments of the invention provide a needle with a sharp open end and a blunt open end, housed in a barrel with an open anterior end and an open posterior end. The barrel can travel along the hub of the needle, for extending the needle for insertion into a blood vessel, and for retracting the needle into the barrel to avoid injury. The blunt open end can be fluidly connected to the inlet opening of a measurement apparatus, so that the blood can flow directly into the measurement apparatus, eliminating the traditional step of transferring the blood from a syringe to the measurement apparatus. The hollow needle assembly can remain attached to the measurement apparatus because of its small size, and the engagement of an optional safety cap to the open anterior end of the barrel, minimizes the risk of injury and blood contamination. Because a small blood sample is required, a very small needle shaft can be used, minimizing the discomfort experienced by the patient.

Priority:

Inventor: SAMSOONDAR JAMES [CA]

Title: Artificial Blood Vessel

Applicant/Assignee: VASCUTEK LIMITED TERUMO CORPORATION

Application No.: 11/792498   Filing Date: 14/Feb/2005

Abstract:There is described an artificial blood vessel for use in a region of a living body which needs to be repeatedly pierced with a needle. The artificial blood vessel includes a main section having a vessel wall which includes a laminated assembly comprising an inner layer, an outer layer, and an intermediate layer positioned therebetween, and a pair of anastomotic sections disposed on the respective opposite ends of the main section. Each of the anastomotic sections has an intermediate layer thinner than the intermediate layer of the main section or is free of an intermediate layer, so that the anastomotic section as a vessel wall thinner than the main section.

Priority: WO2005GB00521 Applic. Date: 2005-02-14

Inventor: FITZPATRICK CHARLES [GB]; OKUBO TADANORI [GB]

Title: Modified coagulation factor IX polypeptides and use thereof for treatment

Applicant/Assignee:

Application No.: 11/818985   Filing Date: 15/Jun/2007

Abstract:Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.

Priority: US20060815113P Applic. Date: 2006-06-19

Inventor: OYHENART JORGE [AR]; GALLET XAVIER [FR]; BORRELLY GILLES [FR]; GUYON THIERRY [FR]; VEGA MANUEL [FR]; DRITTANTI LILA [FR]

Title: Method for treating thrombotic disorders using sulfated polysaccharides

Applicant/Assignee:

Application No.: 11/789447   Filing Date: 24/Apr/2007

Abstract:Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed.

Priority: US20060797079P Applic. Date: 2006-04-27

Inventor: JOHNSON KIRK W [US]

Title: NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/928278   Filing Date: 30/Oct/2007

Abstract:Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US2003-392403 Applic. Date: 2003-03-20; US20020366542P Applic. Date: 2002-03-25; US20020365540P Applic. Date: 2002-03-20

Inventor: MERISKO-LIVERSIDGE ELAINE [US]; BOSCH H W [US]; CARY GRETA G [US]; PRUITT JOHN [US]; RYDE TUULA [US]; JAIN RAJEEV [US]; WALTERS AMY [US]

Title: Microchemical nanofactories

Applicant/Assignee: STATE UNIVERSITY

Application No.: 11/897998   Filing Date: 31/Aug/2007

Abstract:Embodiments of an apparatus, system, and method for chemical synthesis and/or analysis are disclosed. One embodiment of a disclosed apparatus comprises a laminated, microfluidic structure defining a reactor and a separator. Such apparatuses, or portions thereof, generally have dimensions ranging from about 1 micrometer to about 100 micrometers. To implement synthetic processes, disclosed embodiments of the apparatus generally include at least one unit operation, such as a mixer, a valve, a separator, a detector, and combinations thereof. Individual apparatuses may be coupled both in series and in parallel to form a system for making chemical compounds. An individual apparatus or a system also can be used in combination with known devices and processes.

Priority: US20060841778P Applic. Date: 2006-09-01

Inventor: PAUL BRIAN K [US]; CHANG CHIH-HUNG [US]; REMCHO VINCENT T [US]

Title: ANALYTE SENSOR

Applicant/Assignee: DEXCOM, INC

Application No.: 11/691426   Filing Date: 26/Mar/2007

Abstract:Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into communication with a host's circulatory system.

Priority: US2006-543396 Applic. Date: 2006-10-04; US2006-543490 Applic. Date: 2006-10-04; US2006-543404 Applic. Date: 2006-10-04

Inventor: BRISTER MARK [US]; SWANSON VANCE [US]; PETISCE JAMES R [US]; SAINT SEAN [US]; WONG DAVID K [US]; WOO KUM MING [US]

Title: BIODEGRADABLE ELASTOMERIC SCAFFOLDS CONTAINING MICROINTEGRATED CELLS

Applicant/Assignee:

Application No.: 11/837235   Filing Date: 10/Aug/2007

Abstract:Described herein are elastomeric materials, and in particular porous biodegradable elastomeric materials which optionally may have microintegrated cells. Also described herein are bioprosthetic devices that can be manufactured using the biodegradable elastomeric materials, non-limiting examples of such devices including pulmonary valves, vocal chords, and blood vessels.

Priority: US20060822073P Applic. Date: 2006-08-10

Inventor: WAGNER WILLIAM R [US]; STANKUS JOHN [US]; GUAN JIANJUN [US]; FUJIMOTO KAZURO L [US]; NIEPONICE ALEJANDRO [AR]; SOLETTI LORENZO [US]; VORP DAVID A [US]; SACKS MICHAEL S [US]; COURTNEY TODD [US]; MAYER JOHN E [US]

Title: METHOD AND COMPOSITION FOR PREVENTING PAIN IN SICKLE CELL PATIENTS

Applicant/Assignee: TRF PHARMA, INC

Application No.: 12/015885   Filing Date: 17/Jan/2008

Abstract:A method of preventing pain in a sickle cell patient is disclosed. The method includes orally administering to the patient, an amount of an active agent effective on oral administration to inhibit binding of the patient's sickle erythrocytes to P-selectin on the patient's vascular endothelium. The inhibition may be evidenced in a number of ways. The active agent administration inhibits the adhesion of sickle erythrocytes to vascular endothelium in the patient, thereby preventing patient pain associated with vascular occlusion. Also disclosed are compositions useful in practicing the method.

Priority: US2003-418653 Applic. Date: 2003-04-18; US20020373841P Applic. Date: 2002-04-18; US20020373842P Applic. Date: 2002-04-18; US20020373844P Applic. Date: 2002-04-18

Inventor: EMBURY STEPHEN H [US]; MATSUI NEIL M [US]

Title: Analyte sensor

Applicant/Assignee:

Application No.: 11/543396   Filing Date: 04/Oct/2006

Abstract:Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into a host's peripheral vein or artery.

Priority: US2006-543404 Applic. Date: 2006-10-04; US2006-543490 Applic. Date: 2006-10-04

Inventor: BRISTER MARK [US]; SAINT SEAN [US]; SWANSON VANCE [US]; PETISCE JAMES R [US]

Title: Analyte sensor

Applicant/Assignee:

Application No.: 11/543490   Filing Date: 04/Oct/2006

Abstract:Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into a host's peripheral vein or artery.

Priority: US2006-543396 Applic. Date: 2006-10-04; US2006-543404 Applic. Date: 2006-10-04

Inventor: BRISTER MARK [US]; SAINT SEAN [US]; SWANSON VANCE [US]; QUINTANA NELSON [US]

Title: Thyroid Hormone Analogs and Methods of Use

Applicant/Assignee:

Application No.: 11/663047   Filing Date: 15/Sep/2005

Abstract:Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Priority: US2004-943072 Applic. Date: 2004-09-15; US20030502721P Applic. Date: 2003-09-15; US20050670534P Applic. Date: 2005-04-13; WO2005US32813 Applic. Date: 2005-09-15

Inventor: MOUSA SHAKER A [US]; DAVIS FAITH B [US]; DAVIS PAUL J [US]

Title: Method and apparatus for controlling the flow rate of washing solution during the washing step in a blood centrifugation bowl

Applicant/Assignee:

Application No.: 11/604664   Filing Date: 27/Nov/2006

Abstract:A method of washing blood mixed with undesirable elements not normally found in healthy whole blood to remove the undesirable elements, the method comprising: separating the blood into components according to relative densities of the components with a rotating centrifuge bowl

providing a port through which fluid exits the bowl, the exiting fluid having a concentration of undesirable elements

flowing washing solution into the centrifuge bowl at an initial flow rate

monitoring the fluid exiting the bowl with an optical sensor having an output signal indicative of the composition of the exiting fluid

and increasing and decreasing the flow rate of the wash solution as a function of the output signal.

Priority:

Inventor: FORTINI MATTEO [IT]; REGGIANI STEFANO [IT]; PANZANI IVO [IT]

Title: Anti-TREM-like transcript-1 (TLT-1) antibodies, methods and compositions

Applicant/Assignee: GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

Application No.: 11/634331   Filing Date: 04/Dec/2006